Mr. John Selig  
Director  
Arkansas Department of Human Services  
700 Main Street  
Little Rock, AR 72201

Dear Mr. Selig:

The Centers for Medicare & Medicaid Services (CMS) is approving Arkansas’ request to amend its Medicaid demonstration entitled, Arkansas Health Care Independence Program (Private Option), Project Number 11-W-00287/6, originally approved by CMS on September 27, 2013.

This amendment provides a waiver of section 1902(a)(14) of the Social Security Act for Arkansas to establish Independence Accounts (IA) to collect monthly contributions from beneficiaries with incomes from 50 percent up to and including 133 percent of the Federal Poverty Level (FPL). With a few exceptions, beneficiaries with incomes starting from 50 percent up to 133 percent of the FPL will be asked to contribute a monthly amount based on income. Beneficiaries will not lose or be denied eligibility for the Private Option if they do not contribute to the IA. Beneficiaries who do not make monthly IA contributions will be charged cost sharing, in a manner consistent with federal regulations. This amendment will enable the state to test the impact of IA in smoothing beneficiary transitions out of the Private Option and into private market plans or Medicare.

CMS’s approval of this amendment is conditioned upon compliance with the enclosed list of waiver and expenditure authorities and the Special Terms and Conditions (STCs) defining the nature, character, and extent of anticipated federal involvement in the project. The award is subject to our receiving your written acknowledgement of the award and acceptance of these STCs within 30 days of the date of this letter.

Your project officer for this demonstration is Mrs. Vanessa Sammy. She is available to answer any questions concerning your section 1115 demonstration Mrs. Sammy’s contact information is as follows:

Centers for Medicare & Medicaid Services  
Center for Medicaid & CHIP Services  
Mail Stop: S2-01-16  
7500 Security Boulevard  
Baltimore, MD 21244-1850  
Telephone: (410) 786-2613  
Facsimile: (410) 786-5882
E-mail: Vanessa.Sammy@cms.hhs.gov

Official communications regarding program matters should be sent simultaneously to Mrs. Sammy and to Mr. Bill Brooks, Associate Regional Administrator for the Division of Medicaid and Children’s Health in our Dallas Office. Mr. Brooks’ contact information is as follows:

Mr. Bill Brooks  
Associate Regional Administrator  
Division of Medicaid and Children Health Operations  
1301 Young St., Ste. 833  
Dallas, TX  75202

If you have questions regarding this approval, please contact Mr. Eliot Fishman, Director, Children and Adults Health Programs Group, Center for Medicaid & CHIP Services, at (410) 786-5647.

Sincerely,

Marilyn Tavenner

Enclosures

cc:  Bill Brooks, ARA, Region VI
CENTERS FOR MEDICARE & MEDICAID SERVICES
WAIVER LIST

NUMBER: 11-W-00287/6

TITLE: Arkansas Health Care Independence Program (Private Option) Section 1115 Demonstration

AWARDEE: Arkansas Department of Human Services

All requirements of the Medicaid program expressed in law, regulation, and policy statement, not expressly waived or identified as not applicable in accompanying expenditure authorities, shall apply to the demonstration project effective from September 27, 2013 through December 31, 2016. In addition, these waivers may only be implemented consistent with the approved Special Terms and Conditions (STCs).

Under the authority of section 1115(a)(1) of the Social Security Act (the Act), the following waivers of state plan requirements contained in section 1902 of the Act are granted subject to the STCs.

1. Freedom of Choice

   Section 1902(a)(23)(A)

   To the extent necessary to enable Arkansas to limit beneficiaries’ freedom of choice among providers to the providers participating in the network of the Private Option beneficiary’s Qualified Health Plan. No waiver of freedom of choice is authorized for family planning providers.

2. Payment to Providers

   Section 1902(a)(13) and Section 1902(a)(30)

   To the extent necessary to permit Arkansas to provide for payment to providers equal to the market-based rates determined by the Qualified Health Plan providing primary coverage for services under the Private Option.

3. Prior Authorization

   Section 1902(a)(54) insofar as it incorporates Section 1927(d)(5)

   To permit Arkansas to require that requests for prior authorization for drugs be addressed within 72 hours, rather than 24 hours as is currently required in their state policy. A 72-hour supply of the requested medication will be provided in the event of an emergency.

4. Independence Account Contributions

   Section 1902(a)(14) insofar as it incorporates Sections 1916 and 1916A

Approval Period: September 27, 2013 through December 31, 2016
Amended January 1, 2015
To the extent necessary to enable the state to collect monthly contributions for individuals with incomes between 50 and 133 percent of the federal poverty level (FPL).

5. Comparability Section 1902(a)(10)(B)

To the extent necessary to enable the state to impose targeted cost sharing on individuals in the eligibility group found at Section 1902(a)(10)(A)(i)(VIII) of the Act.

To the extent necessary to enable the state to impose targeted cost-sharing on individuals in the eligibility group found at Section 1902(a)(10)(A)(i)(VIII) of the Act who are not current with their Independence Account payments.
Under the authority of section 1115(a)(2) of the Social Security Act (the Act), expenditures made by the state for the items identified below, which are not otherwise included as expenditure under section 1903 shall, for the period of this demonstration be regarded as expenditures under the state’s Title XIX plan but are further limited by the Special Terms and Conditions (STCs) for the Arkansas Health Care Independence Program (Private Option) Section1115 demonstration.

1. **Premium Assistance and Cost Sharing Reduction Payments**  Expenditures for part or all of the cost of private insurance premiums, and for payments to reduce cost sharing for certain individuals eligible under the approved state plan new adult group described in section 1902(a)(10)(A)(i)(XVIII) of the Act.

Requirements Not Applicable to the Expenditure Authority:

1. **Cost Effectiveness**

   **Section 1902(a)(4) and 42 CFR 435.1015(a)(4)**

To the extent necessary to permit the state to offer premium assistance and cost sharing reduction payments that are determined to be cost effective using state developed tests of cost effectiveness that differ from otherwise permissible tests for cost effectiveness.
CENTERS FOR MEDICARE AND MEDICAID SERVICES  
SPECIAL TERMS AND CONDITIONS  

NUMBER:  11-W-00287/6  

TITLE:  Arkansas Health Care Independence Program (Private Option)  

AWARDEE:  Arkansas Department of Human Services  

I.  PREFACE  

The following are the amended Special Terms and Conditions (STCs) for the Arkansas Health Care Independence Program (Private Option) section 1115(a) Medicaid demonstration (hereinafter demonstration) to enable Arkansas (state) to operate this demonstration. The Centers for Medicare & Medicaid Services (CMS) has granted waivers of requirements under section 1902(a) of the Social Security Act (Act), and expenditure authorities authorizing federal matching of demonstration costs that are not otherwise matchable, and which are separately enumerated. These STCs set forth in detail the nature, character, and extent of federal involvement in the demonstration and the state’s obligations to CMS during the life of the demonstration. The amended STCs are effective on the date of the signed approval. Enrollment activities for the new adult population began on October 1, 2013 for the Private Option qualified health plan (QHP) with eligibility effective January 1, 2014. Contributions to Independence Accounts (IA) for certain demonstration populations will begin in accordance with the timeframes established in the operational protocols approved by CMS. Enrollment into the demonstration will be statewide and is approved through December 31, 2016.  

The STCs have been arranged into the following subject areas:  

I.  Preface  
II.  Program Description and Objectives  
III.  General Program Requirements  
IV.  Populations Affected  
V.  Private Option Premium Assistance Enrollment  
VI.  Premium Assistance Delivery System  
VII.  Benefits  
VIII.  Cost Sharing  
IX.  Appeals  
X.  General Reporting Requirements  
XI.  General Financial Requirements  
XII.  Monitoring Budget Neutrality  
XIII.  Evaluation  
XIV.  Monitoring  
XV.  Health Information Technology and Premium Assistance  
XVII.  T-MSIS
II. PROGRAM DESCRIPTION AND OBJECTIVES

Under the Private Option demonstration, the state has been providing premium assistance to support the purchase by beneficiaries eligible under the new adult group under the state plan of coverage from QHPs offered in the individual market through the Marketplace. In Arkansas, individuals eligible for coverage under the new adult group are both (1) childless adults ages 19 through 64 with incomes at or below 133 percent of the federal poverty limit (FPL) or (2) parents and other caretakers ages 19 through 64 with incomes between 17 percent and at or below 133 percent of the FPL (collectively Private Option beneficiaries). Arkansas expected approximately 200,000 beneficiaries to be enrolled into the Marketplace through this demonstration program.

With this amendment, the State will test innovative approaches to newly eligible adult beneficiary cost sharing and individual financial responsibility for care. All Private Option beneficiaries, unless specifically excluded, with incomes between 50 percent and 133 percent of the FPL will be assigned an Independence Account (IA) administered by a third party administrator (TPA). The beneficiary will then receive a credit or debit card to access amounts credited to the IA account for use to cover copayments and coinsurance.

The IA will be funded by both the participant and the state. The new adult population with incomes above 100 percent FPL will be required to make contributions of $10-$25 per month to their IA, depending on income. Such individuals who make the required contributions will be able to pay QHP copayments or coinsurance with the IA credit/debit card. Such individuals who do not make contributions may not pay QHP copayments or coinsurance with the IA credit/debit card, but must pay the QHP’s copayments or coinsurance at the point of service in order to receive services. If the individual restarts making contribution payments, the card will be reactivated to cover QHP-level copayments or coinsurance at the point of service. The state will ensure that the IA is funded sufficient to cover any copayment and coinsurance obligation that is not otherwise the responsibility of the individual. Notices will educate individuals about the value of participating. To provide a financial incentive to participate, individuals making at least six monthly contributions will be eligible to receive credits to offset future QHP premium payments (after enrollment in the private option has terminated), the employee’s contribution to employer-sponsored insurance, or Medicare premiums (for individuals over age 64), so long as the individual resides in Arkansas.

The new adult population with incomes between 50 percent and 100 percent FPL will be required to contribute $5 per month to their IA. Individuals at this income level who do not make a monthly contribution may still use the IA credit/debit card to pay QHP copayments or coinsurance at the point of service, but will be billed for Medicaid-level copayments by the TPA. The beneficiary can avoid future Medicaid-level copayments or coinsurance by making the monthly $5 contribution to their IA.

Private Option beneficiaries will receive the state plan Alternative Benefit Plan (ABP). Services will be delivered primarily through the service delivery network of the QHP that they select and, and the QHP will be the primary payer for such services. Beneficiaries will have cost sharing obligations consistent with the state plan.
With this demonstration Arkansas proposes to further the objectives of Title XIX by:

- Promoting continuity of coverage for individuals,
- Improving access to providers,
- Smoothing the “seams” across the continuum of coverage, and
- Furthering quality improvement and delivery system reform initiatives.

Arkansas proposes that the demonstration will provide integrated coverage for low-income Arkansans, leveraging the efficiencies of the private market to improve continuity, access, and quality for Private Option beneficiaries. The state proposes that the demonstration will also drive structural health care system reform and more competitive premium pricing for all individuals purchasing coverage through the Marketplace by doubling the size of the population enrolling in QHPs offered through the Marketplace.

The state proposes to demonstrate following key features:

**Continuity of coverage and care** – For households with members eligible for coverage under Title XIX and Marketplace coverage as well as those who have income fluctuations that cause their eligibility to change year-to-year, or multiple times throughout the year, the demonstration will create continuity of health plans available for selection as well as provider networks. Households may stay enrolled in the same plan regardless of whether their coverage is subsidized through Medicaid, or Advanced Payment Tax Credits/Cost Sharing Reductions (APTC/CSRs). IAs will also be established for individuals with income from 50–133 percent FPL to help smooth the transition out of the Private Option and into private market plans or Medicare. For those who start at a very low income and progress to higher income levels, IAs can provide a consistent approach to the financing and receipt of health care services.

**Support equalization of provider reimbursement and improve provider access** – The demonstration will support equalization of provider reimbursement across payers, toward the end of expanding provider access and eliminating the need for providers to cross-subsidize. Arkansas Medicaid provides rates of reimbursement lower than Medicare or commercial payers, causing some providers to forego participation in the program and others to “cross subsidize” their Medicaid patients by charging more to private insurers.

**Promote accountability, personal responsibility and transparency, and encourage and reward responsible choices** – The introduction of IAs will provide participants with direct information about the cost of health care services and out-of-pocket costs; It also has the goal of promoting independence and self-sufficiency by providing participants with the possibility of having additional credits to be distributed as cash, which can be used to pay future private market premiums. Credits are intended to provide stability to individuals as they move into the private market, helping to sustain enrollees in the private market for a longer period of time and, in turn, reducing their reliance on state funded public programs.

**Integration and efficiency** – Arkansas is proposing taking an integrated and market-based approach to covering uninsured Arkansans.

**III. GENERAL PROGRAM REQUIREMENTS**
1. Compliance with Federal Non-Discrimination Statutes. The state must comply with all applicable federal statutes relating to non-discrimination. These include, but are not limited to, the Americans with Disabilities Act of 1990, Title VI of the Civil Rights Act of 1964, section 504 of the Rehabilitation Act of 1973, and the Age Discrimination Act of 1975.

2. Compliance with Medicaid and Children’s Health Insurance Program (CHIP) Law, Regulation, and Policy. All requirements of the Medicaid program and CHIP, expressed in law, regulation, and policy statement, not expressly waived or identified as not applicable in the waiver and expenditure authority documents (of which these terms and conditions are part), apply to the demonstration.

3. Changes in Medicaid and CHIP Law, Regulation, and Policy. The state must, within the timeframes specified in law, regulation, or policy statement, come into compliance with any changes in federal law, regulation, or policy affecting the Medicaid or CHIP program that occur during this demonstration approval period, unless the provision being changed is expressly waived or identified as not applicable. In addition, CMS reserves the right to amend the STCs to reflect such changes and/or changes without requiring the state to submit an amendment to the demonstration under STC 7. CMS will notify the state 30 days in advance of the expected approval date of the amended STCs to allow the state to provide comment.

   a. To the extent that a change in federal law, regulation, or policy requires either a reduction or an increase in federal financial participation (FFP) for expenditures made under this demonstration, the state must adopt, subject to CMS approval, a modified budget neutrality agreement as well as a modified allotment neutrality worksheet for the demonstration as necessary to comply with such change. The modified budget neutrality agreement will be effective upon the implementation of the change.
   b. If mandated changes in the federal law require state legislation, the changes must take effect on the day such state legislation becomes effective, or on the last day such legislation was required to be in effect under the law.

5. State Plan Amendments. If the eligibility of a population eligible through the Medicaid or CHIP state plan is affected by a change to the demonstration, a conforming amendment to the appropriate state plan may be required, except as otherwise noted in these STCs. In all such instances the Medicaid state plan governs.
   a. Should the state amend the state plan to make any changes to eligibility for this population, upon submission of the state plan amendment, the state must notify CMS demonstration staff in writing of the pending state plan amendment, and request a corresponding technical correction to the demonstration.

6. Changes Subject to the Amendment Process. Changes related to demonstration features including eligibility, enrollment, benefits, enrollee rights, delivery systems, cost sharing, evaluation design, sources of non-federal share of funding, budget neutrality, and other
comparable program elements must be submitted to CMS as amendments to the demonstration. All amendment requests are subject to approval at the discretion of the Secretary in accordance with section 1115 of the Act. The state must not implement changes to these elements without prior approval by CMS either through an approved amendment to the Medicaid state plan and/or amendment to the demonstration. Amendments to the demonstration are not retroactive and FFP will not be available for changes to the demonstration that have not been approved through the amendment process set forth in STC 7 below.

7. Amendment Process. Requests to amend the demonstration must be submitted to CMS for approval no later than 120 days prior to the planned date of implementation of the change and may not be implemented until approved. CMS reserves the right to deny or delay approval of a demonstration amendment based on non-compliance with these STCs, including but not limited to failure by the State to submit required reports and other deliverables in a timely fashion according to the deadlines specified herein. Amendment requests must include, but are not limited to, the following:
   a. An explanation of the public process used by the State, consistent with the requirements of STC 15, prior to submission of the requested amendment;
   b. A data analysis worksheet which identifies the specific “with waiver” impact of the proposed amendment on the current budget neutrality agreement. Such analysis shall include current total computable “with waiver” and “without waiver” status on both a summary and detailed level through the current approval period using the most recent actual expenditures, as well as summary and detailed projections of the change in the “with waiver” expenditure total as a result of the proposed amendment, which isolates (by Eligibility Group) the impact of the amendment;
   c. An up-to-date CHIP allotment neutrality worksheet, if necessary;
   d. A detailed description of the amendment, including impact on beneficiaries, with sufficient supporting documentation; and
   e. A description of how the evaluation design will be modified to incorporate the amendment provisions.

8. Extension of the Demonstration. States that intend to request demonstration extensions under sections 1115(e) or 1115(f) are advised to observe the timelines contained in those statutes. Otherwise, no later than 12 months prior to the expiration date of the demonstration, the governor or chief executive officer of the State must submit to CMS either a demonstration extension request or a transition and phase-out plan consistent with the requirements of STC 9.
   b. As part of the demonstration extension requests the State must provide documentation of compliance with the transparency requirements 42 CFR §431.412 and the public notice and tribal consultation requirements outlined in STC 15.

9. Demonstration Phase Out. The State may only suspend or terminate this demonstration in whole, or in part, consistent with the following requirements.
a. Notification of Suspension or Termination: The State must promptly notify CMS in writing of the reason(s) for the suspension or termination, together with the effective date and a transition and phase-out plan. The State must submit its notification letter and a draft plan to CMS no less than six (6) months before the effective date of the demonstration’s suspension or termination. Prior to submitting the draft plan to CMS, the State must publish on its website the draft transition and phase-out plan for a 30-day public comment period. In addition, the State must conduct tribal consultation in accordance with its approved tribal consultation state plan Amendment. Once the 30-day public comment period has ended, the State must provide a summary of each public comment received the State’s response to the comment and how the State incorporated the received comment into the revised plan.

b. The State must obtain CMS approval of the transition and phase-out plan prior to the implementation of the phase-out activities. Implementation of activities must be no sooner than 14 days after CMS approval of the plan.

c. Transition and Phase-out Plan Requirements: The State must include, at a minimum, in its plan the process by which it will notify affected beneficiaries, the content of said notices (including information on the beneficiary’s appeal rights), the process by which the State will conduct administrative reviews of Medicaid eligibility prior to the termination of the program for the affected beneficiaries, and ensure ongoing coverage for those beneficiaries determined eligible, as well as any community outreach activities including community resources that are available.

d. Phase-out Procedures: The State must comply with all notice requirements found in 42 CFR Sections 431.206, 431.210, and 431.213. In addition, the State must assure all appeal and hearing rights afforded to demonstration participants as outlined in 42 CFR Sections 431.220 and 431.221. If a demonstration participant requests a hearing before the date of action, the State must maintain benefits as required in 42 CFR Section 431.230. In addition, the State must conduct administrative renewals for all affected beneficiaries in order to determine if they qualify for Medicaid eligibility under a different eligibility category. 42 CFR Section 435.916.

e. Exemption from Public Notice Procedures 42.CFR Section 431.416(g). CMS may expedite the federal and State public notice requirements in the event it determines that the objectives of title XIX and XXI would be served or under circumstances described in 42 CFR Section 431.416(g).

f. Federal Financial Participation (FFP): If the project is terminated or any relevant waivers suspended by the State, FFP shall be limited to normal closeout costs associated with terminating the demonstration including services and administrative costs of disenrolling participants.

10. Post Award Forum. Within six months of the demonstration’s implementation, and annually thereafter, the State will afford the public with an opportunity to provide meaningful comment on the progress of the demonstration. At least 30 days prior to the date of the planned public forum, the State must publish the date, time and location of the forum in a prominent location on its website. The State can either use its Medical Care
Advisory Committee, or another meeting that is open to the public and where an interested party can learn about the progress of the demonstration to meet the requirements of this STC. The State must include a summary of the comments in the quarterly report as specified in STC 46 associated with the quarter in which the forum was held. The State must also include the summary in its annual report as required in STC 48.

11. Federal Financial Participation (FFP). If the project is terminated or any relevant waivers suspended by the State, FFP shall be limited to normal closeout costs associated with terminating the demonstration including services and administrative costs of disenrolling enrollees.

12. Expiring Demonstration Authority. For demonstration authority that expires prior to the demonstration’s expiration date, the State must submit a transition plan to CMS no later than six months prior to the applicable demonstration authority’s expiration date, consistent with the following requirements:
   a. Expiration Requirements. The State must include, at a minimum, in its demonstration expiration plan the process by which it will notify affected beneficiaries, the content of said notices (including information on the beneficiary’s appeal rights), the process by which the State will conduct administrative reviews of Medicaid eligibility for the affected beneficiaries, and ensure ongoing coverage for eligible individuals, as well as any community outreach activities.
   b. Expiration Procedures. The State must comply with all notice requirements found in 42 CFR Sections 431.206, 431.210 and 431.213. In addition, the State must assure all appeal and hearing rights afforded to demonstration enrollees as outlined in 42 CFR Sections 431.220 and 431.221. If a demonstration enrollee requests a hearing before the date of action, the State must maintain benefits as required in 42 CFR Section 431.230. In addition, the State must conduct administrative renewals for all affected beneficiaries in order to determine if they qualify for Medicaid eligibility under a different eligibility category as discussed in October 1, 2010, State Health Official Letter #10-008.
   c. Federal Public Notice. CMS will conduct a 30-day federal public comment period consistent with the process outlined in 42 CFR Section 431.416 in order to solicit public input on the State’s demonstration expiration plan. CMS will consider comments received during the 30-day period during its review and approval of the State’s demonstration expiration plan. The State must obtain CMS approval of the demonstration expiration plan prior to the implementation of the expiration activities. Implementation of expiration activities must be no sooner than 14 days after CMS approval of the plan.
   d. Federal Financial Participation (FFP): FFP shall be limited to normal closeout costs associated with the expiration of the demonstration including services and administrative costs of disenrolling enrollees.

13. Withdrawal of Waiver Authority. CMS reserves the right to amend and withdraw waivers or expenditure authorities at any time it determines that continuing the waivers or expenditure authorities would no longer be in the public interest or promote the objectives
of Title XIX. CMS will promptly notify the State in writing of the determination and the reasons for the amendment and withdrawal, together with the effective date, and afford the State an opportunity to request a hearing to challenge CMS’ determination prior to the effective date. If a waiver or expenditure authority is withdrawn or amended, FFP is limited to normal closeout costs associated with terminating the waiver or expenditure authority, including services and administrative costs of disenrolling enrollees.

14. Adequacy of Infrastructure. The State must ensure the availability of adequate resources for implementation and monitoring of the demonstration, including education, outreach, and enrollment; maintaining eligibility systems; compliance with cost sharing requirements; and reporting on financial and other demonstration components.

15. Public Notice, Tribal Consultation, and Consultation with Interested Parties. The State must comply with the State Notice Procedures set forth in 59 Fed. Reg. 49249 (September 27, 1994). The State must also comply with the tribal consultation requirements in section 1902(a)(73) of the Act as amended by section 5006(e) of the American Recovery and Reinvestment Act (ARRA) of 2009, the implementing regulations for the Review and Approval Process for Section 1115 demonstrations at 42 CFR Section 431.408, and the tribal consultation requirements contained in the State’s approved state plan, when any program changes to the demonstration are proposed by the State.
   a. In States with federally recognized Indian tribes consultation must be conducted in accordance with the consultation process outlined in the July 17, 2001 letter or the consultation process in the State’s approved Medicaid state plan if that process is specifically applicable to consulting with tribal governments on waivers (42 CFR Section 431.408(b)(2)).
   b. In States with federally recognized Indian tribes, Indian health programs, and/or Urban Indian organizations, the State is required to submit evidence to CMS regarding the solicitation of advice from these entities prior to submission of any demonstration proposal, amendment and/or renewal of this demonstration (42 CFR Section 431.408(b)(3)).
   c. The State must also comply with the Public Notice Procedures set forth in 42 CFR Section 447.205 for changes in statewide methods and standards for setting payment rates.

16. Federal Financial Participation (FFP). No federal matching for administrative or service expenditures for this demonstration will take effect until the effective date identified in the demonstration approval letter.

IV. POPULATIONS AFFECTED

The State will use this demonstration to ensure coverage for Private Option eligible beneficiaries provided primarily through QHPs offered in the individual market instead of the fee-for-service delivery system that serves the traditional Medicaid population. The State will provide premium assistance to aid individuals in enrolling in coverage through QHPs in the Marketplace for Private Option beneficiaries and establish IAs to address cost sharing requirements and assist in the transition to private insurance or Medicare coverage.
17. Populations Affected by the Arkansas Health Care Independence (Private Option) Demonstration. Except as described in STCs 18 and 19, the Arkansas Health Care Independence (Private Option) Demonstration affects the delivery of benefits, as set forth in section 1905(y)(2)(B) of the Act and codified at 42 CFR Section 433.204(a)(2), to adults aged 19 through 64 eligible under the state plan under 1902(a)(10)(A)(i)(VIII) of the Act, 42 CFR Section 435.119. Eligibility and coverage for these individuals is subject to all applicable Medicaid laws and regulations in accordance with the Medicaid state plan, except as expressly waived in this demonstration and as described in these STCs. Any Medicaid state plan amendments to this eligibility group, including the conversion to a modified adjusted gross income standard on January 1, 2014, will apply to this demonstration.

Table 1 Eligibility Groups

<table>
<thead>
<tr>
<th>Medicaid State Plan Mandatory Groups</th>
<th>Federal Poverty Level</th>
<th>Funding Stream</th>
<th>Expenditure and Eligibility Group Reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Adult Group</td>
<td>This group includes both the parent and caretakers as well as the childless adults up to 133 percent of the FPL</td>
<td>Title XIX</td>
<td>MEG – 1</td>
</tr>
</tbody>
</table>

18. Medically Frail Individuals. Arkansas will institute a process to determine whether an individual is medically frail. The process will be described in the Alternative Benefit state plan. Medically frail individuals will be excluded from the demonstration.

a. Medically frail individuals will not be subject to cost sharing under the terms of this demonstration, will not have Independence Accounts available and will not be subject to Independence Account requirements or benefits.

b. The term “medically frail” is inclusive of both individuals who meet the medically frail definition in 42 CFR 440.315(f) and individuals who have exceptional medical needs as determined through the Arkansas health care needs questionnaire.

c. Individuals excluded from enrolling in QHPs through the Private Option as a result of a determination of medical frailty as that term is defined above will have the option of receiving direct coverage through the state of either the same ABP offered to the new adult group or an ABP that includes all benefits otherwise available under the approved Medicaid state plan (the standard Medicaid benefit package). Direct coverage will be provided through a fee-for-service (FFS) system.

19. American Indian/Alaska Native Individuals. Individuals identified as American Indian
or Alaskan Native (AI/AN) will not be required to enroll in QHPs in this demonstration, but can choose to opt into the demonstration and access coverage pursuant to all the terms and conditions of this demonstration. AI/AN individuals who elect to participate in the demonstration will not be assigned an IA, instead they will be enrolled in the plan they select and will receive cost sharing protections. Individuals who are AI/AN and who have not opted into the Private Option will receive the ABP available to the new adult group and operated through a fee for service (FFS) system. An AI/AN individual will be able to access covered benefits through Indian Health Service (IHS), Tribal or Urban Indian Organization (collectively, I/T/U) facilities funded through the IHS. Under the Indian Health Care Improvement Act (IHCIA), I/T/U facilities are entitled to payment notwithstanding network restrictions.

V. **PRIVATE OPTION PREMIUM ASSISTANCE ENROLLMENT**

20. **Private Option.** For individuals affected by the Private Option, enrollment in a QHP will be a condition of receiving benefits.

21. **Notices.** Private Option beneficiaries will receive a notice from Arkansas Medicaid advising them of the following:
   a. **QHP Plan Selection.** The notice will include information regarding how Private Option beneficiaries can select a QHP and information on the State’s auto-assignment process in the event that the beneficiary does not select a plan.
   b. **Independence Accounts.** For individuals who will be enrolled in IAs, the notices will include specific information on cost sharing obligations, the requirements related to IAs, how the IAs are established, expected participant contributions into the accounts, the State and other public/private contributions into the IAs, how Private Option Enrollees use the IAs, the incentives that apply to the IAs, and the consequences if contributions are not paid. The notices will also explain when the IAs will become effective.
   c. **Access to Services until QHP Enrollment is Effective.** The notice will include the Medicaid client identification number (CIN) and information on how beneficiaries can use the CIN number to access services until their QHP enrollment is effective.
   d. **Wrapped Benefits.** The notice will also include information on how beneficiaries can use the CIN number to access wrapped benefits. The notice will include specific information regarding services that are covered directly through fee-for-service Medicaid, what phone numbers to call or websites to visit to access wrapped services, and any cost-sharing for wrapped services pursuant to STC 37.
   e. **Appeals.** The notice will also include information regarding the grievance and appeals process.
   f. **Exemption from the Alternative Benefit Plan.** The notice will include information describing how Private Option beneficiaries who believe they may be exempt from the Private Option ABP, and individuals who are medically frail, can request a determination of whether they are exempt from this ABP.
22. **QHP Selection.** The QHP in which Private Option beneficiaries will enroll will be certified through the Arkansas Insurance Department’s QHP certification process. The QHPs available for selection by the beneficiary will be determined by the Medicaid agency.

23. **Enrollment Process.** Individuals receiving coverage through the Private Option demonstration began to enroll during the initial QHP enrollment period (October 1, 2013–March 31, 2014). In accordance with the state established timeframes established in the Enrollment Protocols, individuals will enroll through the following process:

a. Individuals will submit a joint application for insurance affordability programs - Medicaid, CHIP and Advanced Premium Tax Credits/Cost Sharing Reductions - electronically, via phone, by mail, or in-person.

b. An eligibility determination will be made either through the Marketplace or the Arkansas Eligibility & Enrollment Framework (EEF).

c. Once individuals have been determined eligible for coverage under Title XIX, they will have an opportunity to complete the health care needs questionnaire, through the State’s web-based portal, to be assessed for medical frailty as defined in STC 21(a).

d. Individuals who are determined eligible to receive coverage through the Private Option will have the opportunity to shop among QHPs available to Private Option eligible individuals, and to select a QHP, through the State’s web-based portal.

e. The State’s MMIS will capture their plan selection information and will transmit the 834 enrollment transactions to the QHP issuers and transmit a notice to the TPA for enrollment in an IA, if applicable.

f. QHP issuers will issue insurance cards to Private Option enrollees.

g. The State’s MMIS will pay QHP premiums on behalf of beneficiaries directly to the QHP issuer.

h. State MMIS QHP premium payments will continue until the individual is determined to no longer be eligible for the Private Option (including when the individual is determined to be medically frail and will have the option of receiving either the ABP operated through FFS or the ABP that is the Medicaid state plan).

i. An IA will be established with the TPA and the IA debit/credit card will be sent to the individual for use when paying Medicaid coinsurance or copayments.

j. Where applicable, the TPA will pay QHP-level copayments and coinsurance on behalf of beneficiaries to the provider for individuals with IAs who use the IA debit/credit card.

k. For individuals who have an IA and meet their contribution obligations to the IA on a current basis, the TPA will pay copayments and coinsurance when the individual uses the IA debit/credit card, until the individual is notified of ineligibility for the Private Option, including when the individual is determined to be medically frail. When an individual does not make required contributions into the IA, the effect on TPA payment of copayments and coinsurance is the following:

   i. For individuals with incomes between 50 and 100 percent FPL who do not make contributions to the IA, the TPA will continue to pay QHP-level co-
payments and co-insurance when the individual uses the IA debit/credit
card, but will bill the individual for Medicaid copayments. If the individual
fails to pay the amount billed by the TPA, the TPA will deduct the unpaid
amounts from credits in the IA at the point of annual reconciliation, if
applicable. When there are not enough credits in the IA to cover the
amount billed by the TPA at the time of annual reconciliation, the
individual will incur a collectible debt to the State, unless the individual
self-attests to a financial hardship.

ii. For individuals with incomes greater than 100 percent FPL who do not
make contributions to the IA, the TPA will notify the individual, suspend
the operation of the IA debit/credit card, and will not pay copayments or
coinsurance for services received. The individual will be required to pay
the QHP copayments or coinsurance to the provider at the point of service.
The provider can deny services for failure to pay the copayment or
coinsurance. Copayments will be consistent with STC 42.

24. Auto-assignment. In the event that an individual is determined eligible for coverage through
the Private Option, but does not select a plan, the State will auto-assign the enrollee to one of
the available QHPs in the beneficiary’s county. Individuals who are auto-assigned will be
notified of their assignment, and the effective date of QHP enrollment, and will be given a
thirty-day period from the date of enrollment to request enrollment in another plan.

25. Distribution of Members Auto-assigned. In demonstration year one (DY1), Private Option
auto-assignments will be distributed among QHP issuers in good standing with the Arkansas
Insurance Department offering certified silver-level QHPs certified by the Arkansas
Insurance Department with the aim of achieving a target minimum market share of Private
Option enrollees for each QHP issuer in a rating region. Specifically, the target minimum
market share for a QHP issuer offering silver QHP in a rating region will vary based on the
number of competing QHP issuers as follows:

Two QHP issuers: 33 percent of Private Option enrollees in that region.
Three QHP issuers: 25 percent of Private Option enrollees in that region.
Four QHP issuers: 20 percent of Private Option enrollees in that region.
More than four QHP issuers: 10 percent of Private Option enrollees in that region.

26. Changes to Auto-assignment Methodology. The State will advise CMS 60 days prior to
implementing a change to the auto-assignment methodology.

27. Disenrollment. Enrollees in the QHP Private Option may be disenrolled if they are
determined to be medically frail after they were previously determined eligible.

VI. PREMIUM ASSISTANCE DELIVERY SYSTEM

28. Memorandum of Understanding. The Arkansas Department of Human Services and the
Arkansas Insurance Department have entered into a memorandum of understanding (MOU)
with each QHP that will enroll individuals covered under the Demonstration. Areas to be
addressed in the MOU include, but are not limited to:
   a. Enrollment of individuals in populations covered by the Demonstration;
   b. Payment of premiums and cost-sharing reductions;
   c. Reporting and data requirements necessary to monitor and evaluate the Private Option including those referenced in STC 71, ensuring enrollee access to EPSDT and other covered benefits through the QHP;
   d. Noticing requirements; and, Audit rights.

29. Qualified Health Plans. The State will use premium assistance to support the purchase of coverage for Private Option beneficiaries through Marketplace QHPs.

30. Choice. Each Private Option beneficiary will have the option to choose between at least two silver plans covering only Essential Health Benefits that are offered in the individual market through the Marketplace. The State will pay the full cost of QHP premiums.
   a. Private Option beneficiaries will be able to choose from at least two silver plans covering only Essential Health Benefits that are in each rating area of the State
   b. Private Option beneficiaries will be permitted to choose among all silver plans covering only Essential Health Benefits that are offered in their geographic area, and thus all Private Option beneficiaries will have a choice of at least two qualified health plans.
   c. The State will comply with Essential Community Provider network requirements, as part of the Qualified Health Plan certification process.
   d. Private Option beneficiaries will have access to the same networks as other individuals enrolling in silver level QHPs through the individual Marketplace.

31. Coverage Prior to Enrollment in a QHP. The State will provide coverage through fee-for-service Medicaid from the date an individual is determined eligible for the New Adult Group until the individual’s enrollment in the QHP becomes effective.
   a. For individuals who select (or are auto-assigned) to a QHP between the first and fifteenth day of a month, QHP coverage will become effective as of the first day of the month following QHP selection (or auto-assignment).
   b. For individuals who select (or are auto-assigned) to a QHP between the sixteenth and last day of a month, QHP coverage will become effective as of the first day of the second month following QHP selection (or auto-assignment).
   c. For individuals in the Private Option who are eligible for Independence Accounts, participants must make their initial contribution by the monthly due date prior to the end of the second month after their QHP coverage becomes effective.
      i. For individuals with incomes between 50 and 100 percent FPL who do not make contributions to the IA by the monthly due date prior to the first day of the third month of QHP coverage, the TPA will continue to pay the QHP-level co-payments and co-insurance, but will start deducting the copayment amounts from remaining IA balances and/or will start billing the participant for Medicaid copayments.
      ii. For individuals with incomes greater than 100 percent FPL who do not make contributions to the IA by the monthly due date prior to the first day of the third month of QHP coverage, the participant will be required to
make QHP copayments or coinsurance at the point of service in order to receive services. The provider can deny services for failure to pay the copayment or coinsurance.

The timeline for requiring payments for those who do not contribute to their IAs is demonstrated in the example below:

32. **Family Planning.** If family planning services are accessed at a facility that the QHP considers to be an out-of-network provider, the State’s fee-for-service Medicaid program will cover those services.

33. **NEMT.** Non-emergency medical transport services will be provided through the State’s fee-for-service Medicaid program.

**VII. BENEFITS**

34. **Arkansas Health Care Independence Program (Private Option) Benefits.** Individuals affected by this demonstration will receive benefits as set forth in section 1905(y)(2)(B) of the Act and codified at 42 CFR Section 433.204(a)(2). These benefits are described in the Medicaid state plan.

35. **Alternative Benefit Plan.** The benefits provided under the State’s alternative benefit plan for the new adult group are reflected in the State ABP state plan.

36. **Medicaid Wrap Benefits.** The State will provide through its fee-for-service system wrap-around benefits that are required for the ABP but not covered by qualified health plans. These benefits include non-emergency transportation and Early Periodic Screening Diagnosis and Treatment (EPSDT) services for individuals participating in the
demonstration who are under age 21.

37. **Access to Wrap Around Benefits.** In addition to receiving an insurance card from the applicable QHP issuer, Private Option beneficiaries will have a Medicaid CIN through which providers may bill Medicaid for wrap-around benefits. The notice containing the CIN will include information about which services Private Option beneficiaries may receive through fee-for-service Medicaid and how to access those services. This information will also be posted on Arkansas Department of Human Service’s Medicaid website and be provided through information at the Department of Human Service’s call centers and through QHP issuers.

38. **Early and Periodic Screening, Diagnosis, and Treatment (EPSDT).** The State must fulfill its responsibilities for coverage, outreach, and assistance with respect to EPSDT services that are described in the requirements of sections 1905(a)(4)(b) (services), 1902(a)(43) (administrative requirements), and 1905(r) (definitions).

39. **Access to Federally Qualified Health Centers and Rural Health Centers.** Private Option enrollees will have access to at least one QHP in each service area that contracts with at least one FQHC or RHC.

40. **Access to Non-Emergency Medical Transportation.** For individuals in the eligibility group established under Section 1902(a)(10)(A)(i)(VIII), the State will establish prior authorization for NEMT in the ABP, with the exception of the AI/AN and medically frail individuals.

VIII. **COST SHARING**

41. **Cost sharing.** Cost sharing for Private Option enrollees must be in compliance with federal requirements that are set forth in statute, regulation and policies, including exemptions from cost-sharing set forth in 42 CFR Section 447(b).

42. **Cost Sharing Parameters for the Arkansas Premium Assistance program.** With the approval of this Demonstration:
   a. Enrollees under 50 percent of the FPL will have no cost sharing.
   b. Enrollees at 50 percent of the FPL and above will have cost sharing consistent with Medicaid requirements and must include an aggregate cap of no more than 5 percent of family monthly or quarterly income.
   c. Cost sharing limitations described in 42 CFR 447.56(a) will be applied to all program enrollees.
   d. Copayment and coinsurance amounts will be consistent with federal requirements regarding Medicaid cost sharing and with the State’s approved state plan; copayment and coinsurance amounts are listed in Attachment B

43. **Payment Process for Payment of Cost Sharing Reduction to QHPs.** Agreements with QHP issuers may provide for advance monthly cost-sharing reduction (CSR) payments to cover the costs associated with the reduced cost sharing for Private Option beneficiaries.
Such payments will be subject to reconciliation at the conclusion of the benefit year based on actual expenditures by the QHP for cost sharing reduction. If a QHP issuer’s actuary determines during the benefit year that the estimated advance CSR payments are significantly different than the CSR payments the QHP issuer will be entitled to during reconciliation, the QHP issuer may ask Arkansas’ Department of Human Services to adjust the advance payments. Arkansas’ reconciliation process will follow 45 CFR Section 156.430 to the extent applicable.

IX. CONTRIBUTIONS TO ARKANSAS INDEPENDENCE ACCOUNTS

This section provides an overview of the planned framework that will be used to further define the programmatic features of the Arkansas Health Care Independence Program demonstration. Following the development and subsequent approval of the IA Protocols, Private Option beneficiaries enrolled in the demonstration will have responsibility to make contributions to IAs. The State may request changes to the Protocols, which must be approved by CMS, and which will be effective prospectively. Changes may be subject to an amendment to the STCs in accordance with paragraph 7, depending upon the nature of the proposed change. An individual’s IA may be used to pay cost sharing that is imposed by the individual’s QHP that is consistent with STC 42 and all Medicaid requirements that are set forth in statute, regulation and policies, except as expressly modified by the waivers implemented in accordance with the terms and conditions granted for this demonstration. As noted in STC 43, the state may enter into arrangements to prepay for QHP cost sharing that exceeds such limits and is attributable to Medicaid enrollees in the QHP.

44. Arkansas Health Care Independence Program Independence Account Contributions.

Private Option beneficiaries with incomes greater than 50 percent FPL will be required to make monthly contributions into IAs. The TPA will track and record beneficiary contributions and liabilities for cost sharing utilization within each IA. Participants also have the opportunity to receive credits resulting in funds for consistent contribution into these accounts, as specified in the Protocols. A TPA will administer and manage the IAs and associated debit/credit cards used to pay QHP cost sharing. There will be one statewide TPA, which will be selected in accordance with state procurement rules.

Private Option beneficiaries will make contributions up to the amounts described below:

<table>
<thead>
<tr>
<th>INCOME RANGE</th>
<th>&gt;50%-100% FPL</th>
<th>&gt;100% -115% FPL</th>
<th>&gt;115%-129% FPL</th>
<th>&gt;129%-133% FPL</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONTHLY CONTRIBUTION</td>
<td>$5</td>
<td>$10</td>
<td>$17.50</td>
<td>$25</td>
</tr>
</tbody>
</table>

*No household shall pay more than 2 percent of household income.

a. The new adult population with incomes between 50 percent and 100 percent FPL will have an option in which they contribute $5 per month to their IA. The State will also contribute funds to ensure the account covers the individual’s QHP.
copayment and coinsurance obligations. Individuals at this income level who make their contributions will use the IA debit/credit card to pay providers for copayments and coinsurance obligations, and will not be billed by the TPA for Medicaid copayments for services received during the month following the contribution. No reduction will be made in the IA for the amounts charged to the IA debit/credit card.

i. Individuals who contribute to the IA for at least 6 months (which can be non-consecutive months) in a calendar year will also receive a credit that will be distributed as cash to the individual which may be used for future QHP premium payments, or for contributions to employer-sponsored insurance, or Medicare premiums (for individuals over age 64), when the individual is no longer Medicaid eligible in the new adult group, so long as the individual resides in Arkansas. Individuals will accrue a credit of the lesser of the amount contributed or $15 for each month they make a timely contribution to the IA, regardless of the amounts of coinsurance or cost sharing charged to the individual’s IA debit/credit card. Credits will be capped at $200 for the lifetime of the demonstration and have to be used within two years of accrual.

ii. Individuals who do not make a monthly contribution will use the IA debit/credit card to pay providers for QHP copayments and coinsurance obligations and will be billed by the TPA for Medicaid copayment amounts for services received. If the individual fails to pay the TPA the Medicaid coinsurance or copayment amounts due, any previously accrued credit in the IAs will be used to pay the debt. Once those funds have been exhausted, if there are additional coinsurance or copayment amounts due, the individual will incur a debt to the State.

b. The new adult population with incomes above 100 percent FPL through 133 percent FPL will contribute $10-$25 per month to their IA (depending on their income as outlined in Table 2 above). The State will also contribute funds to ensure that the account contain enough funds to cover the individual’s copayment and coinsurance obligations, when applicable. Participants will pay their QHP copayments and coinsurance obligations through the debit/credit card associated with their IA.

i. Participants who contribute to the IA for at least 6 (which can be non-consecutive) months in a calendar year, will also be eligible to receive a credit that will be distributed as cash to the individual which may be used to offset future QHP premium payments, contributions to employer-sponsored insurance, or for Medicare premiums (for individuals over age 64), when the individual is no longer Medicaid-eligible in the new adult group, so long as the individual resides in Arkansas. Individuals will accrue a credit of the lesser of the amount contributed or $15 for each month they make a timely contribution to the IA, regardless of the amounts of coinsurance or cost sharing charged to the individual’s IA debit/credit card. Credits will be capped at $200 for the lifetime of the demonstration and have to be used within two years of accrual.
ii. Individuals who do not make a monthly contribution will be required to pay QHP copayments or coinsurance at the point of service in order to receive services. But such copayments or coinsurance must be consistent with STC 42.

45. Private Option Beneficiary Protections. The following beneficiary protections will be maintained.
   a. No individual may lose eligibility for Medicaid, be denied eligibility for Medicaid, or be denied enrollment in a Private Option health plan for failure to pay cost sharing liabilities.
   b. Beneficiaries between 50 percent FPL and 100 percent FPL who do not make monthly contributions to their IAs will be billed only for copayment amounts as specified in the state plan amendment to be submitted by the State. Beneficiaries between 50 percent FPL and 100 percent FPL may not be denied access to services for failure to make contributions into their IA or failure to pay copayment or coinsurance liabilities.
   c. Only individuals with incomes greater than 100 percent FPL can be denied medical services for failure to pay copayments or coinsurance. Cost sharing will not exceed the maximum allowed under federal Medicaid regulation.
   d. Cost sharing limitations described in 42 CFR 447.56(a) will be applied to all program beneficiaries.
   e. Copayment and coinsurance amounts will be consistent with federal requirements regarding Medicaid cost sharing and with the State’s approved state plan; copayment and coinsurance amounts are listed in Attachment B.

46. Assurance of Compliance. Within 120 days of implementation of the IAs, the State shall provide CMS a progress report that verifies the IAs are operating in accordance with the approved Protocol. Should the program be deemed out of compliance, CMS will request the State to provide a corrective action plan. Failure to correct deficiencies may result in disallowance or program suspension until all operations are compliant.

47. Additional Incentives and Penalties. Following CMS approval of the IA Protocols, the State may submit additional changes to the Protocols, subject to CMS approval, to enhance the program’s incentives and consequences for program enrollees who are not complying with CMS-approved requirements.

48. Independence Account Operational Protocol. The State must submit a draft IA Operational Protocol to CMS for review. The State will update the IA Operational Protocol annually or whenever there are issues identified requiring modification, prior to implementing additional changes to the IA Operational Protocol. The IA Operational Protocol will be included as Attachment C of the special terms and conditions. The initial IA Operational Protocol will include the following items:
   a. The approach to implementation, including the approach for those whose QHP enrollment occurs on or after the effective date of the amendment and the approach to notify and enroll existing QHP enrollees.
b. The strategy and operational description of how IA debits and credits will be accurately tracked.
c. How the state is doing quarterly tracking for all people subject to cost sharing.
d. A description, strategy and implementation plan of the beneficiary education and assistance process including copies of beneficiary notices, a description of beneficiaries’ rights and responsibilities, appeal rights and processes and instructions for beneficiaries about how to interact with state officials for discrepancies or other issues that arise regarding the beneficiaries’ IAs.
e. A strategy for educating participants on how to use the statements and understand that their health care expenditures will be covered.
f. For participants who are determined no longer eligible for the demonstration, a method for the distribution of credits.

X. APPEALS

Beneficiary safeguards of appeal rights will be provided by the State, including fair hearing rights. No waiver will be granted related to appeals. The State must ensure compliance with all federal and State requirements related to beneficiary appeal rights. Pursuant to the Intergovernmental Cooperation Act of 1968, the State may submit a state plan amendment delegating certain responsibilities to the Arkansas Insurance Department or another state agency.

XI. GENERAL REPORTING REQUIREMENTS

49. General Financial Requirements. The State must comply with all general financial requirements under Title XIX, including reporting requirements related to monitoring budget neutrality, set forth in Section XII of these STCs.

50. Reporting Requirements Related to Budget Neutrality. The State must comply with all reporting requirements for monitoring budget neutrality set forth in Section XII of these STCs.

51. Monitoring Calls. CMS will convene periodic conference calls with the State. The purpose of these calls is to discuss any significant actual or anticipated developments affecting the demonstration; including planning for future changes in the program or intent to further implement the Private Option beyond December 31, 2016. CMS will provide updates on any amendments or concept papers under review, as well as federal policies and issues that may affect any aspect of the demonstration. The State and CMS will jointly develop the agenda for the calls.

Areas to be addressed include, but are not limited to:

a. Transition and implementation activities;
b. Stakeholder concerns;
c. QHP operations and performance;
d. Enrollment;
e. Cost sharing;
f. Independence Accounts

g. Quality of care;

h. Beneficiary access,

i. Benefit package and wrap around benefits;

j. Audits;

k. Lawsuits;

l. Financial reporting and budget neutrality issues;

m. Progress on evaluation activities and contracts;

n. Related legislative developments in the State; and

o. Any demonstration changes or amendments the State is considering.

52. Quarterly Progress Reports. The State will provide quarterly reports to CMS.

a. The reports shall provide sufficient information for CMS to understand implementation progress of the demonstration, including the reports documenting key operational and other challenges, underlying causes of challenges, how challenges are being addressed, as well as key achievements and to what conditions and efforts successes can be attributed.

b. Monitoring and performance metric reporting templates are subject to review and approval by CMS. Where possible, information will be provided in a structured manner that can support federal tracking and analysis.

53. Compliance with Federal Systems Innovation. As MACBIS or other federal systems continue to evolve and incorporate 1115 waiver reporting and analytics, the State shall work with CMS to revise the reporting templates and submission processes to accommodate timely compliance with the requirements of the new systems.

54. Demonstration Annual Report. The annual report must, at a minimum, include the requirements outlined below. The State will submit the draft annual report no later than 90 days after the end of each demonstration year. Within 30 days of receipt of comments from CMS, a final annual report must be submitted for the demonstration year (DY) to CMS.

a. All items included in the quarterly report pursuant to STC 46 must be summarized to reflect the operation/activities throughout the DY;

b. Total annual expenditures for the demonstration population for each DY, with administrative costs reported separately;

c. Total contributions, withdrawals, balances, and credits related to IAs; and

d. Yearly enrollment reports for demonstration enrollees for each DY (enrollees include all individuals enrolled in the demonstration) that include the member months, as required to evaluate compliance with the budget neutrality agreement;

55. Final Report. Within 120 days following the end of the demonstration, the State must submit a draft final report to CMS for comments. The State must take into consideration CMS’ comments for incorporation into the final report. The final report is due to CMS no later than 120 days after receipt of CMS’ comments.

XII. GENERAL FINANCIAL REQUIREMENTS
This project is approved for Title XIX expenditures applicable to services rendered during the demonstration period. This section describes the general financial requirements for these expenditures.

56. Quarterly Expenditure Reports. The State must provide quarterly Title XIX expenditure reports using Form CMS-64, to separately report total Title XIX expenditures for services provided through this demonstration under section 1115 authority. CMS shall provide Title XIX FFP for allowable demonstration expenditures, only as long as they do not exceed the pre-defined limits on the costs incurred, as specified in section XII of the STCs.

57. Reporting Expenditures under the Demonstration. The following describes the reporting of expenditures subject to the budget neutrality agreement:

a. Tracking Expenditures. In order to track expenditures under this demonstration, the State will report demonstration expenditures through the Medicaid and State Children's Health Insurance Program Budget and Expenditure System (MBES/CBES), following routine CMS-64 reporting instructions outlined in section 2500 and Section 2115 of the SMM. All demonstration expenditures subject to the budget neutrality limit must be reported each quarter on separate forms CMS-64.9 WAIVER and/or 64.9P WAIVER, identified by the demonstration project number assigned by CMS (including the project number extension, which indicates the DY in which services were rendered or for which capitation payments were made). For monitoring purposes, and consistent with annual CSR reconciliation, cost settlements must be recorded on the appropriate prior period adjustment schedules (forms CMS-64.9 Waiver) for the summary line 10B, in lieu of lines 9 or 10C. For any other cost settlements (i.e., those not attributable to this demonstration), the adjustments should be reported on lines 9 or 10C, as instructed in the SMM. The term, “expenditures subject to the budget neutrality limit,” is defined below in STC 62.

b. Cost Settlements. For monitoring purposes, and consistent with annual CSR reconciliation, cost settlements attributable to the demonstration must be recorded on the appropriate prior period adjustment schedules (forms CMS-64.9P Waiver) for the summary sheet line 10B, in lieu of lines 9 or 10C. For any cost settlement not attributable to this demonstration, the adjustments should be reported as otherwise instructed in the SMM.

c. Premium and Cost Sharing Contributions. Premiums and other applicable cost sharing contributions from enrollees that are collected by the state from enrollees under the demonstration must be reported to CMS each quarter on Form CMS-64 summary sheet line 9.D, columns A and B. In order to assure that these collections are properly credited to the demonstration, premium and cost-sharing collections (both total computable and federal share) should also be reported separately by DY on the form CMS-64 narrative. In the calculation of expenditures subject to the budget neutrality expenditure limit, premium collections applicable to demonstration populations will be offset against...
expenditures. These section 1115 premium collections will be included as a manual adjustment (decrease) to the demonstration’s actual expenditures on a quarterly basis.

d. Pharmacy Rebates. Pharmacy rebates are not considered here as this program is not eligible.

e. Use of Waiver Forms for Medicaid. For each DY, separate Forms CMS-64.9 Waiver and/or 64.9P Waiver shall be submitted reporting expenditures for individuals enrolled in the demonstration, subject to the budget neutrality limit (Section XII of these STCs). The State must complete separate waiver forms for the following eligibility groups/waiver names:

   1. MEG 1 – “New Adult Group”

f. The first Demonstration Year (DY1) will begin on January 1, 2014. Subsequent DYS will be defined as follows:

<table>
<thead>
<tr>
<th>Demonstration Year 1 (DY1)</th>
<th>January 1, 2014</th>
<th>12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demonstration Year 2 (DY2)</td>
<td>January 1, 2015</td>
<td>12 months</td>
</tr>
<tr>
<td>Demonstration Year 3 (DY3)</td>
<td>January 1, 2016</td>
<td>12 months</td>
</tr>
</tbody>
</table>

58. Administrative Costs. Administrative costs will not be included in the budget neutrality limit, but the State must separately track and report additional administrative costs that are directly attributable to the demonstration, using Forms CMS-64.10 Waiver and/or 64.10P Waiver, with waiver name Local Administration Costs (“ADM”).

59. Claiming Period. All claims for expenditures subject to the budget neutrality limit (including any cost settlements resulting from annual reconciliation) must be made within 2 years after the calendar quarter in which the State made the expenditures. Furthermore, all claims for services during the demonstration period (including any cost settlements) must be made within 2 years after the conclusion or termination of the demonstration. During the latter 2-year period, the State must continue to identify separately net expenditures related to dates of service during the operation of the section 1115 demonstration on the Form CMS-64 and Form CMS-21 in order to properly account for these expenditures in determining budget neutrality.

60. Reporting Member Months. The following describes the reporting of member months for demonstration populations:

   a. For the purpose of calculating the budget neutrality expenditure cap and for other purposes, the State must provide to CMS, as part of the quarterly report required under STC 46, the actual number of eligible member months for the demonstration populations defined in STC 17. The State must submit a
statement accompanying the quarterly report, which certifies the accuracy of this information. To permit full recognition of “in-process” eligibility, reported counts of member months may be subject to revisions after the end of each quarter. Member month counts may be revised retrospectively as needed.

b. The term “eligible member months” refers to the number of months in which persons are eligible to receive services. For example, a person who is eligible for three months contributes three eligible member months to the total. Two individuals who are eligible for two months each contribute two eligible member months to the total, for a total of four eligible member months.

61. **Standard Medicaid Funding Process.** The standard Medicaid funding process must be used during the demonstration. The State must estimate matchable demonstration expenditures (total computable and federal share) subject to the budget neutrality expenditure cap and separately report these expenditures by quarter for each federal fiscal year on the Form CMS-37 for both the Medical Assistance Payments (MAP) and State and Local Administration Costs (ADM). CMS will make federal funds available based upon the State's estimate, as approved by CMS. Within 30 days after the end of each quarter, the State must submit the Form CMS-64 quarterly Medicaid expenditure report, showing Medicaid expenditures made in the quarter just ended. The CMS will reconcile expenditures reported on the Form CMS-64 quarterly with federal funding previously made available to the State, and include the reconciling adjustment in the finalization of the grant award to the State.

62. **Extent of FFP for the Demonstration.** Subject to CMS approval of the source(s) of the non-federal share of funding, CMS will provide FFP at the applicable federal matching rate for the demonstration as a whole as outlined below, subject to the limits described in STC 64:

a. Administrative costs, including those associated with the administration of the demonstration.

b. Net expenditures and prior period adjustments of the Medicaid program that are paid in accordance with the approved State plan.

c. Medical Assistance expenditures made under section 1115 demonstration authority, including those made in conjunction with the demonstration, net of enrollment fees, cost sharing, pharmacy rebates, and all other types of third party liability or CMS payment adjustments.

63. **Sources of Non-Federal Share.** The State must certify that the matching non-federal share of funds for the demonstration is state/local monies. The State further certifies that such funds shall not be used as the match for any other federal grant or contract, except as permitted by law. All sources of non-federal funding must be compliant with section 1903(w) of the Act and applicable regulations. In addition, all sources of the non-federal share of funding are subject to CMS approval.

a. CMS may review the sources of the non-federal share of funding for the demonstration at any time. The State agrees that all funding sources deemed unacceptable by CMS shall be addressed within the time frames set by CMS.

b. Any amendments that impact the financial status of the program shall require the State to provide information to CMS regarding all sources of the non-federal
share of funding.
c. The State assures that all health care-related taxes comport with section 1903(w) of the Act and all other applicable federal statutory and regulatory provisions, as well as the approved Medicaid State plan.

64. State Certification of Funding Conditions. The State must certify that the following conditions for non-federal share of demonstration expenditures are met:
   a. Units of government, including governmentally operated health care providers, may certify that State or local tax dollars have been expended as the non-federal share of funds under the demonstration.
   b. To the extent the State utilizes certified public expenditures (CPEs) as the funding mechanism for Title XIX (or under section 1115 authority) payments, CMS must approve a cost reimbursement methodology. This methodology must include a detailed explanation of the process by which the State would identify those costs eligible under Title XIX (or under section 1115 authority) for purposes of certifying public expenditures.
   c. To the extent the State utilizes CPEs as the funding mechanism to claim federal match for payments under the demonstration, governmental entities to which general revenue funds are appropriated must certify to the State the amount of such tax revenue (State or local) used to satisfy demonstration expenditures. The entities that incurred the cost must also provide cost documentation to support the State’s claim for federal match.
   d. The State may use intergovernmental transfers to the extent that such funds are derived from State or local tax revenues and are transferred by units of government within the State. Any transfers from governmentally operated health care providers must be made in an amount not to exceed the non-federal share of Title XIX payments.

Under all circumstances, health care providers must retain 100 percent of the reimbursement amounts claimed by the State as demonstration expenditures. Moreover, no pre-arranged agreements (contractual or otherwise) may exist between the health care providers and the State and/or local government to return and/or redirect any portion of the Medicaid payments. This confirmation of Medicaid payment retention is made with the understanding that payments that are the normal operating expenses of conducting business (such as payments related to taxes - including health care provider-related taxes - fees, and business relationships with governments that are unrelated to Medicaid and in which there is no connection to Medicaid payments) are not considered returning and/or redirecting a Medicaid payment.

XIII. MONITORING BUDGET NEUTRALITY FOR THE DEMONSTRATION

65. Limit on Title XIX Funding. The State shall be subject to a limit on the amount of federal Title XIX funding that the State may receive on selected Medicaid expenditures during the period of approval of the demonstration. The limit is determined by using the per capita cost method described in STC 63, and budget neutrality expenditure limits are set on a yearly basis with a cumulative budget neutrality expenditure limit for the length of the entire
demonstration. The data supplied by the State to CMS to set the annual caps is subject to review and audit, and if found to be inaccurate, will result in a modified budget neutrality expenditure limit. CMS’ assessment of the State’s compliance with these annual limits will be done using the Schedule C report from the CMS-64.

66. **Risk.** The State will be at risk for the per capita cost (as determined by the method described below) for demonstration populations as defined in STC 63, but not at risk for the number of enrollees in the demonstration population. By providing FFP without regard to enrollment in the demonstration populations, CMS will not place the State at risk for changing economic conditions that impact enrollment levels. However, by placing the State at risk for the per capita costs of current eligibles, CMS assures that the demonstration expenditures do not exceed the levels that would have been realized had there been no demonstration.

67. **Calculation of the Budget Neutrality Limit.** For the purpose of calculating the overall budget neutrality limit for the demonstration, separate annual budget limits will be calculated for each DY on a total computable basis, as described in STC63 below. The annual limits will then be added together to obtain a budget neutrality limit for the entire demonstration period. The federal share of this limit will represent the maximum amount of FFP that the State may receive during the demonstration period for the types of demonstration expenditures described below. The federal share will be calculated by multiplying the total computable budget neutrality limit by the Composite Federal Share, which is defined in STC 63 below.

68. **Demonstration Populations Used to Calculate the Budget Neutrality Limit.** For each DY, separate annual budget limits of demonstration service expenditures will be calculated as the product of the trended monthly per person cost times the actual number of eligible/member months as reported to CMS by the State under the guidelines set forth in STC 66. The trend rates and per capita cost estimates for each Mandatory Enrollment Group (MEG) for each year of the demonstration are listed in the table below.

<table>
<thead>
<tr>
<th>MEG</th>
<th>TREND</th>
<th>DY 1 - PMPM</th>
<th>DY 2 – PMPM</th>
<th>DY 3 – PMPM</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Adult Group</td>
<td>4.7%</td>
<td>$477.63</td>
<td>$500.08</td>
<td>$523.58</td>
</tr>
</tbody>
</table>

a. If the State’s experience of the take up rate for the new adult group and other factors that affect the costs of this population indicates that the PMPM limit described above in paragraph (a) may underestimate the actual costs of medical assistance for the new adult group, the State may submit an adjustment to paragraph (a), along with detailed expenditure data to justify this, for CMS review without submitting an amendment pursuant to STC 7. Adjustments to the PMPM limit for a demonstration year must be submitted to CMS by no later than October.
1 of the demonstration year for which the adjustment would take effect.

b. The budget neutrality cap is calculated by taking the PMPM cost projection for the above group in each DY, times the number of eligible member months for that group and DY, and adding the products together across DYs. The federal share of the budget neutrality cap is obtained by multiplying total computable budget neutrality cap by the federal share.

c. The State will not be allowed to obtain budget neutrality “savings” from this population.

69. Composite Federal Share Ratio. The Composite Federal Share is the ratio calculated by dividing the sum total of federal financial participation (FFP) received by the State on actual demonstration expenditures during the approval period, as reported through the MBES/CBES and summarized on Schedule C (with consideration of additional allowable demonstration offsets such as, but not limited to, premium collections) by total computable demonstration expenditures for the same period as reported on the same forms. Should the demonstration be terminated prior to the end of the extension approval period (see STC 8), the Composite Federal Share will be determined based on actual expenditures for the period in which the demonstration was active. For the purpose of interim monitoring of budget neutrality, a reasonable estimate of Composite Federal Share may be developed and used through the same process or through an alternative mutually agreed upon method.

70. Future Adjustments to the Budget Neutrality Expenditure Limit. CMS reserves the right to adjust the budget neutrality expenditure limit to be consistent with enforcement of impermissible provider payments, health care related taxes, new federal statutes, or policy interpretations implemented through letters, memoranda, or regulations with respect to the provision of services covered under the demonstration.

71. Enforcement of Budget Neutrality. CMS shall enforce budget neutrality over the life of the demonstration rather than on an annual basis. However, if the State’s expenditures exceed the calculated cumulative budget neutrality expenditure cap by the percentage identified below for any of the demonstration years, the State must submit a corrective action plan to CMS for approval. The State will subsequently implement the approved corrective action plan.

<table>
<thead>
<tr>
<th>Year</th>
<th>Cumulative target definition</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>DY 1</td>
<td>Cumulative budget neutrality limit plus:</td>
<td>3%</td>
</tr>
<tr>
<td>DY 2</td>
<td>Cumulative budget neutrality limit plus:</td>
<td>1.5%</td>
</tr>
<tr>
<td>DY 3</td>
<td>Cumulative budget neutrality limit plus:</td>
<td>0%</td>
</tr>
</tbody>
</table>

72. Exceeding Budget Neutrality. If at the end of the demonstration period the cumulative budget neutrality limit has been exceeded, the excess federal funds will be returned to CMS.
If the demonstration is terminated prior to the end of the budget neutrality agreement, an evaluation of this provision will be based on the time elapsed through the termination date.

**XIV. EVALUATION**

73. **Submission of Evaluation Design.** The State shall submit a draft evaluation design to CMS no later than 60 days after the award of the Demonstration. The evaluation design, including the budget and adequacy of approach to meet the scale and rigor of the requirements of STC 3, is subject to CMS approval. CMS shall provide comment within 30 days of receipt from the State. The State shall provide the Final Evaluation Design within 45 days of receipt of CMS comments. If CMS finds that the Final Evaluation Design adequately accommodates its comments, then CMS will approve the Final Evaluation Design within 30 days and attach to these STCs as Attachment A.

74. **Cost-effectiveness.** While not the only purpose of the evaluation, the core purpose of the evaluation is to support a determination as to whether the preponderance of the evidence about the costs and effectiveness of the Arkansas Private Option Demonstration using premium assistance when considered in its totality demonstrates cost effectiveness taking into account both initial and longer term costs and other impacts such as improvements in service delivery and health outcomes.
   a. The evaluation will explore and explain through developed evidence the effectiveness of the demonstration for each hypothesis, including total costs in accordance with the evaluation design as approved by CMS.
   b. Included in the evaluation will be examinations using a robust set of measures of provider access and clinical quality measures under the Private Option Demonstration compared to what would have happened for a comparable population in Medicaid fee-for-service.
   c. The State will compare total costs under the Private Option Demonstration to costs of what would have happened under a traditional Medicaid expansion. This will include an evaluation of provider rates, healthcare utilization and associated costs, and administrative expenses over time.
   d. The State will compare changes in access and quality to associated changes in costs within the Private Option. To the extent possible, component contributions to changes in access and quality and their associated levels of investment in Arkansas will be determined and compared to improvement efforts undertaken in other delivery systems.

75. **Evaluation Requirements.** The State shall engage the public in the development of its evaluation design. The evaluation design shall incorporate an interim and summative evaluation and will discuss the following requirements as they pertain to each:
   a. The scientific rigor of the analysis;
   b. A discussion of the goals, objectives and specific hypotheses that are to be tested;
   c. Specific performance and outcomes measures used to evaluate the demonstration’s impact;
   d. How the analysis will support a determination of cost effectiveness;
   e. Data strategy including sources of data, sampling methodology, and how data
will be obtained;
  f. The unique contributions and interactions of other initiatives; and 
g. How the evaluation and reporting will develop and be maintained.

The demonstration evaluation will meet the prevailing standards of scientific and academic 
rigor, as appropriate and feasible for each aspect of the evaluation, including standards for 
the evaluation design, conduct, and interpretation and reporting of findings. The 
demonstration evaluation will use the best available data; use controls and adjustments for 
and reporting of the limitations of data and their effects on results; and discuss the 
generalizability of results.

The State shall acquire an independent entity to conduct the evaluation. The evaluation 
design shall discuss the State’s process for obtaining an independent entity to conduct the 
evaluation, including a description of the qualifications the entity must possess, how the State 
will assure no conflict of interest, and a budget for evaluation activities.

76. Evaluation Design. The Evaluation Design shall include the following core components to 
be approved by CMS:
  a. Research questions and hypotheses: This includes a statement of the specific 
research questions and testable hypotheses that address the goals of the 
demonstration. At a minimum, the research questions shall address the goals of 
 improving access, reducing churning, improving quality of care thereby leading 
 to enhanced health outcomes, and lowering costs. The research questions will 
 have appropriate comparison groups and may be studied in a time series. The 
 analyses of these research questions will provide the basis for a robust assessment 
 of cost effectiveness.

The following are among the hypotheses to be considered in 
development of the evaluation design and will be included in the design 
as appropriate:
  i. Premium Assistance beneficiaries will have equal or better 
access to care, including primary care and specialty physician 
networks and services.
  ii. Premium Assistance beneficiaries will have equal or better 
access to preventive care services.
  iii. Premium Assistance beneficiaries will have lower non-emergent 
use of emergency room services.
  iv. Premium Assistance beneficiaries will have fewer gaps in 
insurance coverage.
  v. Premium Assistance beneficiaries will maintain continuous 
access to the same health plans, and will maintain continuous 
access to providers.
  vi. Premium Assistance beneficiaries, including those who become 
able eligible for Exchange Marketplace coverage, will have fewer 
gaps in plan enrollment, improved continuity of care, and 
resultant lower administrative costs.
vii. Premium Assistance beneficiaries will have lower rates of potentially preventable emergency department and hospital admissions.

viii. Premium assistance beneficiaries will report equal or better satisfaction in the care provided.

ix. Premium Assistance beneficiaries who are young adults eligible for EPSDT benefits will have at least as satisfactory and appropriate access to these benefits.

x. Premium Assistance beneficiaries will have appropriate access to non-emergency transportation.

xi. Premium Assistance will reduce overall premium costs in the Exchange Marketplace and will increase quality of care.

xii. The cost for covering Premium Assistance beneficiaries will be comparable to what the costs would have been for covering the same expansion group in Arkansas Medicaid fee-for-service in accordance with STC 69 on determining cost effectiveness and other requirements in the evaluation design as approved by CMS.

b. Study Design: The design will consider through its research questions and analysis plan the appropriate application of the following dimensions of access and quality:

i. Comparisons of provider networks;

ii. Consumer satisfaction and other indicators of consumer experience;

iii. Provider experience; and

iv. Evidence of improved access and quality across the continuum of coverage and related health outcomes.

The design will include a description of the quantitative and qualitative study design (e.g., cohort, controlled before-and-after studies, interrupted time series, case-control, etc.), including a rationale for the design selected. The discussion will include a proposed baseline and approach to comparison; examples to be considered as appropriate include the definition of control and/or comparison groups or within-subjects design, use of propensity score matching and difference in differences design to adjust for differences in comparison populations over time. The discussion will include approach to benchmarking, and should consider applicability of national and state standards. The application of sensitivity analyses as appropriate shall be considered.

c. Study Population: This includes a clear description of the populations impacted by each hypothesis, as well as the comparison population, if applicable. The discussion may include the sampling methodology for the selected population, as well as support that a statistically reliable sample size is available.

d. Access, Service Delivery Improvement, Health Outcome, Satisfaction and Cost Measures: This includes identification, for each hypothesis, of quantitative and/or qualitative process and/or outcome measures that
adequately assess the effectiveness of the Demonstration. Nationally recognized measures may be used where appropriate. Measures will be clearly stated and described, with the numerator and denominator clearly defined. To the extent possible, the State may incorporate comparisons to national data and/or measure sets. A broad set of performance metrics may be selected from nationally recognized metrics, for example from sets developed by the Center for Medicare and Medicaid Innovation, for meaningful use under HIT, and from the Medicaid Core Adult sets. Among considerations in selecting the metrics shall be opportunities identified by the State for improving quality of care and health outcomes, and controlling cost of care.

e. Data Collection: This discussion shall include:
A description of the data sources; the frequency and timing of data collection; and the method of data collection. The following shall be considered and included as appropriate:
   i. Medicaid encounters and claims data,
   ii. Enrollment data, and
   iii. Consumer and provider surveys
f. Assurances Needed to Obtain Data: The design report will discuss the State’s arrangements to assure needed data to support the evaluation design are available.

g. Data Analysis: This includes a detailed discussion of the method of data evaluation, including appropriate statistical methods that will allow for the effects of the Demonstration to be isolated from other initiatives occurring in the State. The level of analysis may be at the beneficiary, provider, and program level, as appropriate, and shall include population stratifications, for further depth. Sensitivity analyses may be used when appropriate. Qualitative analysis methods may also be described, if applicable.

h. Timeline: This includes a timeline for evaluation-related milestones, including those related to procurement of an outside contractor, if applicable, and deliverables.

i. Evaluator: This includes a discussion of the State’s process for obtaining an independent entity to conduct the evaluation, including a description of the qualifications that the selected entity must possess; how the state will assure no conflict of interest, and a budget for evaluation activities.

77. Interim Evaluation Report. The State is required to submit a draft Interim Evaluation Report 90 days following completion of year two of the demonstration. The Interim Evaluation Report shall include the same core components as identified in STC 73 for the Summative Evaluation Report and should be in accordance with the CMS approved evaluation design. CMS will provide comments within 60 days of receipt of the draft Interim Evaluation Report. The State shall submit the final Interim Evaluation Report within 30 days after receipt of CMS’ comments.

78. Summative Evaluation Report. The Summative Evaluation Report will include analysis of data from Year Three of the Premium Assistance Demonstration. The State is required to
submit a preliminary summative report in 180 days of the expiration of the demonstration including documentation of outstanding assessments due to data lags to complete the summative evaluation. Within 360 days of the expiration date of the Premium Assistance Demonstration, the State shall submit a draft of the final summative evaluation report to CMS. CMS will provide comments on the draft within 60 days of draft receipt. The State should respond to comments and submit the Final Summative Evaluation Report within 30 days.

79. The Final Summative Evaluation Report shall include the following core components:
   a. Executive Summary. This includes a concise summary of the goals of the Demonstration; the evaluation questions and hypotheses tested; and key findings including whether the evaluators find the demonstration to be budget neutral and cost effective, and policy implications.
   b. Demonstration Description. This includes a description of the Demonstration programmatic goals and strategies, particularly how they relate to budget neutrality and cost effectiveness.
   c. Study Design. This includes a discussion of the evaluation design employed including research questions and hypotheses; type of study design; impacted populations and stakeholders; data sources; and data collection; analysis techniques, including controls or adjustments for differences in comparison groups, controls for other interventions in the State and any sensitivity analyses, and limitations of the study.
   d. Discussion of Findings and Conclusions. This includes a summary of the key findings and outcomes, particularly a discussion of cost effectiveness, as well as implementation successes, challenges, and lessons learned.
   e. Policy Implications. This includes an interpretation of the conclusions; the impact of the Demonstration within the health delivery system in the State; the implications for State and Federal health policy; and the potential for successful Demonstration strategies to be replicated in other State Medicaid programs.
   f. Interactions with Other State Initiatives. This includes a discussion of this demonstration within an overall Medicaid context and long range planning, and includes interrelations of the demonstration with other aspects of the State’s Medicaid program, and interactions with other Medicaid waivers, the SIM award and other federal awards affecting service delivery, health outcomes and the cost of care under Medicaid.

80. State Presentations for CMS. The State will present to and participate in a discussion with CMS on the final design plan, post approval, in conjunction with STC 71. The State will present on its interim evaluation in conjunction with STC 72. The State will present on its summative evaluation in conjunction with STC 73.

   a. For a period of 24 months following CMS approval of the Summative Evaluation Report, CMS will be notified prior to the public release or presentation of these
reports and related journal articles, by the State, contractor or any other third party. Prior to release of these reports, articles and other documents, CMS will be provided a copy including press materials. CMS will be given 30 days to review and comment on journal articles before they are released. CMS may choose to decline some or all of these notifications and reviews.

82. **Electronic Submission of Reports.** The State shall submit all required plans and reports using the process stipulated by CMS, if applicable.

83. **Cooperation with Federal Evaluators.** Should CMS undertake an evaluation of the demonstration or any component of the demonstration, or an evaluation that is isolating the effects of Premium Assistance, the State shall cooperate fully with CMS and its contractors. This includes, but is not limited to, submitting any required data to CMS or the contractor in a timely manner and at no cost to CMS or the contractor.

84. **Cooperation with Federal Learning Collaboration Efforts.** The State will cooperate with improvement and learning collaboration efforts by CMS.

85. **Evaluation Budget.** A budget for the evaluation shall be provided with the evaluation design. It will include the total estimated cost, as well as a breakdown of estimated staff, administrative and other costs for all aspects of the evaluation such as any survey and measurement development, quantitative and qualitative data collection and cleaning, analyses, and reports generation. A justification of the costs may be required by CMS if the estimates provided do not appear to sufficiently cover the costs of the design or if CMS finds that the design is not sufficiently developed.

86. **Deferral for Failure to Provide Summative Evaluation Reports on Time.** The State agrees that when draft and final Interim and Summative Evaluation Reports are due, CMS may issue deferrals in the amount of $5,000,000 if they are not submitted on time to CMS or are found by CMS not to be consistent with the evaluation design as approved by CMS.

**XV. MONITORING**

87. **Evaluation Monitoring Protocol.** The State shall submit for CMS approval a draft monitoring protocol no later than 60 days after the award of the Demonstration. The protocol is subject to CMS approval. CMS shall provide comment within 30 days of receipt from the State. The State shall provide the final protocol within 30 days of receipt of CMS comments. If CMS finds that the final protocol adequately accommodates its comments, then CMS will approve the final protocol within 30 days.

   a. The monitoring protocol, including metrics and network characteristics shall align with the CMS approved evaluation design.

   b. The State shall make the necessary arrangements to assure that the data needed from the health plans to which premium assistance will apply, and data needed from other sources, are available as required by the CMS approved monitoring protocol.

   c. The monitoring protocol and reports shall be posted on the State Medicaid
website within 30 days of CMS approval.

88. Quarterly Evaluation Operations Report. The State will provide quarterly reports to CMS.
   a. The reports shall provide sufficient information for CMS to understand implementation progress of the demonstration and whether there has been progress toward the goals of the demonstration, including the reports will document key operational and other challenges, to what they attribute the challenges and how the challenges are being addressed, as well as key achievements and to what conditions and efforts they attribute the successes.

89. Annual Discussion with CMS. In addition to regular monitoring calls, the State shall on an annual basis present to and participate in a discussion with CMS on implementation progress of the demonstration including progress toward the goals, and key challenges, achievements and lessons learned.

90. Rapid Cycle Assessments. The State shall specify for CMS approval a set of performance and outcome metrics and network characteristics, including their specifications, reporting cycles, level of reporting (e.g., the State, health plan and provider level, and segmentation by population) to support rapid cycle assessment in trends under premium assistance and Medicaid fee-for-service, and for monitoring and evaluation of the demonstration.

XVI. HEALTH INFORMATION TECHNOLOGY AND PREMIUM ASSISTANCE

91. Health Information Technology (Health IT). The State will use HIT to link services and core providers across the continuum of care to the greatest extent possible. The State is expected to achieve minimum standards in foundational areas of HIT and to develop its own goals for the transformational areas of HIT use.
   a. Health IT: Arkansas must have plans for health IT adoption for providers. This will include creating a pathway (and/or a plan) to adoption of certified EHR technology and the ability to exchange data through the State’s health information exchanges. If providers do not currently have this technology, there must be a plan in place to encourage adoption, especially for those providers eligible for the Medicare and Medicaid EHR Incentive Program.
   b. The State must participate in all efforts to ensure that all regions (e.g., counties or other municipalities) have coverage by a health information exchange. Federal funding for developing HIE infrastructure may be available, per State Medicaid Director letter #11-004, to the extent that allowable costs are properly allocated among payers. The State must ensure that all new systems pathways efficiently prepare for 2014 eligibility and enrollment changes.
   c. All requirements must also align with Arkansas’ State Medicaid HIT Plan and other planning efforts such as the ONC HIE Operational Plan.

XVII. T-MSIS REQUIREMENTS

On August 23, 2013, a State Medicaid Director Letter entitled, “Transformed Medicaid
Statistical Information System (T-MSIS) Data”, was released. It states that all States are expected to demonstrate operational readiness to submit T-MSIS files, transition to T-MSIS, and submit timely T-MSIS data by July 1, 2014. Among other purposes, these data can support monitoring and evaluation of the Medicaid program in Arkansas against which the premium assistance demonstration will be compared.

Should the MMIS fail to maintain and produce all federally required program management data and information, including the required T-MSIS, eligibility, provider, and managed care encounter data, in accordance with requirements in the State Medicaid Manual Part 11, FFP may be suspended or disallowed as provided for in federal regulations at 42 CFR 433 Subpart C, and 45 CFR Part 95.
Arkansas Health Care Independence Program ("Private Option")
Proposed Evaluation for Section 1115 Demonstration Waiver

February 20, 2014
The State of Arkansas is implementing a novel approach to expanding coverage for individuals newly eligible for Medicaid under the Patient Protection and Affordable Care Act (PPACA). Through a Section 1115 demonstration waiver, the State will utilize premium assistance to secure private health coverage offered on the newly formed individual health insurance marketplace (the Marketplace) to individuals who are ages 19–64 years with incomes at or below 138 percent of the federal poverty level (FPL). As of April 2013, the Health Care Independence Program (HCIP), as it is formally known, was projected to enroll approximately 211,000 people. While this projection only included individuals who were currently without insurance, it is also likely that there will be some individuals who are insured but meet the requirements and may therefore enroll.

Authorized by the Arkansas Health Care Independence Act of 2013, the HCIP premium assistance approach is commonly referred to as the “Private Option.” This approach is designed to achieve equal access, network availability, quality of care, and opportunities for improved outcomes for HCIP enrollees (i.e., those who would be eligible for traditional, fee-for-service Medicaid through PPACA expansion) when compared with their privately insured counterparts. The waiver demonstration for use of the premium assistance approach through the state’s new Health Insurance Marketplace (“the Marketplace”) established by the PPACA requires an evaluation to characterize the experience and determine the impact of this new coverage strategy.

While not the only purpose, the core purpose of the evaluation is to support a cost-effectiveness determination. To determine whether or not the Arkansas HCIP is cost effective, the totality of both initial and longer-term costs and other impacts for HCIP enrollees, such as improvements in service delivery and health outcomes, will be compared with cost, service measures, and health outcomes that would have been expected for the same enrollees in the traditional Medicaid program.

1. Background

Arkansas is a largely rural state with significant health care challenges including high health-risk burdens; low median family income; high rates of uninsured individuals; and limited provider capacity, particularly in non-urban areas of the state. Arkansas’s Medicaid program currently has one of the most stringent eligibility thresholds in the nation, largely limiting coverage to the aged, disabled, and parents with extremely low incomes and limited assets.

Arkansas is implementing the Marketplace through a state–federal partnership model with the state conducting plan management and consumer outreach and education. There are seven distinct Marketplace service areas across the state; within each area two to four carriers have committed to offer qualified health plans (QHPs). HCIP authorizing legislation provides for the use of PPACA funds for premium assistance and requires all Marketplace participating carriers to enroll newly eligible HCIP adults in their QHP offerings.

Working closely with the Division of Medicaid Services within the Arkansas Department of Human Services, the Arkansas Insurance Department has issued guidance and directives to achieve plan offerings that conform to Centers for Medicaid and Medicare Services (CMS) and Center for

---

Consumer Information and Insurance Oversight (CCIIO) requirements for plan actuarial value, cost-sharing reductions, benefit components, and reporting requirements.

2. Section 1115 Waiver: The Health Care Independence Act

The U.S. Supreme Court’s June 2012 ruling allowed states to decide whether or not to extend Medicaid benefits to their citizens who qualify under PPACA expansion. Members of the Arkansas 89th General Assembly took a bipartisan approach to this prospect and crafted a unique proposal that will use federal Medicaid funding to provide health care benefits to individuals eligible under the PPACA expansion. These individuals will receive coverage via private insurance plans offered through the Marketplace. Commonly known as the “Private Option,” the Health Care Independence Act and its accompanying appropriation was passed by the required three-fourths majority vote in both the Arkansas House and Senate and signed into law by Governor Mike Beebe on April 23, 2013.

The act calls on the Arkansas Department of Human Services (DHS) to explore program design options that reform Arkansas Medicaid so that it is a fiscally sustainable, cost-effective, personally responsible, and opportunity-driven program using competitive and value-based purchasing to:

- maximize the available service options;
- promote accountability, personal responsibility, and transparency;
- encourage and reward healthy outcomes and responsible choices; and
- promote efficiencies that will deliver value to the taxpayers.

Arkansas DHS has secured approval of a waiver demonstration application submitted to the U.S. Department of Health and Human Services specifically designed to implement the act’s requirements.

Expanding the existing state Medicaid program to nearly all individuals with incomes at or below 138 percent of the federal poverty level (FPL), as set out in the PPACA, would have presented several challenges for Arkansas. First, the newly eligible adults are likely to have frequent income fluctuations that lead to changes in eligibility. In fact, studies indicate that more than 35 percent of adults will experience a change in eligibility within six months of their eligibility determination. Without carefully crafted policy and operational interventions, these frequent changes in eligibility could lead to:

- coverage gaps during which individuals lack any health coverage, even though they are eligible for coverage under Title XIX or Advanced Payment Tax Credits (collectively, along with CHIP, “Insurance Affordability Programs” or “IAPs”) and/or
- disruptive changes in benefits, provider networks, premiums, and cost-sharing as individuals transition from one IAP to another.

---

In addition, if the traditional Medicaid program were expanded to include all individuals with incomes at or below 138 percent FPL, Arkansas would have increased its state Medicaid program population by nearly 40 percent. The state’s existing network of participating fee-for-service Medicaid providers is already at capacity. As a result, Arkansas would have been faced with the challenge of increasing providers’ capacity to serve Medicaid beneficiaries to ensure adequate access to care.

In short, absent the federal waiver to implement the act, a traditional Medicaid expansion would rely on the existing Medicaid delivery system and perpetuate an inadequately coordinated approach to patient care for those newly eligible under the PPACA. While reforms associated with the Arkansas Payment Improvement Initiative (www.paymentinitiative.org) are designed to address the quality and cost of care in Medicaid and the private market, these reforms do not include increased payment rates needed to expand provider access for the 250,000 new adults who will enroll through the expansion.

A. HCIP Eligibility

The act extends coverage to newly eligible individuals who meet the following requirements:

- Adults between the ages of 19 and 65 years.
- A U.S. citizen or qualified, documented alien.
- Those not otherwise eligible for Medicaid under current eligibility requirements, such as those who are disabled, children, dual eligible, or are parents earning less than 17 percent FPL.
- Those not enrolled in Medicare.
- Those not incarcerated.

Essentially, the expansion is to childless adults earning between 1 percent and 138 percent of the FPL or parents who earn between 17 percent and 138 percent of the FPL.

B. HCIP Funding and Costs

The act allows the program to continue in perpetuity during the period of the waiver that has been submitted by the Arkansas DHS but is contingent upon annual appropriations by the Arkansas General Assembly. The waiver has been approved by U.S. DHHS for 2014–2016. The costs of the program are shared by the federal government through provisions of the PPACA. In years 2014–2016 the federal share will be 100%, followed by 95%, 94%, 93%, and 90% in years 2017, 2018, 2019, and 2020 and beyond, respectively. The state will provide the additional funding beginning in 2017.

In ACHI’s comparison of options for extending health insurance coverage to low-income Arkansans, the impact of the Health Care Independence Act on the state and federal budgets were estimated as follows.6

State budget:

- State general revenue obligations will be reduced by ~$40 million per year due to avoided uncompensated care.6

---

Proposed Evaluation Strategy Page 5 of 28

Arkansas Health Care Independence Program ("Private Option")
Proposed Evaluation for Section 1115 Demonstration Waiver February 2014

- State spending will increase by $47 million in FY15 with 100% federal support and $275 million in FY20 at 10% state/90% federal match requirement for expansion population.7
- Additional premium tax revenue over the first 10 years of the Private Option will generate $436 million.7
- The net impact on the state budget is a favorable $670 million over 10 years.7

Federal budget:
- The federal government will benefit from ~$1.1 billion per year in new taxes and Medicare payment reductions.8
- The increase in federal costs for expansion and ongoing Medicaid is projected at $1.59 billion in FY15 and $2.35 billion in FY20.6
- The net impact on the federal budget approaches neutrality over 10 years (not including economic stimulant effects).6

C. Private Plans Available to Arkansans

The act requires the state to take an integrated and market-based approach to covering low-income Arkansans by offering new coverage opportunities, stimulating market competition, and offering alternatives to the existing Medicaid program.3

An early benefit of this approach can be found in the number of private insurance companies who have expressed their intention to offer plans across the state (Figure 1).9 As a result, Arkansas citizens living in each region of the state will have a choice of plans from at least two companies.10 In comparison, neighboring Mississippi had 36 counties without a single plan offered through its health insurance marketplace and has only two participating insurance companies.

Figure 1: Number of Issuers Offering Individual Plans by Service Area

<table>
<thead>
<tr>
<th>Issuers:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Arkansas Blue Cross Blue Shield of Little Rock</td>
</tr>
<tr>
<td>• National Blue Cross Blue Shield Multi-state Plan</td>
</tr>
<tr>
<td>• QCA Health Plan of Little Rock (QualChoice of Arkansas Inc.)</td>
</tr>
<tr>
<td>• Arkansas Health &amp; Wellness Solutions (Ambetter)</td>
</tr>
</tbody>
</table>

D. Arkansas’ HCIP Proposal

The Private Option is crafted to address the provider capacity and care coordination issues noted above. By using premium assistance to purchase qualified health plans (QHPs) offered in the Health Insurance Marketplace, Arkansas will promote continuity of coverage and expand provider access, while improving efficiency and accelerating multi-payer cost-containment and quality-improvement efforts. Further, it is expected that by providing a source of payment to an estimated 250,000 currently uninsured citizens, an economic impetus will be created that will lead to an increase in the supply of health care services available, particularly in currently underserved areas counties. In fact, a recent study sponsored by ACHI and conducted by the RAND Corporation indicated that full implementation of expanded coverage under the PPACA would result in a $550 million annual increase in Arkansas’s gross domestic product and the creation of 6,200 jobs, with the majority of this impact accruing to rural Arkansas where the uninsured rates are relatively higher.

Continuity of Coverage

For households with members eligible for coverage under Title XIX or the Health Insurance Marketplace as well as those who have income fluctuations that cause their eligibility to change year to year, the act will create continuity of health plans and provider networks. Households can stay enrolled in the same plan regardless of whether their coverage is subsidized through Medicaid, CHIP (after year one), or Advanced Payment Tax Credits.

Rational Provider Reimbursements and Improved Provider Access

Arkansas’s network of providers serving existing Medicaid beneficiaries has fundamental limitations restricting capacity to serve individuals newly eligible under the ACA. First, Arkansas Medicaid’s reimbursement rates are generally lower than Medicare or commercial payers, causing some providers to forgo participation in the program and others to “cross-subsidize” their Medicaid patients by charging more to private insurers. Second, due to restrictive eligibility limitations except for children, pregnant women, the dual eligible population, and select services (e.g., family planning), the Medicaid network for adult services has capacity limitations. The act’s intent through the use of QHPs is to expand provider access for the newly eligible adult population and reduce the need for providers to cross-subsidize. Through the HCIP, the state expects to avoid inflationary pressure on existing Medicaid rates to establish required access and provide deflationary relief in the Marketplace by reducing cross-subsidization.

Integration and Efficiency

Arkansas is taking an integrated and market-based approach to covering Arkansans, rather than relying on a system for insuring lower-income families that is separate and duplicative. The transition to private markets under this program is an efficient way to capitalize on the enhanced market competition and to cover Arkansans who often have income fluctuations.

---

"All Payer" Health Care Reform

Arkansas is at the forefront of payment innovation and delivery system reform, and the Health Care Independence Act will accelerate and leverage the state’s Arkansas Health Care Payment Improvement Initiative by increasing the number of carriers participating in the effort, and the number of privately insured Arkansans who benefit from a direct application of these reforms.

3. Evaluation Strategy

A. Goals and Objectives

The HCIP programmatic goals and objectives include successful enrollment, enhanced access, improved quality of care and clinical outcomes, and enhanced continuity of coverage and care at times of reenrollment and income fluctuation. These goals and objectives must be achieved within a cost-effective framework for the Medicaid program compared with what would have occurred if the state had provided coverage for the same expansion group in Arkansas Medicaid’s traditional fee-for-service delivery system.

Figure 2: Arkansas Demonstration Waiver Evaluation Logic Model

New enrollees will successfully enroll through the Marketplace, state enrollment portal, and targeted outreach efforts (e.g., Supplemental Nutrition Assistance Program participant engagement). Compared with what would have been in a traditional Medicaid expansion, HCIP enrollees will receive coverage that improves access to providers and health care services by using carrier networks with provider reimbursements under deflationary pressure, thereby reducing payment differentials between Medicaid and privately insured individuals. Through this improved access, newly eligible HCIP individuals will receive more appropriate care including prevention, chronic disease management, and therapeutic interventions leading to better clinical outcomes. At times of reenrollment and/or changes in family income, individuals will have a greater ability to continue
coverage with the same carrier and clinical relationships with the same providers, which will lead to more seamless transitions and continuity of care. Finally, the enhancements to HCIP clients’ experiences described above will be assessed to determine the cost effectiveness of the HCIP demonstration waiver for Medicaid and the broader impact on the health care system.

**B. Hypotheses**

Research questions of interest identified in the development and approval process for the HCIP waiver include those examining the goals of improving access, improving care and outcomes, reducing churning, and lowering costs. Appendix 1 provides a table that includes a description of each of the original 12 hypotheses outlined in STC #70 that have been re-organized into the following four categories:

1. **HCIP beneficiaries will have equal or better access to health care compared with what they would have otherwise had in the Medicaid fee-for-service system over time.** Access will be evaluated using the following measures:
   a. Use of primary care and specialty physician services, including analysis of provider networks
   b. Use of emergency room services (including emergent and non-emergent use)
   c. Potentially preventable emergency department and hospital admissions
   d. EPSDT benefit access for young, eligible adults
   e. Non-emergency transportation access

2. **HCIP beneficiaries will have equal or better care and outcomes compared with what they would have otherwise had in the Medicaid fee-for-service system over time.** Health care and outcomes will be evaluated using the following measures:
   a. Use of preventive and health care services
   b. Experience with the care provided
   c. Use of emergency room services* (including emergent and non-emergent use)
   d. Potentially preventable emergency department and hospital admissions*

3. **HCIP beneficiaries will have better continuity of care compared with what they would have otherwise had in the Medicaid fee-for-service system over time.** Continuity will be evaluated using the following measures:
   a. Gaps in insurance coverage
   b. Maintenance of continuous access to the same health plans
   c. Maintenance of continuous access to the same providers

4. **Services provided to HCIP beneficiaries will prove to be cost effective.** Cost effectiveness will be evaluated using findings above in combination with the following costs determinations:
   a. Administrative costs for the HCIP beneficiaries, including those who become eligible for Marketplace coverage
   b. Overall premium costs in the Marketplace
c. Cost for covering HCIP beneficiaries compared with costs expected for covering the same expansion group in Arkansas fee-for-service Medicaid

*The outcomes of interest and evaluation approaches associated with hypotheses 2c and 2d are shared with 1b and 1c. They are listed here, but will not be replicated throughout the rest of this document to avoid redundancy.

C. Metrics and Data Available

The following sets of metrics will be used throughout the evaluation. Appendix 2 provides a detailed description of each candidate metric including the original definition from the original sources (arranged by source across Appendices 2A, 2B, 2C, and 2D). Appendix 3 provides a table with a complete list of each selected metric with the targeted set of hypotheses it will support.

While these metrics will be the main set for consideration, further refinement is expected after the contractor is selected and preliminary data become available. For example, as a first step the analytic team will need to generate power analyses based on the enrolled populations after the first and second year of the HCIP to determine whether or not there are sufficient sample sizes to support the use of disease specific and age specific metrics. It is anticipated that there will be a core set of measures selected from this larger group that will be used to answer a majority of the questions, while additional measures will be used to supplement these findings. These details will be examined in consultation with the study team and CMS upon initial examination of the enrolled populations and the data available at the start of the evaluation in year 2.

Enrollment

We anticipate enrollment data to be available for HCIP, subsidized tax credit, and full-cost participants in the Marketplace. In addition to enrollment numbers, the method of enrollment—Federally Facilitated Marketplace (FFM), state-based portal, or outreach (e.g., SNAP enrollment)—and the geographic location of enrollees will provide information on the success of outreach and enrollment efforts across the state. Indicators considered for monitoring include the following:

- Total and subgroup enrollment within carrier (e.g., market penetration)
- Total and subgroup enrollment within each plan (e.g., plan differentiation)
- Total and subgroup enrollment within each method of entry (e.g., enrollment path)
- Total and subgroup enrollment within each market (e.g., geographic uptake variation)

At reenrollment, both the proportion of enrollees who are maintained in HCIP and those who successfully transition coverage as a result of family income changes (either into FFM or from the FFM) will be of key interest. Conversely, those who fail to transition and contribute to “churn”—the discontinuity of coverage due to income eligibility for various programs—will also be monitored as these are the cases that the HCIP is explicitly designed to minimize. Transitions across coverage periods will result in maintenance within the same plan or intentional decisions to change plans. Importantly, the demonstration will assess these types of transitions not only across plan year but also as individuals transition across the 138 percent FPL line into and out of Medicaid eligibility. Orderly transitions based on individual choice are expected and would not indicate a negative event. Disruptions in coverage at transition points are the basis for hypotheses related to continuity and churn. Potential indicators of interest for development and use include the following:

- **Continuity**: Maintenance of enrollment within program, within plan, and across re-enrollment periods without disruption of coverage
• **Reduced churn**: Maintenance of enrollment between programs (e.g., FFM vs. HCIP), within plan, and across re-enrollment periods without disruption of coverage.

These data will primarily be used to address hypotheses related to continuity of care.

**Medicaid Adult Core Set**

The Medicaid Adult Core Set is a set of health quality measures identified by CMS in partnership with the Agency for Healthcare Research and Quality (AHRQ) ([http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Quality-of-Care/Downloads/Medicaid-Adult-Core-Set-Manual.pdf](http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Quality-of-Care/Downloads/Medicaid-Adult-Core-Set-Manual.pdf)). We will use this as our base set of health indicator measures for the evaluation and supplement with additional indicators to address additional hypotheses. See Appendix 2A for a detailed description of each metric.

**HEDIS**

The Healthcare Effectiveness Data and Information Set (HEDIS) is one of the most widely used sets of health care performance measures by health plans in the United States to compare how well plans perform in quality of care, access to care, and patient experience with the health plan and plan physicians. National benchmarks and both national and regional thresholds for HEDIS measures and HEDIS/CAHPS survey results are used to score health plans annually. The National Committee for Quality Assurance (NCQA) develops and maintains the measurement set annually.

For the purposes of this evaluation, we propose a subset of candidate measures from HEDIS that include quality of care, access to care, and patient experience measures. See Appendix 2B for definitions of selected metrics and Appendix 3 for a complete list of candidate metrics and their corresponding hypotheses.

**CAHPS**

Nationwide experience with the Consumer Assessment of Health Plan Survey (CAHPS) has led to important new insights into patient experiences with care both for the Medicaid and the commercially insured populations. Various CAHPS surveys are available that ask consumers and patients to report on their experiences with health care and cover important topics including quality of care, access to care, and experience with care. Surveys are available in the public domain.

The Arkansas Foundation for Medical Care is the current contractor that collects CAHPS for the Arkansas Medicaid program every two years. They use the CAHPS 5.0H Medicaid Adult survey version. These surveys contain the following categories of metrics that could be used for the current evaluation (see Appendix 2C and 2D for background on CAHPS and Appendix 3 for the candidate list of CAHPS metrics and corresponding hypotheses):

- Access to and availability of services
- Consistency of care providers and networks
- Use of primary and specialty care services
- Experience with care

For the purpose of this evaluation, CAHPS will be collected in the second quarter of demonstration year 2 (DY2) and DY3. A stratified sampling procedure will be used to ensure representative participants from each of the geographic regions of the state, as well as age and insurance groups (i.e., traditional Medicaid vs. HCIP).
D. Design Approaches

We propose four strategic approaches to address the hypotheses within this evaluation. These approaches will utilize different comparison groups, metrics, and statistical methods to address the research questions. Importantly, the state is stimulating major health system reform through its multi-payer payment improvement initiative consisting of patient-centered medical homes, payments for episodes of care, and development of health homes for targeted populations. Efforts to isolate the effect of the demonstration from other market transition issues will require thoughtful consideration. In addition, risk adjustment for both family income and health care burden will be a challenge to isolating the effects of HCIP throughout the evaluation. Modeling may be required using family income as a variable to control for relationships associated with financial status. Use of the health plan risk mitigation strategies of HHS—determination of plan eligibility or obligations under the risk corridor, reinsurance, or risk adjustment methodologies—could provide an avenue for developing more robust modeling controlling for confounding factors that could influence outcomes.

The following sections provide information about each of the four major approaches, including the proposed comparison group(s), metrics, and statistical methods. See Appendix 4 for a table of all hypotheses with corresponding candidate metrics and design approaches.

D1. Statewide Comparisons

This approach will compare all individuals in the HCIP to individuals enrolled in traditional Medicaid, controlling for region and individual demographics. Arkansas Medicaid identifies individuals as eligible for services in conjunction with the state’s DHS county offices or District Social Security Offices. The Social Security Administration automatically sends Supplemental Security Income (SSI) recipient information to DHS. The restricted eligibility for this program depends on age, income, and assets. Traditionally, the only adults who could qualify for Medicaid were the elderly, disabled, pregnant women, and parent/caretakers with incomes up to 17 percent FPL. Most people who qualify for Medicaid are typically in one or more of the following categories:

- Age 65 and older
- Under the age of 19
- Blind
- Pregnant
- The parent or the relative who is the caretaker of a child with an absent, disabled, or unemployed parent
- Living in a nursing home
- Under age 21 and in foster care
- In medical need of certain home- and community-based services
- Persons with breast or cervical cancer
- Disabled, including the working disabled

In comparison with the HCIP enrollees, individuals enrolled in the traditional Medicaid program will have much stricter income requirements and, in many cases, more complex health care needs. Statistical considerations will need to account for these differences.

There will be four major metric groups used with this approach (see Appendix 4 for the complete list of candidate metrics by approach). First, enrollment data will be used to assess the continuity of access to providers and plans. CAHPS data will also be used to assess consistency of care and access to primary and specialty services, as well as the use of services and patient experiences of care. Transportation and claims data will be combined to assess the use of non-emergency transportation services. Lastly, claims data will be used following the CMS Adult Core Reporting guidelines and HEDIS indicators definitions to examine utilization and quality/outcome measures.

### Statistical Analysis

A series of multivariate regression models will be fitted for each metric (see Appendix 4). Each model will include a dummy variable “program type” to test the comparison between traditional Medicaid and HCIP. In quasi-experimental studies (i.e., non-randomized experiments) such as the current evaluation, it is important for research designs to control for important differences between the treatment and comparison groups that may affect the dependent variables but are confounding the observed effect of the independent variable of interest. One way to do this is through the use of covariates. Covariates will include, but are not limited to, age, gender, race and ethnicity (where available), known health conditions, income, and geographic region. We will also test the interaction between income and program type to examine moderation effects, particularly given the known differences in income level between the traditional Medicaid program and the newly enrolled beneficiaries in the HCIP. Another way to control for unmeasured variables is to incorporate an instrumental variable into models to account for unobserved variable bias. With this method it is often difficult to identify an appropriate instrumental variable, so this approach will have to be considered in light of available data. The contracted research team will explore the appropriate use of such instrumental variables to control for bias, if possible. To test the hypothesis of “equal or better than,” for each metric the models will look for either a non-significant parameter estimate on program type (indicating equal outcomes) or a parameter estimate that favors the HCIP group based on a one-sided statistical test. All statistical tests will be performed with the probability of a Type I error of alpha=0.05.

### D2. Subgroup Pre–Post Comparisons

There are two important subgroups that will allow for a longitudinal pre-post research design: youth ages 17–18 who qualify for the Early and Periodic Screening, Diagnosis, and Treatment (EPSDT) program and women with breast or cervical cancer. Prior to the HCIP, individuals in these subgroups were part of the traditional Medicaid program. With the implementation of HCIP, these individuals will now be provided insurance coverage through premium assistance.

For the EPSDT group we propose identifying a group of youth ages 17–18 during 2012 and 2013 who were enrolled in the traditional Medicaid program, and who upon turning 19 years of age will be eligible to enroll in HCIP. Estimates from 2011 suggest that across this two-year time frame approximately 12,000 youth will qualify for EPSDT services in this age group.

The second subgroup will be women with breast or cervical cancer. In Arkansas, a program called BreastCare provides free breast and cervical cancer screenings and treatment for Arkansas women ages 40–64 years who have no health insurance coverage and who have a household income at or below 200% FPL. During FY2012, this program served more than 12,000 women, 230 of whom were diagnosed with breast or cervical cancer and received treatment. Starting in 2014, women receiving treatment will be served through the HCIP rather than traditional Medicaid. The purpose of this analysis will be to evaluate the continuity of specialty services for women while they were in traditional Medicaid, and compare that with their continuity of services once enrolled in HCIP. It
may also be possible to compare continuity of care across this transition, though it is hypothesized that increased network access may provide opportunities for enrollees to select different providers that they did not previously have access to.

**Statistical Analysis**

Multiple regression models similar to those used for D1 (above) will be used with this group. In this case, however, models will include a dummy variable of “time” to test whether or not differences in outcomes can be attributed to the transition between the traditional Medicaid program and the HCIP, where Time 1 (omitted category) will include outcomes associated with enrollment in traditional Medicaid while Times 2, 3, and possibly 4 would be associated with HCIP enrollment. While we intend to use the same control covariates as D1 (above), considerations of sample size will need to be made particularly for the BreastCare program. In this case, a limited set of covariates including age and geographic region may be utilized to maximize power.

**D3. Regression Discontinuity Analysis**

In cases where random assignment to treatment and control groups is not feasible, comparisons can be done by examining subgroups of individuals based on scores just above or below a cutoff value of a predetermined variable. The assumption is that such individuals with similar scores may not differ significantly on the characteristics of interest, even though the cut point places the individuals into different treatment groups. Consider, for example, grade school students enrolled in a summer enrichment program based on mathematics test scores. Those who score 59% or below are enrolled in the summer program, while students scoring at 60% or above do not.

For illustration, consider what the outcome might look like if the program had a positive effect on future mathematics scores. For simplicity, assume that the program, which only enrolls people who score below a certain level, had a constant effect which raised each participant’s outcome measure by ten points.

The dashed line (Figure 3) shows what we would expect the treated group’s regression line to look like if the program had no effect. A program effect is suggested when we observe a “jump” or discontinuity in the regression lines at the cutoff point.

![Figure 3: Regression-Discontinuity Design with Ten-point Treatment Effect](image)
For the case of Arkansas’ HCIP, there are two groups for which this method can be applied. First are low-income parents at the threshold of 17% FPL. Those parents with incomes less than 17% FPL will receive traditional Medicaid benefits, while parents above 17% FPL will enroll in the HCIP. By selecting parents at the threshold (10–17% FPL vs. 18–25% FPL), we can use a regression discontinuity (RD) design to compare metrics.

The second RD group will comprise individuals newly eligible for coverage who will participate in a screening process to determine if they have sufficient medical needs to warrant retention in the traditional Medicaid program. The HCIP authorizing legislation directs DHS to identify those individuals who have exceptional medical needs for whom coverage through the Marketplace is determined to be impractical, overly complex, or would undermine continuity or effectiveness of care and to retain them in the traditional Medicaid program. Because no previous claims history or diagnostic roster is available, identification of these individuals will require use of a prospective medical frailty screener.

In consultation with health status and exceptional needs measurement experts at the University of Michigan and the Agency for Healthcare Research and Quality, Arkansas has developed a screening process that seeks to identify the top 10 percent most medically needy to be included in this population—such as individuals who would benefit from long-term services and supports and targeted outreach and care coordination through the state’s emerging health home program and Community First Choice state plan option. The final screener consists of 12 questions that will provide self-reported information; responses will be scored and calibrated to estimate the population who will be retained in the traditional Medicaid program. Downstream refinements to the screener algorithm will occur as data accumulates and individual screening results are compared with actual utilization patterns.

There are two stages to the screening process. At the first stage, individuals with significant limitations for daily living and other “automatic” triggers will be identified. The second stage involves a weighted set of indicators from the remaining set of questions that will be used to identify a cut point around which decisions will be made about eligibility. This cut point provides a unique opportunity to employ regression discontinuity techniques with the individuals who are screened during the second stage.
Statistical Analysis

For each outcome measure that we have selected for evaluation, we regress the posttest scores, Y, on the modified pretest X (X=pretest scores minus the cutoff point), the treatment variable Z, and all higher-order transformations and interactions. The regression coefficient associated with the Z term (i.e., the group membership variable) is the estimate of the main effect of the program. If there is a vertical discontinuity at the cutoff it will be estimated by this coefficient.

D4. Provider Network Adequacy

A major set of hypothesis grounded in Arkansas’ use of premium assistance through the Health Insurance Marketplace is that by utilizing the delivery system available to the privately enrolled individuals in the marketplace the availability and accessibility of both primary care and specialists will exceed that of a more traditional Arkansas Medicaid expansion. By purchasing health insurance offered on the newly established Health Insurance Marketplace and utilizing private sector provider networks and their established payment rates, traditional barriers to equitable health care including limited specialist participation and provider availability will be minimized. In fact, as deployed, providers will not be able to differentiate privately insured individuals supported by Medicaid premium assistance (e.g., those earning ≤138% FPL), those supported by tax credits (139%–400% FPL), or those earning above 400% FPL purchasing from the carriers offering on the exchange.

45 CFR § 156.230 requires that Qualified Health Plans (QHPs) “…maintain a network that is sufficient in number and types of providers, including providers that specialize in mental health and substance abuse services, to assure that all services will be accessible without unreasonable delay.” The Arkansas Insurance Department has developed the following network adequacy targets and data submission requirements to ensure adequacy of provider networks in QHPs offered in the Federally-Facilitated Marketplace (FFM, or “Marketplace”).

The Arkansas Insurance Department at the recommendation of the Marketplace Plan Management Advisory Committee is developing network adequacy requirements (see Appendix 5) to be reported by participating carriers on an annual basis. Utilizing geomapping techniques the recommendation, which follows qualified health plan accreditation requirements, requires stratification of network participating information as follows:

- **Primary Care**: GeoAccess maps must be submitted demonstrating a 30-mile or 30-minute coverage radius from each general/family practitioner or internal medicine provider, and each family practitioner/pediatrician. Maps should also show providers accepting new patients. Dental carriers are not required to submit separate categories, but should include only non-specialists in this requirement.

- **Specialty Care**: GeoAccess maps must be submitted demonstrating a 60-mile or 60-minute coverage radius from each category of specialist (see list of categories below). Maps should also show providers accepting new patients. Specialists should be categorized according to the list below. (Dental carriers do not need to categorize specialists.)
  - Cardiologists
  - Endocrinologists
  - Home Health Agencies
  - Hospitals*
  - Obstetricians
  - Oncologists
  - Ophthalmologists
• Psychiatric and State Licensed Clinical Psychologist
• Pulmonologists
• Rheumatologists
• Skilled Nursing Facilities
• Urologists
  "Hospitals types should be categorized according to hospital licensure type in Arkansas.

• Mental Health/Behavioral Health/Substance Abuse (MH/BH/SA): GeoAccess maps must be submitted demonstrating a 45-mile or 45-minute coverage radius from MH/BH/SA providers for each of the categories below. Maps should also show providers accepting new patients.
  o Psychiatric and State Licensed Clinical Psychologist
  o Other (submit document outlining provider or facility types included)

• Essential Community Providers (ECP): GeoAccess maps must be submitted demonstrating a 30-mile or 30-minute coverage radius from ECPs for each of the categories below. The provider types included in each of the categories align with federal guidelines for ECP providers, with the addition of school-based providers included in the “Other ECP” category.
  o Family Planning Provider
  o Federally Qualified Health Center
  o Hospital
  o Indian Provider
  o Other ECP
  o Ryan White Provider

To evaluate and compare the differences in access and availability by each of the provider types above for the networks of Medicaid demonstration participants compared with the traditional Medicaid network, geomapping efforts for adult patients in the traditional Medicaid would be replicated to enable comparisons of networks available through the Marketplace and those through traditional Medicaid provider panels. In addition serial examinations of primary care, specialists, and select providers within carrier networks will enable examinations of access continuity for primary care and specialists that compare the traditional Medicaid provider networks with the provider networks evidenced through the HCIP.

E. Approach for Test of Cost Effectiveness

The Arkansas Demonstration proposes to enhance care received by Medicaid beneficiaries through the use of premium assistance to purchase private coverage from QHPs on the Arkansas Health Insurance Marketplace. Opportunities for enhanced access to primary care and specialty networks, continuity in insurance coverage and provider relationships, improved preventive and chronic care management, enhanced patient experiences in care and improved outcomes are described above. In addition, by nearly doubling the number of individuals who will enroll in QHPs through the Marketplace, the Demonstration is expected to encourage carrier entry, expanded service areas, and competitive pricing in the Marketplace, thereby enabling QHP carriers to better leverage economies of scale to drive pricing down even further.

However, core requirements of the Demonstration are to evaluate the cost effectiveness of utilizing Medicaid funds to procure insurance coverage through premium assistance at scale in the new
Health Insurance Marketplace. The proposed approach summarizes existing knowledge of available comparison groups, anticipated data, and a summary of methodological considerations compiled by staff from the office of the Assistant Secretary for Planning and Evaluation (ASPE) and based on input from Arkansas’ waiver team; conversations between Arkansas, ASPE, and CMS.

The approaches represented recognize the expectation for Arkansas to undertake a robust evaluation to adequately test health outcomes and financial implications of Medicaid coverage expansion through premium assistance, as well as the need to accommodate certain limitations (e.g., comparison groups and data availability). We represent below the requirements, the current approach, challenges identified, anticipated uncertainties, and potential future policy implications. For the purpose of this Evaluation Plan, we have limited approaches to those for which the state can assure available data to the selected external contractor. Given the potential value of comparison with another state, the evaluation team will continue to explore this possibility with CMS guidance. Currently, CMS is exploring making available utilization data from another state to support secondary analyses. Should these data become available, the evaluation team will explore with CMS what analyses could reasonably be undertaken. Findings and key challenges will be shared in the summative evaluation report.

**E1. Cost Effectiveness Requirement – STC #68**

“While not the only purpose of the evaluation, a core purposes of the waiver evaluation is to support a determination as to whether a preponderance of evidence about the Arkansas Private Option Demonstration using premium assistance, when considered in its totality, demonstrates cost effectiveness taking into account both initial and longer-term costs and other effects such as improvements in service delivery and health outcomes.

a. The evaluation will explore and explain through developed evidence the effectiveness of the demonstration for each hypothesis, including total costs in accordance with the evaluation design as approved by CMS.

b. Included in the evaluation will be examinations using a robust set of measures of provider access and clinical quality measures under the Private Option Demonstration compared to a comparable population in Medicaid fee-for-service.

c. The State will compare total costs under the Private Option Demonstration to costs under a traditional Medicaid expansion. This will include an evaluation of provider rates, healthcare utilization and associated costs, and administrative expenses over time.

d. The State will compare changes in access and quality to associated changes in costs in the Private Option. To the extent possible, component contributions to changes in access and quality and their associated levels of investment in Arkansas will be determined and compared to improvement efforts undertaken in other delivery systems.”

**E2. Recommended Approach**

The proposed methodology was selected from among a range of analytic options to best address the real-world circumstances under which Arkansas’ premium assistance waiver is being demonstrated. Of particular importance, Arkansas has not previously expanded Medicaid with full benefits for the target population under its traditional fee-for-service population; coverage has been limited to either individuals with extreme needs (e.g., the disabled) or those experiencing extreme poverty (e.g., parents of children in families earning at or below 17% FPL). Thus, the lack of directly comparable information will require quasi-experimental methods to address the absence of randomized
enrollment and to recognize existing limits on available data for preferred comparison groups (i.e.,
matched populations from similar states following a different path to expansion/no expansion).
Thus, data availability, research design, and outcome (both cost and effectiveness) measures were
considered simultaneously; an effort is underway to understand, before the program is implemented,
the analytic framing for the evaluation.

A cost-effectiveness analysis (CEA) of the HCIP Private Option in Arkansas versus enrollment in
the regular Medicaid fee-for-service (FFS) program has several important dimensions:13

- Perspective and length of follow-up
- Measurement of costs
- Measurement of effectiveness (e.g., continuity in coverage, provider access, health outcomes,
  quality of coverage, patient experiences)
- Control group identification when randomization is not possible
- Methods for obtaining estimates
- Accounting for uncertainty

Each issue is discussed briefly below.

Perspective and Length of Follow-up

A societal perspective (including net costs to the Marketplace and any out-of-pocket beneficiary
costs) would be most comprehensive. However, for policy-making purposes, conducting the analysis
from the Medicaid perspective may be sufficient to determine whether in its totality the evaluation
demonstrates cost effectiveness (i.e., is either cost saving or attains increases in outcomes that are
worth any increase in cost). For simplicity, the remainder of this document will focus on estimation
of key components of the incremental cost-effectiveness ratio (ICER) from the Medicaid payer
perspective:

\[
ICER = \frac{(COST_{HCIP} - COST_{Control})}{(EFFECT_{HCIP} - EFFECT_{Control})}
\]

where \(EFFECT\) reflects some health outcome that is not easily quantified in monetary terms.
Because the goal is to provide immediate feedback to Arkansas and CMS, the ICER can be initially
estimated for the first year of program enrollment. As future years are included, discounting
(translating of future costs and benefits into current values) would be required.

It is important to note that in many CEAs, a single value measure of effectiveness (e.g. quality-
adjusted life years, life years saved, etc.) is used to calculate the ICER. For HCIP, there will be
numerous potential measures of effectiveness. Thus, there are at least two choices: find some
methods for combining the various effectiveness measures into a single metric, or make more
qualitative judgments about the overall balance of the incremental effectiveness measures relative to
incremental costs.

---

13 Gold MR, Siegel JE, Russell LB, and Weinstein MC. Cost-effectiveness in health and medicine: The report of the
Costs

Medicaid will pay the QHP premium each month for each person with an income between 18% and 138% of the FPL, except for people who are determined to be medically needy. This premium could include the QHP’s administrative costs plus the expected average age-adjusted service cost per enrollee for the plan chosen. Subject to further consideration of the accuracy of the premium to reflect these costs (discussed in more detail below), the premium provides an easy way to measure the costs of the HCIP to Medicaid for the first year of the program. For the control group (also discussed later), Arkansas will also estimate the Medicaid administrative cost per enrollee (avoided claims administration, oversight, appeals, program integrity, and other) and use claims to measure the service costs. Therefore, the numerator of the ICER is:

\[
\text{COST}_{\text{HCIP}} - \text{COST}_{\text{control}} = \text{Premium}_{\text{HCIP}} - (\text{Medicaid Admin Costs} + \text{Medicaid FFS Claim Payments})_{\text{control}}
\]

The components in Eq. 2 would be summed over all HCIP enrollees and control persons for the first year of the program.

The extent to which the HCIP premium accurately represents the average cost of the HCIP individuals depends on how well the Marketplace predicts service use. The state will rely on its actuaries to develop an accurate representation of HCIP premium costs for each year of the Private Option. Considerations include the following:

- Premiums set in advance for one year may be greater or less than actual experience; actual experience could lead to increases or decreases in premiums in future years.

- The state is entitled to repayment from carriers for premiums exceeding claims cost plus administration, subject to the minimum loss ratio in effect in the Marketplace, and this calculation and restitution will occur in Year 2 for claims costs and premiums incurred in Year 1.

- While the premiums depend on the experience of all Marketplace enrollees (not just HCIP), obtaining claims from the Marketplace for the HCIP enrollees as well as the premiums for the second year of the Marketplace will enable a more nuanced analysis of the financial experience for Medicaid during the first year of the HCIP as well as an understanding of the extent to which the second-year experience may be different.

If the incremental difference in costs (Eq. 2) is negative, then on average the HCIP program is cost saving; if the incremental difference is positive, then the HCIP may be cost effective if the program also increased some health outcome measure (e.g., health status, access, experiences) such that the increase in outcome is worth the increase in cost to the Medicaid program. However, even if HCIP is estimated to be cost saving on average for the first year, uncertainty in this estimate should be considered because the estimate is based on a particular group of enrollees in the first year. More specifically, it is unlikely that the HCIP would be 100% certain to be cost saving, so Arkansas might consider cost effectiveness using some estimated measure of effect.

In anticipation of a need to assess the overall balance of the incremental effectiveness measures relative to incremental costs across multiple facets of the Arkansas Demonstration, we propose the following analytic application of potential incremental outcomes for subgroup and total program assessments. As arrayed, three different options for measured effects (improved, no change, degraded) and costs (net decrease, no change, net increase) are anticipated for modeled options (see Figure 4). We anticipate findings resulting in segment A and B as optimal outcomes, D and E as
acceptable outcomes, C warranting policy discussion of the “value” of observed improvements, and results in segment F–I as negative outcomes. As referenced above and described below, different effects principally tested will include a variety of hypotheses for exploration within the Arkansas Demonstration.

**Figure 4: Potential Incremental Outcomes for Subgroup and Total Program Assessments**

<table>
<thead>
<tr>
<th>Effect</th>
<th>Lower Net Cost</th>
<th>No Cost Change</th>
<th>Higher Net Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improved</td>
<td>A</td>
<td>B</td>
<td>C</td>
</tr>
<tr>
<td>No Change</td>
<td>D</td>
<td>E</td>
<td>F</td>
</tr>
<tr>
<td>Degraded</td>
<td>G</td>
<td>H</td>
<td>I</td>
</tr>
</tbody>
</table>

**Effects (Health Outcomes)**

Standard and single-value measures of health outcome for economic evaluation, such as quality-adjusted life years, may not be feasible for assessment of the HCIP, especially because mortality differences would not likely be detectable within the first year of the program for this population. In this case, the effectiveness measures are appropriately related to the quality of insurance coverage provided in the Marketplace relative to the traditional Medicaid program. Therefore, a variety of measures might be used including those related to continuity of coverage, health status, access, utilization, and enrollee experiences. Another consideration is which measures can reasonably be expected to be affected by coverage over the time horizon for the project. Measures of utilization or process measures of care quality might be observed in a one-year time frame, but impacts on health status measures would likely take longer. One possible measure of effect that might be relevant to the Medicaid program would be reductions in potentially avoidable readmissions. Although the actual cost of hospitalizations is reflected in the numerator of the ICER, hospitalizations involve many unmeasured costs (e.g., pain, discomfort, lost work time, etc.), so reduction in inappropriate/avoidable hospital use is generally beneficial and reflective of health status improvements. Among the characteristics that will be considered in selecting effectiveness measures are the following:

- There is general agreement they measure important aspects of quality for insurance coverage.
- They are likely to be affected by new coverage within a reasonable time frame.
- Data to calculate them will be available at reasonable intervals for both treatment and control groups.

With these criteria in mind, the state will plan to select a representative number of outcomes measures to include in tests of cost effectiveness. These measures will be drawn from those vetted for inclusion in the evaluation of experiences in care, effectiveness of care, utilization, and provider network. Candidate indicators for consideration in testing select hypotheses include the following.

---

Hypothesis 4a: Fewer gaps in enrollment, improved continuity of care, and resultant lower administrative costs

For this hypothesis, candidate metrics include the following:

1. Enrollment metrics (AR Medicaid Eval 9 and 10) to be generated from cross-year carrier and Medicaid enrollment inclusive of re-enrollment and transitions of enrollment across the 138% FPL threshold (e.g., gaps in enrollment coverage)

2. Continuity and accessibility metrics (AR Medicaid Eval 03-08) to be generated from cross-year carrier and Medicaid network provider information for both primary care providers and specialty providers operationalized as a positive event (expanded accessibility, greater PCP/specialty access, greater inferred continuity in PCP attachment) and maintained accessibility across participation years

3. Administrative costs as discussed above from identification and categorization of costs attributed to the state Medicaid plan, incorporated into carrier management, and otherwise required for a traditional Medicaid expansion

Hypothesis 4b: Reduced premium costs in the Marketplace and increased quality of care

Arkansas’ Demonstration Waiver incorporated anticipated changes in the Marketplace as a result of Medicaid premium assistance including stabilization of the actuarial risk pool in the private health insurance exchange, deflationary pressure through reduced cost-shifting for Medicaid underpayments to providers, increased plan competition resulting in increased participant choice, and finally enhanced quality of care due to active clinical and network management by private carriers.

1. As discussed above, Marketplace characteristics (e.g., carrier competition, premium costs, actuarial stability) will be operationalized through performance characteristics of the Arkansas Marketplace.

2. Access, quality of care, and patient experiences as previously discussed for both regression discontinuity analyses and statewide assessments will be employed for assessments of quality of care (directionality as appropriate for specific metrics). Total costs of the HCIP will include actual premiums and consider a sensitivity assessment based upon the actuarial projections included in the Demonstration Waiver (e.g., costs private plans would have paid without premium assistance, costs projected for HCIP, costs of additional reductions with maturation of the Arkansas Exchange Marketplace).

Hypothesis 4c: Overall costs for covering beneficiaries

While no comparison group exists to enable measurement of the hypothetical costs of covering the entire expansion population in Arkansas’ traditional fee-for-service Medicaid program, original actuarial modeling developed by Optumas employed in waiver development and shared with CMS; planned assessments of experienced quality and costs above; and actual premium costs and concurrent Medicaid costs for DY1, DY2, and DY3 will enable estimates for comparison of total program costs of the Demonstration and alternative hypothetical Medicaid expansion. Subgroup comparisons for delivery costs for
care will be employed building upon cost-effectiveness analyses above. The following are candidate metrics:

1. Statewide projections for delivery costs for care will be modeled building off of subgroup comparisons and modeling efforts to estimate required provider rates for comparable access under expansion assumptions regarding access requirements.

2. Comparison of cost-estimates to actuarial modeling inclusive of sensitivity analyses are anticipated to provide a bounded range of comparative costs between the Arkansas Demonstration and an Arkansas traditional Medicaid expansion.

Control Group Identification and Methods for Obtaining Estimates

HCIP enrollment will not be randomized but instead will occur automatically for all persons with incomes of 18%–138% FPL who were not previously eligible for Medicaid and who are not identified as “high need” based on the medical needs screener. A set of different control groups and analytic methods may be considered to get estimates of the effect of HCIP for different components of the Medicaid population. For example, regression discontinuity methods\textsuperscript{15,16,17} could be used to estimate costs and effects for HCIP and control for enrollees at two different thresholds for Hypothesis 4a:

- HCIP enrollees who score close to (but just below) the high-need cutoff (e.g., persons who score in the 80\textsuperscript{th}–90\textsuperscript{th} percentiles of the predicted risk scores) could be compared with the high-need enrollees who are placed in regular Medicaid FFS because they score in the 90\textsuperscript{th}–100\textsuperscript{th} percentiles of the predicted risk scores. (Note: people who qualify automatically for the high-need Medicaid FFS due to characteristics such as specific disabilities will automatically be enrolled in the treatment group, so no controls can be identified among HCIP enrollees; therefore, these FFS enrollees should not be included in the control group.)

- HCIP enrollees who are relatively low income (e.g., 18%–25% FPL) could be compared with Medicaid FFS enrollees just below the low-income threshold (e.g., 10%–17% FPL).

While estimates of the ICER for these two groups would not reflect the effect of HCIP for the full set of HCIP enrollees, they would provide useful estimates for two important and potentially high-cost groups (medically needy and/or extremely low income). The precision of the estimate will depend on the number of people whose high-need measure or income qualify them to be in the analysis (either HCIP treatment or FFS control); it will be possible to estimate 95% confidence intervals for the estimates, but small samples would limit the value/precision of the estimates. Hypotheses 4b and 4c will extract from regression discontinuity approaches applied in hypothesis 4a but also require Arkansas Exchange Marketplace cost information in addition to comparative exchange information from states without premium assistance.

It would desirable, of course, to get an estimate of HCIP for the rest of the Medicaid expansion population (e.g., people not previously eligible for Medicaid who are at 26%–138% FPL and have a predicted risk score of <80%). Given lack of randomization, the control group would need to come


from another state (either one that previously expanded Medicaid coverage or is currently expanding coverage under PPACA); because Arkansas is using a FFS approach rather than managed care for Medicaid beneficiaries outside the Demonstration, the control state(s) should also use a FFS rather than managed care approach. Georgia, Oklahoma, and Alabama are potential Medicaid FFS states that could be included, while Missouri, Tennessee, and Kentucky are not likely candidates because they utilize a Medicaid managed care approach. To do the analyses, person-level enrollment and claims data from an appropriate control state would need to be obtained, as it seems unlikely that administrative reports would be sufficient to identify the experience for the control patients. Even with these data, it might be necessary to use a statistical approach, such as propensity score matching, to identify whether the Medicaid enrollees from the comparison state would have been in the HCIP (e.g., unless the control state has information similar to Arkansas’s high-need screener); however, the data available to use this approach may be limited. In total, the potential for bias in the estimated impact from this comparison might be much greater than for the estimates obtained for the high-need and low-income groups using the regression discontinuity approach; however, the estimate might provide some sort of bound or improved understanding of the possible full impact of HCIP enrollment.

**Potential Statistical Methods**

The choice of statistical methods must be consistent with data availability and choices for the comparison groups. As described above, one set of comparisons for this evaluation may involve individuals close to the thresholds that assign them either to traditional Medicaid or HCIP. The appropriate statistical technique for these situations is known as regression discontinuity designs or RDD. Regression discontinuity analysis applies to situations in which candidates are selected for treatment based on whether their value for a numeric rating exceeds a designated threshold or cut-point. Under an RDD, the effect of an intervention can be estimated as the difference in mean outcomes between treatment and comparison group units, adjusting statistically for the relationship between the outcomes and the variable used to assign units to the intervention, typically referred to as the “forcing” or “assignment” variable (see section D3, above, for more detail on the RDD method).

**Accounting for Uncertainty in Estimates**

Because the estimates of costs and effects are based on first-year HCIP enrollees and control Medicaid enrollees, the estimates of both the numerator and the denominator of the ICER are subject to sources of uncertainty that are likely correlated. The uncertainty arises because the group of enrollees in one year may differ from groups of enrollees in future years. Methods have been established to address uncertainty in estimates of cost effectiveness. For example, the analysis can generate bootstrap replications of the estimates of the ICER; these replications can be used to construct a cost-effectiveness acceptability curve (CEAC) that depicts the probably that HCIP is cost effective at different levels of willingness to pay for an avoidable hospitalization averted.

---

4. Evaluation Implementation Strategy, Timeline, & Budget

A. Independent Evaluation

An independent third party will be selected, after applicable state procurement, selection, and contracting procedures have been performed, to conduct the interim (DY2) and final (DY3) evaluations. The third party selected for the evaluation will be screened to assure independence and freedom from conflict of interest. The assurance of such independence will be a required condition by the state in awarding the evaluation effort to a third party. The selection of this independent evaluator will be based on their demonstrated capacity to conduct rigorous evaluations similar to the current proposal, qualification of proposed staff, and evidence of the ability to meet project objectives within the proposed timeline and budget.

The evaluation will meet all standards of leading academic institutions and academic journal peer review, as appropriate for each aspect of the evaluation, including standards for the evaluation design, conduct, interpretation, and reporting of findings. Among the characteristics of rigor that will be met for the interim and final evaluations are use of best available data and controls for and reporting of the limitations of data and their effects on results and the generalizability of results. Treatment and control or comparison groups will be used, and appropriate methods will be used to account and control for confounding variables. The evaluation design and interpretation of findings will include triangulation of various analyses, wherein conclusions are informed by all results with a full explanation of the analytic limitations and differences.

B. Data Availability

Arkansas has developed and continues to develop strategies to secure needed data inclusive of enrollment, claims, and consumer experience related to the demonstration. We anticipate developing the required data components in concert with the evolution of the HCIP demonstration. For example, we anticipate outreach and enrollment to be a focus in DY1, improved access and utilization in DY2, and clinical outcomes in DY3; re-enrollment and elimination of churn to be an ongoing assessment following DY1; and cost-effectiveness to be a critical DY3 determination.

The Arkansas Insurance Department (AID) has issued guidance that carriers will be required to submit claims for the Marketplace experience inclusive of the demonstration participants—initially required reporting by the end of quarter 1 in DY2 for DY1 experience and on a quarterly basis thereafter. The submission process will utilize the X12 standards (www.X12.org) in eligibility files and medical claims, and the National Council for Prescription Drug Programs Standards in Pharmacy Claims files (see Appendix 6 for more information). These claims data will be the basis for development of access, utilization, and clinical quality indicators from established and accepted national metrics.

The Division of Medicaid Services (DMS) within the Arkansas Department of Human Services has historic and will have temporal claims data for existing Medicaid enrollees. In addition, DMS conducts the CAHPS with Arkansas Medicaid enrollees on a semi-annual basis.

CMS is exploring availability of additional state data from a comparable state to be used for comparison. If these data become available, the evaluation team will work with CMS to include these data in the evaluation.
C. Timeline

Table 1 provides a proposed timeline for the work of this evaluation. It is anticipated that the hired contractor will use this general timeline to create a more thorough timeline and workplan once they are hired. Though the Demonstration is scheduled for 3 years, we have included a Year 4 in this evaluation proposal to encompass all the required reports that will be submitted subsequent to DY3. The three major pieces of work include the recruitment and hiring of an independent evaluation team, the collection and analysis of data, and the submission of reports.

We propose three major reports and 13 enrollment reports to be completed. The enrollment reports will include information about enrollment patterns, reenrollment patterns, and retention patterns throughout DY1-4. We also propose to include an implementation update at the conclusion of DY1 that will consist of quarterly enrollment updates, market area assessments, and any “transition to market” issues identified through the implementation of HCIP. We anticipate these findings will not only be needed for any programmatic or technical modifications in Arkansas’s program but also beneficial should other states pursue a similar Medicaid expansion.

The Interim Evaluation Report will be completed as stipulated in STC 70 after completion of DY2. This report will include findings from data collected including two years of enrollment data, two years of geomapping data, one year of CAHPS data (collected during DY2), and two years of claims data. The Final Evaluation Report will be submitted after completion of DY3. It will include three years of enrollment, geomapping, and claims data, as well as two years of CAHPS data.

The Interim Evaluation Report, Draft and Final Summative Evaluation Reports will follow the outline and included components in STC 70.
### Table 1. Proposed Project Timeline

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Enrollment</td>
<td>U</td>
<td>U</td>
<td>U</td>
<td>U</td>
</tr>
<tr>
<td>Reenrollment</td>
<td></td>
<td>U</td>
<td>U</td>
<td>U</td>
</tr>
<tr>
<td>Retention</td>
<td></td>
<td></td>
<td>U</td>
<td>U</td>
</tr>
<tr>
<td>Implementation Update</td>
<td></td>
<td></td>
<td>U</td>
<td>U</td>
</tr>
<tr>
<td>Interim Report</td>
<td></td>
<td></td>
<td></td>
<td>R</td>
</tr>
<tr>
<td>Final Draft Report</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Final Summary Report</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Data Collection &amp; Analysis:</th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enrollment</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Geomapping</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CAHPS</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Carrier Claims</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

U=Non-required Update
R=Required Report
X=Data Collection
*=Data Analysis
D. Budget

To be determined after the scope of the analytic proposal is approved.

5. Supplemental Hypotheses and Future Policy Implications

Additional questions of policy relevance are of interest; however, they are outside of the scope of STC #68 that requires examination of the Arkansas Demonstration in comparison with what would have happened under a traditional Medicaid expansion. These questions will be important completely frame the experience and understanding generated by the first major use of premium expansion through the new health insurance exchanges to cover low-income Americans. We anticipate framing these questions, securing supplemental funding, and conducting appropriate research to capture the experience and learning opportunities of the Arkansas Demonstration.

These policy-relevant questions include both questions of global significance to the Medicaid program and health care system that will inform future policies about safety-net providers, workforce needs, specialty availability, population health impact, and marketplace stabilization. As a poor state with poor health status and outcomes combined with high rates of the uninsured, Arkansas may serve as an incubator to evaluate the following questions.

- By using premium assistance to purchase private health insurance on behalf of low-income Americans, how equitable was the access, outcomes, and experiences between Medicaid beneficiaries and their private-sector counterparts (regression discontinuity above and below 138% FPL)?
- Where differences exist in access, outcomes, and experiences of Medicaid beneficiaries and their private-sector counterparts, what are plausible causes and potential policy solutions?
- How did Arkansas expansion of health insurance affect a change on population health indicators compared with sister states with similar risk profiles who elected to delay implementation?
- If Arkansas’ Demonstration proves to advantage the health insurance exchange and the Medicaid program through system improvements, actuary risk-pool stability, and/or deflationary pressure on premiums, what are the indirect long-term benefits of a more efficient market and stable risk pool to the federal treasury through lower expenditures on advanced premium tax credits?
- How did Arkansas’ use of Supplemental Nutrition Assistance Program eligibility contribute to the stability of the risk pool compared with self-initiated enrollment of newly eligible beneficiaries?
- How did providers—both primary care and specialists—react to a major reduction in the numbers of the uninsured and receipt of equivalent payment rates for beneficiaries in the exchange marketplace? Did private-sector providers relocate over time or find alternative delivery strategies to highly concentrated areas of uncompensated care caused by the lack of insurance?
- How did safety-net providers—federally qualified health centers, rural health centers, critical access hospitals, educational institutions—fare under Medicaid expansion utilizing premium assistance through commercial carriers?
These and additional policy-relevant questions will be identified through the implementation experience of the Arkansas Demonstration Waiver. As other states consider Medicaid expansion through the use of premium assistance, both replication of Arkansas’s approach and minor variations on coverage strategies could enable multi-state collaborative and cross-state comparisons. We anticipate additional opportunities for exploration outside of the scope of the Demonstration Waiver terms and conditions and welcome exploration, development, and pursuit of funding opportunities to support these analyses.

6. Appendices

Appendix 1: Arkansas Evaluation Hypotheses: Proposed & Original Crosswalk
Appendix 2: Proposed Measure Descriptions and Definitions
   A. Selected Measures from Initial Core Set of Health Care Quality Measures for Adults Enrolled in Medicaid
   B. Selected Measures from Healthcare Effectiveness Data and Information Set (HEDIS) 2014
   C. Consumer Assessment of Healthcare Providers and Systems Survey—Health Plan 5.0
   D. Consumer Assessment of Healthcare Providers and Systems Survey—Supplemental Items 4.0
Appendix 3: HCIP Waiver Evaluation Planning: State’s Medicaid Reporting Measures
Appendix 4: Candidate Metrics by Approach
Appendix 5: Arkansas Insurance Department Network Adequacy Guidelines and Targets
Appendix 6: Arkansas Insurance Department Requirements for Qualified Health Plan Certification in the Arkansas Federally-Facilitated Partnership Exchange
Appendix 1

Arkansas Evaluation Hypotheses: Proposed & Original Crosswalk
## Appendix 1

### Arkansas Evaluation Hypotheses: Proposed & Original Crosswalk

<table>
<thead>
<tr>
<th>Arkansas Proposed Evaluation Hypotheses</th>
<th>Arkansas Original Terms and Conditions Hypotheses (Section 8, STC 70, #1)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1—Access</strong></td>
<td></td>
</tr>
<tr>
<td>a. Use of PCP/specialist</td>
<td>i. Premium Assistance beneficiaries will have equal or better access to care, including primary care and specialty physician networks and services.</td>
</tr>
<tr>
<td>b. Non-emergent ER use</td>
<td>iii. Premium Assistance beneficiaries will have lower non-emergent use of emergency room services.</td>
</tr>
<tr>
<td>c. Preventable ER</td>
<td>vii. Premium Assistance beneficiaries will have lower rates of potentially preventable emergency department and hospital admissions.</td>
</tr>
<tr>
<td>d. EPSDT</td>
<td>ix. Premium Assistance beneficiaries who are young adults eligible for EPSDT benefits will have at least as satisfactory and appropriate access to these benefits.</td>
</tr>
<tr>
<td>e. Non-emergency transportation</td>
<td>x. Premium Assistance beneficiaries will have appropriate access to non-emergency transportation.</td>
</tr>
<tr>
<td><strong>2—Care/outcomes</strong></td>
<td></td>
</tr>
<tr>
<td>a. Preventive and health care services</td>
<td>ii. Premium Assistance beneficiaries will have equal or better access to preventive care services.</td>
</tr>
<tr>
<td>b. Experience</td>
<td>viii. Premium Assistance beneficiaries will report equal or better experience in the care provided.</td>
</tr>
<tr>
<td>c. Non-emergent ER use*</td>
<td>iii. Premium Assistance beneficiaries will have lower non-emergent use of emergency room services.</td>
</tr>
<tr>
<td>d. Preventable ER*</td>
<td>vii. Premium Assistance beneficiaries will have lower rates of potentially preventable emergency department and hospital admissions.</td>
</tr>
<tr>
<td><strong>3—Continuity</strong></td>
<td></td>
</tr>
<tr>
<td>a. Gaps in coverage</td>
<td>iv. Premium Assistance beneficiaries will have fewer gaps in insurance coverage.</td>
</tr>
<tr>
<td>b. Continuous access to same health plans</td>
<td>v. Premium Assistance beneficiaries will maintain continuous access to the same health plans, and will maintain continuous access to providers.</td>
</tr>
<tr>
<td>c. Continuous access to same providers</td>
<td></td>
</tr>
</tbody>
</table>
Arkansas Proposed Evaluation Hypotheses | Arkansas Original Terms and Conditions Hypotheses  
--- | ---  
4—Cost effectiveness  
a. Admin costs  
b. Reduce premiums  
c. Comparable costs  
vi. Premium Assistance beneficiaries, including those who become eligible for Exchange Marketplace coverage, will have fewer gaps in plan enrollment, improved continuity of care, and resultant lower administrative costs.  
xi. Premium Assistance will reduce overall premium costs in the Exchange Marketplace and will increase quality of care.  
xii. The cost for covering Premium Assistance beneficiaries will be comparable to what the costs would have been for covering the same expansion group in Arkansas Medicaid fee-for-service in accordance with STC 68 on determining cost effectiveness and other requirements in the evaluation design as approved by CMS.  

* The outcomes of interest and evaluation approaches associated with hypotheses 2c and 2d are shared with 1b and 1c.
Appendix 2

Proposed Measure Descriptions and Definitions
Appendix 2A—Selected Measures from Initial Core Set of Health Care Quality Measures for Adults Enrolled in Medicaid

Measure 1: Flu Shots for Adults Ages 50 to 64

National Committee for Quality Assurance

A. DESCRIPTION

A rolling average represents the percentage of Medicaid enrollees ages 50 to 64 that received an influenza vaccination between September 1 of the measurement year and the date when the CAHPS 5.0H adult survey was completed.

Guidance for Reporting:

- This measure uses a rolling two-year average to achieve a sufficient number of respondents for reporting. First-year data collection will generally not yield enough responses to be reportable.

B. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Age</th>
<th>50 to 64 years as of September 1 of the measurement year.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous enrollment</td>
<td>The measurement year.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>No more than one gap of enrollment of up to 45 days during the measurement year.</td>
</tr>
<tr>
<td>Current enrollment</td>
<td>Currently enrolled at the time the survey is completed.</td>
</tr>
</tbody>
</table>

C. QUESTIONS INCLUDED IN THE MEASURE

<table>
<thead>
<tr>
<th>Question</th>
<th>Response Choices</th>
</tr>
</thead>
<tbody>
<tr>
<td>H16 Have you had a flu shot since September 1, YYYY? *</td>
<td>Yes</td>
</tr>
</tbody>
</table>

*YYYY = the measurement year (2012 for the survey fielded in 2013).

D. CALCULATION OF MEASURE

A rolling average is calculated using the following formula.

Rate = \((\text{Year 1 Numerator} + \text{Year 2 Numerator}) / (\text{Year 1 Denominator} + \text{Year 2 Denominator})\)

If the denominator is less than 100, a measure result of NA is assigned. If the denominator is 100 or more, a rate is calculated. If the state did not report results in the prior year (Year 1), but reports results for the current year and achieves a denominator of 100 or more (Year 2), a rate is calculated; if the denominator is less than 100, the rate is not reported.

Denominator: The number of Medicaid enrollees with a Measure Eligibility Flag of “Eligible” who responded “Yes” or “No” to the question “Have you had a flu shot since September 1, YYYY?”

Numerator: The number of Medicaid enrollees in the denominator who responded “Yes” to the question “Have you had a flu shot since September 1, YYYY?”
Appendix 2—Proposed Measure Descriptions and Definitions

Measure 2: Breast Cancer Screening

National Committee for Quality Assurance

A. DESCRIPTION
The percentage of Medicaid-enrolled women ages 42 to 69 that received a mammogram to screen for breast cancer.

Guidance for Reporting:
- This measure applies to Medicaid enrollees ages 42 to 69. For purposes of Medicaid Adult Core Set reporting, states should calculate and report this measure for two age groups (as applicable): ages 42 to 64 and ages 65 to 69.
- Include all paid, suspended, reversed, pending, and denied claims.

B. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Age</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous enrollment</td>
<td>The measurement year and the year prior to the measurement year.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>No more than a 1-month gap in coverage.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>December 31 of the measurement year.</td>
</tr>
<tr>
<td>Benefit</td>
<td>Medical.</td>
</tr>
<tr>
<td>Event/diagnosis</td>
<td>None.</td>
</tr>
</tbody>
</table>

C. ADMINISTRATIVE SPECIFICATION

Denominator: The eligible population.

Numerator: One or more mammograms during the measurement year or the year prior to the measurement year. A woman had a mammogram if a submitted claim/encounter contains any code in Table 3.1.

Table 3.1. Codes to Identify Breast Cancer Screening

<table>
<thead>
<tr>
<th>CPT</th>
<th>HCPCS</th>
<th>ICD-9-CM Procedure</th>
<th>UB Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>77055-77057</td>
<td>G0202, G0204, G0206</td>
<td>87.36, 87.37</td>
<td>0401, 0403</td>
</tr>
</tbody>
</table>

Table 3.2. Codes for Identifying Exclusions

<table>
<thead>
<tr>
<th>Description</th>
<th>CPT</th>
<th>ICD-9-CM Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bilateral mastectomy</td>
<td></td>
<td>85.42, 85.44, 85.46, 85.48</td>
</tr>
<tr>
<td>Unilateral mastectomy</td>
<td>19180, 19200, 19220, 19240, 19303-19307</td>
<td>85.41, 85.43, 85.45, 85.47</td>
</tr>
<tr>
<td>Bilateral modifier (a bilateral procedure performed during the same operative session)</td>
<td>50, 09950</td>
<td></td>
</tr>
<tr>
<td>Right side modifier</td>
<td>RT</td>
<td></td>
</tr>
<tr>
<td>Left side modifier</td>
<td>LT</td>
<td></td>
</tr>
</tbody>
</table>
D. ADDITIONAL NOTES

This measure evaluates primary screening. Do not count biopsies, breast ultrasounds, or MRIs because they are not appropriate methods for primary breast cancer screening.

**Measure 3: Cervical Cancer Screening**

National Committee for Quality Assurance

A. DESCRIPTION

The percentage of Medicaid-enrolled women ages 24 to 64 that received one or more Pap tests to screen for cervical cancer.

Guidance for Reporting:
- Include all paid, suspended, reversed, pending, and denied claims.

B. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Age</th>
<th>Women ages 24 to 64 as of December 31 of the measurement year.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous enrollment</td>
<td>The measurement year.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>No more than a 1-month gap in coverage.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>December 31 of the measurement year.</td>
</tr>
<tr>
<td>Benefit</td>
<td>Medical.</td>
</tr>
<tr>
<td>Event/diagnosis</td>
<td>None.</td>
</tr>
</tbody>
</table>

C. ADMINISTRATIVE SPECIFICATION

Denominator: The eligible population.

Numerator: One or more Pap tests during the measurement year or the two years prior to the measurement year. A woman had a Pap test if a submitted claim/encounter contains any code in Table 4.1.

Table 4.1. Codes to Identify Cervical Cancer Screening

<table>
<thead>
<tr>
<th>CPT</th>
<th>HCPCS</th>
<th>ICD-9-CM Procedure</th>
<th>UB Revenue</th>
<th>LOINC</th>
</tr>
</thead>
<tbody>
<tr>
<td>88141-88143, 88147,</td>
<td>G0123, G0124,</td>
<td>91.46</td>
<td>0923</td>
<td>10524-7, 18500-9, 19762-4,</td>
</tr>
</tbody>
</table>
Table 4.2. Codes to Identify Exclusions

<table>
<thead>
<tr>
<th>Description</th>
<th>CPT</th>
<th>ICD-9-CM Diagnosis</th>
<th>ICD-9-CM Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hysterectomy</td>
<td>51925, 56308, 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200, 58210, 58240, 58260, 58262, 58263, 58267, 58270, 58275, 58280, 58285, 58290-58294, 58548, 58550-58554, 58570-58573, 58951, 58953, 58954, 58956, 59135</td>
<td>618.5, 752.43, V67.01, V76.47, V88.01, V88.03</td>
<td>68.4-68.8</td>
</tr>
</tbody>
</table>

D. ADDITIONAL NOTES

Lab results that indicate the sample contained “no endocervical cells” may be used if a valid result was reported for the test.

Exclusions (optional)

Refer to Administrative Specification for exclusion criteria. Exclusionary evidence in the medical record must include a note indicating a hysterectomy with no residual cervix. The hysterectomy must have occurred by December 31 of the measurement year. Documentation of “complete,” “total,” or “radical” abdominal or vaginal hysterectomy meets the criteria for hysterectomy with no residual cervix.

Documentation of a “vaginal pap smear” in conjunction with documentation of “hysterectomy” meets exclusion criteria, but documentation of hysterectomy alone does not meet the criteria because it does not indicate that the cervix was removed.

**Measure 4: Plan All-Cause Readmission Rate**

National Committee for Quality Assurance

A. DESCRIPTION

For Medicaid enrollees age 18 and older, the number of acute inpatient stays during the measurement year that were followed by an acute readmission for any diagnosis within 30 days and the predicted probability of an acute readmission. Data are reported in the following three categories:

- Count of Index Hospital Stays (IHS) (denominator)
- Count of 30-Day Readmissions (numerator)
- Average Adjusted Probability of Readmission (rate)

Guidance for Reporting:

- This measure applies to Medicaid enrollees age 18 and older. For purposes of Medicaid Adult Core Set reporting, states should calculate and report this measure for two age groups (as applicable): ages 18 to 64 and age 65 and older.
- Include all paid, suspended, pending, and denied claims.
- This measure requires risk adjustment. Risk adjustment tables for Medicare and commercial populations are posted at [http://www.ncga.org](http://www.ncga.org). There are no standardized risk adjustment tables for Medicaid. States reporting this measure should describe the method they used for risk adjustment weighting and calculation of the adjusted probability of readmission. Appendix A provides additional information on risk adjustment methods in the non-Medicaid population.
B. DEFINITIONS

<table>
<thead>
<tr>
<th>IHS</th>
<th>Index hospital stay. An acute inpatient stay with a discharge on or between January 1 and December 1 of the measurement year. Exclude stays that meet the exclusion criteria in the denominator section.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Index Admission Date</td>
<td>The IHS admission date.</td>
</tr>
<tr>
<td>Index Discharge Date</td>
<td>The IHS discharge date. The index discharge date must occur on or between January 1 and December 1 of the measurement year.</td>
</tr>
<tr>
<td>Index Readmission Stay</td>
<td>An acute inpatient stay for any diagnosis with an admission date within 30 days of a previous Index Discharge Date.</td>
</tr>
<tr>
<td>Index Readmission Date</td>
<td>The admission date associated with the Index Readmission Stay.</td>
</tr>
<tr>
<td>Classification Period</td>
<td>365 days prior to and including an Index Discharge Date.</td>
</tr>
</tbody>
</table>

C. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Age</th>
<th>Age 18 and older as of the Index Discharge Date.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous Enrollment</td>
<td>365 days prior to the Index Discharge Date through 30 days after the Index Discharge Date.</td>
</tr>
<tr>
<td>Allowable Gap</td>
<td>No more than one gap in enrollment of up to 45 days during the 365 days prior to the Index Discharge Date and no gap during the 30 days following the Index Discharge Date.</td>
</tr>
<tr>
<td>Anchor Date</td>
<td>Index Discharge Date.</td>
</tr>
<tr>
<td>Benefit</td>
<td>Medical.</td>
</tr>
<tr>
<td>Event/ Diagnosis</td>
<td>An acute inpatient discharge on or between January 1 and December 1 of the measurement year. The denominator for this measure is based on discharges, not Medicaid enrollees. Include all acute inpatient discharges for Medicaid enrollees who had one or more discharges on or between January 1 and December 1 of the measurement year. The state should follow the steps below to identify acute inpatient stays.</td>
</tr>
</tbody>
</table>

D. Denominator: The eligible population.

Numerator: At least one acute readmission for any diagnosis within 30 days of the Index Discharge Date.

E. ADDITIONAL NOTES

States may not use Risk Assessment Protocols to supplement diagnoses for calculation of the risk adjustment scores for this measure. The PCR measurement model was developed and tested using only claims-based diagnoses and diagnoses from additional data sources would affect the validity of the models as they are currently implemented in the specification.
Measure 5: Diabetes Short-Term Complications Admission Rate

Agency for Healthcare Research and Quality

A. DESCRIPTION

The number of discharges for diabetes short-term complications per 100,000 Medicaid enrollees age 18 and older.

Guidance for Reporting:
- This measure applies to Medicaid enrollees age 18 and older. For purposes of Medicaid Adult Core Set reporting, states should calculate and report this measure for two age groups (as applicable): ages 18 to 64 and age 65 and older.

B. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Member months</th>
<th>All member months for Medicaid enrollees age 18 and older as of the 30th day of the month.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous enrollment</td>
<td>There is no continuous enrollment requirement.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>There is no gap in coverage requirement.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>There is no anchor date.</td>
</tr>
</tbody>
</table>

C. ADMINISTRATIVE SPECIFICATION

Denominator: Medicaid enrollees age 18 and older.

Numerator: All discharges with ICD-9-CM principal diagnosis code for short-term complications (ketoacidosis, hyperosmolarity, coma).

 Include ICD-9-CM diagnosis codes:

25010 DM KETO T2, NT ST UNCNTRLD
25011 DM KETO T1, NT ST UNCNTRLD
25012 DM KETOACD UNCONTROLD
25013 DM KETOACD UNCONTROLD
25020 DMII HPRSM NT ST UNCNTRL
25021 DMI HPRSM NT ST UNCNTRL
25022 DMII HPROSMRL UNCONTROLD
25023 DMI HPROSMRL UNCONTROLD
25030 DMII O CM NT ST UNCNTRL
25031 DMI O CM NT UNCNTRL
25032 DMII OTH COMA UNCONTROLD
25033 DMI OTH COMA UNCONTROLD
Exclusions

- Transfer from a hospital (different facility)
- Transfer from a Skilled Nursing Facility (SNF) or Intermediate Care Facility (ICF)
- Transfer from another health care facility
- With missing gender (SEX = missing), age (AGE = missing), quarter (DQTR = missing), year (YEAR = missing), principal diagnosis (DX1 = missing), or county (PSTCO = missing)
- MDC 14 (pregnancy, childbirth, and puerperium)

**Measure 6: Chronic Obstructive Pulmonary Disease (COPD) Admission Rate**

Agency for Healthcare Research and Quality

A. DESCRIPTION

The number of discharges for chronic obstructive pulmonary disease (COPD) per 100,000 Medicaid enrollees age 18 and older.

Guidance for Reporting:

- This measure applies to Medicaid enrollees age 18 and older. For purposes of Medicaid Adult Core Set reporting, states should calculate and report this measure for two age groups (as applicable): ages 18 to 64 and age 65 and older.

B. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Member months</th>
<th>All member months for Medicaid enrollees age 18 and older as of the 30th day of the month.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous enrollment</td>
<td>There is no continuous enrollment requirement.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>There is no gap in coverage requirement.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>There is no anchor date.</td>
</tr>
</tbody>
</table>

C. ADMINISTRATIVE SPECIFICATION

Denominator: Medicaid enrollees age 18 and older.

Numerator: All non-maternal discharges with an ICD-9-CM principal diagnosis code for COPD. Select codes appearing in the primary diagnosis position must be accompanied by a secondary diagnosis of COPD.

Include ICD-9-CM COPD diagnosis codes:

- 4660 ACUTE BRONCHITIS*
- 490 BRONCHITIS NOS*
- 4910 SIMPLE CHR BRONCHITIS
- 4911 MUCOPURUL CHR BRONCHITIS
- 49120 OBST CHR BRONC W/O EXAC
- 49121 OBS CHR BRONC W(AC) EXAC
4918 CHRONIC BRONCHITIS NEC
4919 CHRONIC BRONCHITIS NOS
4920 EMPHYSEMATOUS BLEB
4928 EMPHYSEMA NEC
494 BRONCHIECTASIS
4940 BRONCHIECTAS W/O AC EXAC
4941 BRONCHIECTASIS W AC EXAC
496 CHR AIRWAY OBSTRUCT NEC

*Must be accompanied by a secondary diagnosis code of COPD.

Exclusions
- Transfer from a hospital (different facility)
- Transfer from a skilled Nursing Facility (SNF) or Intermediate Care Facility (ICF)
- Transfer from another health care facility
- With missing gender (SEX = missing), age (AGE = missing), quarter (DQTR = missing), year (YEAR = missing), principal diagnosis (DX1 = missing), or county (PSTCO = missing)
- MDC 14 (pregnancy, childbirth, and puerperium)

Measure 7: Congestive Heart Failure (CHF) Admission Rate

Agency for Healthcare Research and Quality

A. DESCRIPTION
The number of discharges for congestive heart failure (CHF) per 100,000 Medicaid enrollees age 18 and older.

Guidance for Reporting:
- This measure applies to Medicaid enrollees age 18 and older. For purposes of Medicaid Adult Core Set reporting, states should calculate and report this measure for two age groups (as applicable): ages 18 to 64 and age 65 and older.

B. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Member months</th>
<th>All member months for Medicaid enrollees ages 18 and older as of the 30th day of the month.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous enrollment</td>
<td>There is no continuous enrollment requirement.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>There is no gap in coverage requirement.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>There is no anchor date.</td>
</tr>
</tbody>
</table>

C. ADMINISTRATIVE SPECIFICATION
Denominator: Medicaid enrollees age 18 and older.

Numerator: All discharges with ICD-9-CM principal diagnosis code for CHF.
ICD-9-CM Diagnosis Codes (Discharges after September 30, 2002):
39891 RHEUMATIC HEART FAILURE
4280 CONGESTIVE HEART FAILURE
4281 LEFT HEART FAILURE
42820 SYSTOLIC HRT FAILURE NOS OCT02-
42821 AC SYSTOLIC HRT FAILURE OCT02-
42822 CHR SYSTOLIC HRT FAILURE OCT02-
42823 AC ON CHR SYST HRT FAIL OCT02-
42830 DIASTOLIC HRT FAILURE NOS OCT02-
42831 AC DIASTOLIC HRT FAILURE OCT02-
42832 CHR DIASTOLIC HRT FAIL OCT02-
42840 SYST/DIASTOLIC HRT FAIL NOS OCT02-
42841 AC SYST/DIASTOL HRT FAIL OCT02-
42842 CHR SYST/DIASTOL HRT FAIL OCT02-
42843 AC/CHR SYST/DIASTOL HRT FAIL OCT02-
4289 HEART FAILURE NOS

ICD-9-CM Diagnosis Codes (Discharges before September 30, 2002):
40201 MAL HYPERT HRT DIS W CHF
40211 BENIGN HYP HRT DIS W CHF
40291 HYPERTEN HEART DIS W CHF
40401 MAL HYPER HRT/REN W CHF
40403 MAL HYP HRT/REN W CHF/RF
40411 BEN HYPER HRT/REN W CHF
40413 BEN HYP HRT/REN W CHF/RF
40491 HYPER HRT/REN NOS W CHF
40493 HYP HT/REN NOS W CHF/RF

Exclusions
- Transfer from a hospital (different facility)
- Transfer from a skilled Nursing Facility (SNF) or Intermediate Care Facility (ICF)
- Transfer from another health care facility
- With missing gender (SEX = missing), age (AGE = missing), quarter (DQTR = missing), year (YEAR = missing), principal diagnosis (DX1 = missing), or county (PSTCO = missing)
• MDC 14 (pregnancy, childbirth, and puerperium) With a cardiac procedure code

With a cardiac procedure code-
ICD-9-CM Cardiac Procedure Codes:

0050 IMPL CRT PACEMAKER SYS OCT02-
0051 IMPL CRT DEFIBRILLAT OCT02-
0052 IMP/REP LEAD LF VEN SYS OCT02-
0053 IMP/REP CRT PACEMKR GEN OCT02-
0054 IMP/REP CRT DEFIB GENAT OCT02-
0056 INS/REP IMPL SENSOR LEAD OCT06-
0057 IMP/REP SUBCUE CARD DEV OCT06-
0066 PTCA OCT06-
1751 IMPLANTATION OF RECHARGEABLE CARDIAC CONTRACTILITY MODULATION [CM], TOTAL SYSTEM OCT09-
1752 IMPLANTATION OR REPLACEMENT OF CARDIAC CONTRACTILITY MODULATION [CM] RECHARGEABLE PULSE, GENERATOR ONLY OCT09-
3500 CLOSED VALVOTOMY NOS
3501 CLOSED AORTIC VALVOTOMY
3502 CLOSED MITRAL VALVOTOMY
3503 CLOSED PULMON VALVOTOMY
3504 CLOSED TRICUSP VALVOTOMY
3510 OPEN VALVULOPLASTY NOS
3511 OPN AORTIC VALVULOPLASTY
3512 OPN MITRAL VALVULOPLASTY
3513 OPN PULMON VALVULOPLASTY
3514 OPN TRICUS VALVULOPLASTY
3520 REPLACE HEART VALVE NOS
3521 REPLACE AORT VALV-TISSUE
3522 REPLACE AORTIC VALVE NEC
3523 REPLACE MITR VALV-TISSUE
3524 REPLACE MITRAL VALVE NEC
3525 REPLACE PULM VALV-TISSUE
3526 REPLACE PULMON VALVE NEC
3527 REPLACE TRIC VALV-TISSUE
3528 REPLACE TRICUSP VALV NEC
3531 PAPILLARY MUSCLE OPS
3532 CHORDAE TENDINEAE OPS
3533 ANNULOPLASTY
3534 INFUNDIBULECTOMY
3535 TRABECUL CARNEAE CORD OP
3539 TISS ADJ TO VALV OPS NEC
3541 ENLARGE EXISTING SEP DEF
3542 CREATE SEPTAL DEFECT
3550 PROSTH REP HRT SEPTA NOS
3551 PROS REP ATRIAL DEF-OPN
3552 PROS REPAIR ATRIA DEF-CL
3553 PROST REPAIR VENTRIC DEF
3554 PROS REP ENDOCAR CUSHION
3555 PROS REP VENTRC DEF-CLOS OCT06-
3560 GRFT REPAIR HRT SEPT NOS
3561 GRAFT REPAIR ATRIAL DEF
3562 GRAFT REPAIR VENTRIC DEF
3563 GRFT REP ENDOCAR CUSHION
3570 HEART SEPTA REPAIR NOS
3571 ATRIA SEPTA DEF REP NEC
3572 VENTR SEPTA DEF REP NEC
3573 ENDOCAR CUSHION REP NEC
3581 TOT REPAIR TETRAL FALLOT
3582 TOTAL REPAIR OF TAPVC
3583 TOT REP TRUNCUS ARTERIOS
3584 TOT COR TRANSPOS GRT VES
3591 INTERAT VEN RETRN TRANSP
3592 CONDUIT RT VENT-PUL ART
3593 CONDUIT LEFT VENTR-AORTA
3594 CONDUIT ARTIUM-PULM ART
3595 HEART REPAIR REVISION
3596 PERC HEART VALVULOPLASTY
3598 OTHER HEART SEPTA OPS
3599 OTHER HEART VALVE OPS
3601 PTCA-1 VESSEL W/O AGENT
3602 PTCA-1 VESSEL WITH AGNT
3603 OPEN CORONRY ANGIOPLASTY
Appendix 2—Proposed Measures (Medicaid Adult Core Set)
3760 IMPLANTATION OR INSERTION OF BIVENTRICULAR EXTERNAL HEART ASSIST SYSTEM OCT08
3761 IMPLANT OF PULSATION BALLOON
3762 INSERTION OF NON-IMPLANTABLE HEART ASSIST SYSTEM
3763 REPAIR OF HEART ASSIST SYSTEM
3764 REMOVAL OF HEART ASSIST SYSTEM
3765 IMPLANT OF EXTERNAL HEART ASSIST SYSTEM
3766 INSERTION OF IMPLANTABLE HEART ASSIST SYSTEM
3770 INT INSERT PACEMAK LEAD
3771 INT INSERT LEAD IN VENT
3772 INT INSERT LEAD ATRI-VENT
3773 INT INSER LEAD IN ATRIUM
3774 INT OR REPL LEAD EPICAR
3775 REVISION OF LEAD
3776 REPL TV ATRI-VENT LEAD
3777 REMOVAL OF LEAD W/O REPL
3778 INSER TEAM PACEMAKER SYS
3779 REVIS OR RELOCATE POCKET
3780 INT OR REPL PERM PACEMKR
3781 INT INSERT 1-CHAM, NON
3782 INT INSERT 1-CHAM, RATE
3783 INT INSERT DUAL-CHAM DEV
3785 REPL PACEM W 1-CHAM, NON
3786 REPL PACEM 1-CHAM, RATE
3787 REPL PACEM W DUAL-CHAM
3789 REVISE OR REMOVE PACEMAK
3794 IMPLT/REPL CARDDEFIB TOT
3795 IMPLT CARDIODEFIB LEADS
3796 IMPLT CARDIODEFIB GENATR
3797 REPL CARDIODEFIB LEADS
3798 REPL CARDIODEFIB GNRATR
Appendix A

Proposed Evaluation for Section 1115 Demonstration Waiver
Arkansas Health Care Independence Program (“Private Option”)

Measure 8: Adult Asthma Admission Rate

Agency for Healthcare Research and Quality

A. DESCRIPTION

The number of discharges for asthma in adults per 100,000 Medicaid enrollees age 18 and older.

Guidance for Reporting:
- This measure applies to Medicaid enrollees age 18 and older. For purposes of Medicaid Adult Core Set reporting, states should calculate and report this measure for two age groups (as applicable): ages 18 to 64 and age 65 and older.

B. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Member months</th>
<th>All member months for Medicaid enrollees age 18 and older as of the 30th day of the month.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous enrollment</td>
<td>There is no continuous enrollment requirement.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>There is no gap in coverage requirement.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>There is no anchor date.</td>
</tr>
</tbody>
</table>

C. ADMINISTRATIVE SPECIFICATION

Denominator: Medicaid enrollees age 18 and older.

Numerator: All non-maternal discharges for enrollees age 18 and older with an ICD-9-CM principal diagnosis code of asthma.

Include ICD-9-CM diagnosis codes:

49300 EXT ASTHMA W/O STAT ASTH
49301 EXT ASTHMA W STATUS ASTH
49302 EXT ASTHMA W ACUTE EXAC OCT00-
49310 INT ASTHMA W/O STAT ASTH
49311 INT ASTHMA W STAT ASTH
49312 INT ASTHMA W ACUTE EXAC OCT00-
49320 CH OB ASTH W/O STAT ASTH
49321 CH OB ASTHMA W STAT ASTH
49322 CH OBS ASTH W ACUTE EXAC OCT00-
49381 EXERCISE IND BRONCHOSPASM OCT03-
49382 COUGH VARIANT ASTHMA OCT03-
49390 ASTHMA W/O STATUS ASTHM
49391 ASTHMA W STATUS ASTHMAT

49392 ASTHMA W ACUTE EXACERBTN OCT00-

Exclusions

- Transfer from a hospital (different facility)
- Transfer from a skilled Nursing Facility (SNF) or Intermediate Care Facility (ICF)
- Transfer from another health care facility
- With missing gender (SEX = missing), age (AGE = missing), quarter (DQTR = missing), year (YEAR = missing), principal diagnosis (DX1 = missing), or county (PSTCO = missing)
- MDC 14 (pregnancy, childbirth, and puerperium) With any diagnosis code of cystic fibrosis and anomalies of the respiratory system

ICD-9-CM Cystic Fibrosis and Anomalies of the Respiratory System Diagnosis Codes:

27700 CYSTIC FIBROS W/O ILEUS
27701 CYSTIC FIBROSIS W ILEUS
27702 CYSTIC FIBROS W PUL MAN
27703 CYSTIC FIBROSIS W GI MAN
27709 CYSTIC FIBROSIS NEC
51661 NEUROEND CELL HYPRPL INF
51662 PULM INTERSTITL GLYCOGEN
51663 SURFACTANT MUTATION LUNG
51664 ALV CAP DYSP W VN MISALIGN
51669 OTH INTRST LUNG DIS CHLD
7421 ANOMALIES OF AORTIC ARCH
7483 LARYNGOTRACH ANOMALY NEC
7484 CONGENITAL CYSTIC LUNG
7485 AGENESIS OF LUNG
74860 LUNG ANOMALY NOS
74861 CONGEN BRONCHIECTASIS
74869 LUNG ANOMALY NEC
7488 RESPIRATORY ANOMALY NEC
7489 RESPIRATORY ANOMALY NOS
7503 CONG ESOPH FISTULA/ATRES
7593 SITUS INVERSUS
7707 PERINATAL CHR RESP DIS
Measure 9: Follow-Up After Hospitalization for Mental Illness

National Committee for Quality Assurance

A. DESCRIPTION

The percentage of discharges for Medicaid enrollees age 21 and older that were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an intensive outpatient encounter, or partial hospitalization with a mental health practitioner. Two rates are reported:

- Percentage of discharges for which the enrollee received follow-up within 30 days of discharge
- Percentage of discharges for which the enrollee received follow-up within 7 days of discharge

Guidance for Reporting:
- In the original HEDIS specification, the eligible population for this measure includes patients age 6 and older as of the date of discharge. The Medicaid Adult Core Set measure has an eligible population of adults age 21 and older. States should calculate and report the two rates listed above for each of the two age groups (as applicable): ages 21 to 64 and age 65 and older.
- Include all paid, suspended, pending, reversed, and denied claims.

B. DEFINITION

Mental Health Practitioner

A practitioner who provides mental health services and meets any of the following criteria:

- An MD or doctor of osteopathy (DO) who is certified as a psychiatrist or child psychiatrist by the American Medical Specialties Board of Psychiatry and Neurology or by the American Osteopathic Board of Neurology and Psychiatry; or, if not certified, who successfully completed an accredited program of graduate medical or osteopathic education in psychiatry or child psychiatry and is licensed to practice patient care psychiatry or child psychiatry, if required by the state of practice.
- An individual who is licensed as a psychologist in his/her state of practice.
- An individual who is certified in clinical social work by the American Board of Examiners; who is listed on the National Association of Social Worker’s Clinical Register; or who has a master’s degree in social work and is licensed or certified to practice as a social worker, if required by the state of practice.

C. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Age</th>
<th>Age 21 and older as of date of discharge.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous enrollment</td>
<td>Date of discharge through 30 days after discharge.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>No gaps in enrollment.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>None.</td>
</tr>
<tr>
<td>Benefit</td>
<td>Medical and mental health (inpatient and outpatient).</td>
</tr>
</tbody>
</table>
**Event/diagnosis**

Discharged alive from an acute inpatient setting (including acute care psychiatric facilities) with a principal mental health diagnosis (Table 13.1) on or between January 1 and December 1 of the measurement year. Use only facility claims to identify discharges with a principal mental health diagnosis. Do not use diagnoses from professional claims to identify discharges. The denominator for this measure is based on discharges, not enrollees. If enrollees had more than one discharge, include all discharges on or between January 1 and December 1 of the measurement year.

Mental health readmission or direct transfer:

If the discharge is followed by readmission or direct transfer to an acute facility for a mental health principal diagnosis (Tables 13.1 and 13.2) within the 30-day follow-up period, count only the readmission discharge or the discharge from the facility to which the member was transferred. Although rehospitalization might not be for a selected mental health disorder, it is probably for a related condition.

Exclude both the initial discharge and the readmission/direct transfer discharge if the readmission/direct transfer discharge occurs after December 1 of the measurement year.

Exclude discharges followed by readmission or direct transfer to a nonacute facility for a mental health principal diagnosis (Tables 13.1 and 13.2) within the 30-day follow-up period. These discharges are excluded from the measure because readmission or transfer may prevent an outpatient follow-up visit from taking place. Refer to Table 13.3 for codes to identify nonacute care.

Non-mental health readmission or direct transfer:

Exclude discharges in which the enrollee was transferred directly or readmitted within 30 days after discharge to an acute or nonacute facility for a non-mental health principal diagnosis. This includes an ICD-9-CM Diagnosis code or DRG code other than those in Tables 13.1 and 13.2. These discharges are excluded from the measure because rehospitalization or transfer may prevent an outpatient follow-up visit from taking place.

| Table 13.1. Codes to Identify Mental Health Diagnosis ICD-9- |
| CM Diagnosis                        |
| 295–299, 300.3, 300.4, 301, 308, 309, 311–314 |

| Table 13.2. Codes to Identify Inpatient Services MS—DRG |
| 876, 880-887; exclude discharges with ICD-9-CM Principal Diagnosis code 317-319 |
Table 13.3. Codes to Identify Nonacute Care

<table>
<thead>
<tr>
<th>Description</th>
<th>HCPCS</th>
<th>UB Revenue</th>
<th>UB Type of Bill</th>
<th>POS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospice</td>
<td>0115, 0125,</td>
<td>81x, 82x</td>
<td></td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>0135, 0145,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0155, 0650,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0656, 0658,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0659</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SNF</td>
<td>019x</td>
<td>21x, 22x, 28x</td>
<td></td>
<td>31, 32</td>
</tr>
<tr>
<td>Hospital transitional care, swing bed or rehabilitation</td>
<td></td>
<td>18x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rehabilitation</td>
<td>0118, 0128,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0138, 0148,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0158</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respite</td>
<td>0655</td>
<td></td>
<td></td>
<td>54</td>
</tr>
<tr>
<td>Intermediate care facility</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Residential substance abuse treatment facility</td>
<td></td>
<td>1002</td>
<td></td>
<td>55</td>
</tr>
<tr>
<td>Psychiatric residential treatment center</td>
<td>T2048, H0017-H0019</td>
<td>1001</td>
<td></td>
<td>56</td>
</tr>
<tr>
<td>Comprehensive inpatient rehabilitation facility</td>
<td></td>
<td></td>
<td></td>
<td>61</td>
</tr>
<tr>
<td>Other nonacute care facilities that do not use the UB revenue or type of bill codes for billing (e.g., ICF, SNF)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D. ADMINISTRATIVE SPECIFICATION

Denominator: The eligible population.

Numerator:

30-Day Follow-Up

An outpatient visit, intensive outpatient encounter, or partial hospitalization (Table 13.4) with a mental health practitioner within 30 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge.

7-Day Follow-Up

An outpatient visit, intensive outpatient encounter, or partial hospitalization (Table 13.4) with a mental health practitioner within 7 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge.
Table 13.4. Codes to Identify Visits

<table>
<thead>
<tr>
<th>CPT</th>
<th>HCPCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follow-up visits identified by the following CPT or HCPCS codes must be with a mental health practitioner</td>
<td></td>
</tr>
<tr>
<td>90804-90815, 98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99383-99387, 99393-99397, 99401-99404, 99411, 99412, 99510</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CPT</th>
<th>POS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follow-up visits identified by the following CPT/POS codes must be with a mental health practitioner</td>
<td></td>
</tr>
<tr>
<td>90801, 90802, 90816-90819, 90821-90824, 90826-90829, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90875, 90876</td>
<td></td>
</tr>
<tr>
<td>WITH 03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 24, 33, 49, 50, 52, 53, 71, 72</td>
<td></td>
</tr>
<tr>
<td>99221-99223, 99231-99233, 99238, 99239, 99251-99255</td>
<td></td>
</tr>
<tr>
<td>WITH 52, 53</td>
<td></td>
</tr>
</tbody>
</table>

UB Revenue

The organization does not need to determine practitioner type for follow-up visits identified by the following UB revenue codes

| 0513, 0900-0905, 0907, 0911-0917, 0919 |

Visits identified by the following revenue codes must be with a mental health practitioner or in conjunction with a diagnosis code from Table 13.1

| 0510, 0515-0517, 0519-0523, 0526-0529, 0982, 0983 |

E. ADDITIONAL NOTES

There may be different methods for billing intensive outpatient encounters and partial hospitalizations. Some methods may be comparable to outpatient billing, with separate claims for each date of service; others may be comparable to inpatient billing, with an admission date, a discharge date and units of service. Where billing methods are comparable to inpatient billing, each unit of service may be counted as an individual visit. The unit of service must have occurred during the required time frame for the rate (e.g., within 30 days after discharge or within 7 days after discharge).
Measure 10: Annual HIV/AIDS Medical Visit

National Committee for Quality Assurance

A. DESCRIPTION

The percentage of Medicaid enrollees age 18 and older with a diagnosis of HIV/AIDS and with at least two medical visits during the measurement year, with a minimum of 90 and 180 days between each visit.

Guidance for Reporting:

• This measure applies to Medicaid enrollees age 18 and older. For purposes of Medicaid Adult Core Set reporting, states should calculate and report this measure for two age groups (as applicable): ages 18 to 64 and age 65 and older.
• Include all paid, suspended, pending, reversed, and denied claims.

B. DEFINITION

| Medical Visit | Any visit with a health care professional who provides routine primary care for the patient with HIV/AIDS (may be a primary care physician, OB/GYN, pediatrician or infectious diseases specialist). |

C. ADMINISTRATIVE SPECIFICATION

Denominator: All enrollees age 18 and older with a diagnosis of HIV/AIDS (Table 16.1).

Table 16.1. Codes to Identify HIV/AIDS

<table>
<thead>
<tr>
<th>Description</th>
<th>ICD-9-CM Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-AIDS</td>
<td>042, V08</td>
</tr>
</tbody>
</table>

Numerator 1: Enrollees with at least two medical visits (Table 16.2) during the measurement year, with a minimum of 90 days between each visit.

Numerator 2: Enrollees with at least two medical visits (Table 16.2) during the measurement year, with a minimum of 180 days between each visit.

Table 16.2. Codes to Identify Medical Visits

<table>
<thead>
<tr>
<th>Description</th>
<th>CPT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Visits</td>
<td>99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99381, 99382, 99383, 99384, 99385, 99386, 99387, 99391, 99392, 99393, 99394, 99395, 99396, 99397, 99241, 99242, 99243, 99244, 99245</td>
</tr>
</tbody>
</table>
Appendix 2—Proposed Measures (Medicaid Adult Core Set)

Arkansas Health Care Independence Program ("Private Option")
Proposed Evaluation for Section 1115 Demonstration Waiver
February 2014

Measure 11: Comprehensive Diabetes Care: LDL-C Screening

National Committee for Quality Assurance

A. DESCRIPTION

The percentage of Medicaid enrollees ages 18 to 75 with diabetes (type 1 and type 2) who had a LDL-C screening test.

Guidance for Reporting:

- This measure is based on the original HEDIS specification that includes multiple diabetes care indicators. Only the LDL screening indicator is included in this measure.
- This measure applies to Medicaid enrollees ages 18 to 75. For purposes of Medicaid Adult Core Set reporting, states should calculate and report this measure for two age groups (as applicable): ages 18 to 64 and ages 65 to 75.
- Include all paid, suspended, pending, reversed, and denied claims.

B. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Age</th>
<th>Ages18 to 75 as of December 31 of the measurement year.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous enrollment</td>
<td>The measurement year.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>No more than 1-month gap in coverage.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>December 31 of the measurement year.</td>
</tr>
<tr>
<td>Benefit</td>
<td>Medical.</td>
</tr>
<tr>
<td>Event/diagnosis</td>
<td>There are two ways to identify Medicaid enrollees with diabetes: by pharmacy data and by claim/encounter data. The organization must use both methods to identify the eligible population, but an enrollee only needs to be identified by one method to be included in the measure. Medicaid enrollees may be identified as having diabetes during the measurement year or the year prior to the measurement year. Pharmacy data. Medicaid enrollees who were dispensed insulin or oral hypoglycemics/antihyper-glycemics during the measurement year or year prior to the measurement year on an ambulatory basis (Table 18.1). Claim/encounter data. Medicaid enrollees who had two face-to-face encounters, in an outpatient setting or nonacute inpatient setting, on different dates of service, with a diagnosis of diabetes (Table 18.2), or one face-to-face encounter in an acute inpatient or ED setting, with a diagnosis of diabetes, during the measurement year or the year prior to the measurement year. The state may count services that occur over both years. Refer to Table 18.3 for codes to identify visit type.</td>
</tr>
</tbody>
</table>
Table 18.1. Prescriptions to Identify Medicaid Enrollees with Diabetes

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-glucosidase inhibitors</td>
<td>Acarbose</td>
</tr>
<tr>
<td></td>
<td>Miglitol</td>
</tr>
<tr>
<td>Amylin analogs</td>
<td>Pramlinitide</td>
</tr>
<tr>
<td>Antidiabetic combinations</td>
<td>Glimepiride-pioglitazone</td>
</tr>
<tr>
<td></td>
<td>Glimepiride-rosiglitazone</td>
</tr>
<tr>
<td></td>
<td>Glipizide-metformin</td>
</tr>
<tr>
<td></td>
<td>Glyburide-metformin</td>
</tr>
<tr>
<td></td>
<td>Linagliptin-metformin-pioglitazone</td>
</tr>
<tr>
<td></td>
<td>Metformin-rosiglitazone</td>
</tr>
<tr>
<td></td>
<td>Metformin-saxagliptin</td>
</tr>
<tr>
<td></td>
<td>Metformin-sitagliptin</td>
</tr>
<tr>
<td></td>
<td>Saxagliptin</td>
</tr>
<tr>
<td></td>
<td>Sitagliptin-simvastatin</td>
</tr>
<tr>
<td>Insulin</td>
<td>Insulin aspart</td>
</tr>
<tr>
<td></td>
<td>Insulin aspart-insulin aspart protamine</td>
</tr>
<tr>
<td></td>
<td>Insulin detemir</td>
</tr>
<tr>
<td></td>
<td>Insulin glargine</td>
</tr>
<tr>
<td></td>
<td>Insulin glulisine</td>
</tr>
<tr>
<td></td>
<td>Insulin inhalation</td>
</tr>
<tr>
<td></td>
<td>Insulin isophane beef-pork</td>
</tr>
<tr>
<td></td>
<td>Insulin isophane human</td>
</tr>
<tr>
<td></td>
<td>Insulin isophane-insulin regular</td>
</tr>
<tr>
<td></td>
<td>Insulin lispro</td>
</tr>
<tr>
<td></td>
<td>Insulin lispro-insulin lispro protamine</td>
</tr>
<tr>
<td></td>
<td>Insulin regular human</td>
</tr>
<tr>
<td></td>
<td>Insulin zinc human</td>
</tr>
<tr>
<td>Meglitinides</td>
<td>Nateglinide</td>
</tr>
<tr>
<td></td>
<td>Repaglinide</td>
</tr>
<tr>
<td>Miscellaneous antidiabetic agents</td>
<td>Exenatide</td>
</tr>
<tr>
<td></td>
<td>Linagliptin</td>
</tr>
<tr>
<td></td>
<td>Liraaglutide</td>
</tr>
<tr>
<td></td>
<td>Metformin-repaglinide</td>
</tr>
<tr>
<td></td>
<td>Sitagliptin</td>
</tr>
<tr>
<td>Sulfonyureas</td>
<td>Acetohexamide</td>
</tr>
<tr>
<td></td>
<td>Chlorpropamide</td>
</tr>
<tr>
<td></td>
<td>Glimepiride</td>
</tr>
<tr>
<td></td>
<td>Glipizide</td>
</tr>
<tr>
<td></td>
<td>Glyburide</td>
</tr>
<tr>
<td></td>
<td>Tolazamide</td>
</tr>
<tr>
<td></td>
<td>Tolbutamide</td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>Pioglitazone</td>
</tr>
<tr>
<td></td>
<td>Rosiglitazone</td>
</tr>
</tbody>
</table>

Note: Glucophage/metformin is not included because it is used to treat conditions other than diabetes; members with diabetes on these medications are identified through diagnosis.
Appendix

Proposed Evaluation for Section 1115 Demonstration Waiver
Arkansas Health Care Independence Program ("Private Option")

Table 18.2. Codes to Identify Diabetes

<table>
<thead>
<tr>
<th>Description</th>
<th>ICD-9-CM Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>250, 357.2, 362.0, 366.41, 648.0</td>
</tr>
</tbody>
</table>

Table 18.3. Codes to Identify Visit Type

<table>
<thead>
<tr>
<th>Description</th>
<th>CPT</th>
<th>UB Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outpatient</td>
<td>99201-99205, 99211-99215, 99217-99220,</td>
<td>051x, 0520-0523, 0526-0529, 057x-059x, 082x-085x, 088x, 0982, 0983</td>
</tr>
<tr>
<td></td>
<td>99241-99245, 99341-99345, 99347-99350,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>99384-99387, 99394-99397, 99401-99404,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>99411, 99412, 99420, 99429, 99455, 99456</td>
<td></td>
</tr>
<tr>
<td>Nonacute inpatient</td>
<td>99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337</td>
<td>0118, 0128, 0138, 0148, 0158, 019x, 0524, 0525, 055x, 066x</td>
</tr>
<tr>
<td>Acute inpatient</td>
<td>99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291</td>
<td>010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x, 021x, 072x, 080x, 0987</td>
</tr>
<tr>
<td>ED</td>
<td>99281-99285</td>
<td>045x, 0981</td>
</tr>
</tbody>
</table>

C. ADMINISTRATIVE SPECIFICATION

Denominator: The eligible population.

Numerator: An LDL-C test performed during the measurement year, as identified by claim/encounter or automated laboratory data. Use any code listed in Table 18.4.

The state may use a calculated or direct LDL for LDL-C screening and control indicators.

Table 18.4. Codes to Identify LDL-C Screening

<table>
<thead>
<tr>
<th>CPT</th>
<th>CPT Category II</th>
<th>LOINC</th>
</tr>
</thead>
<tbody>
<tr>
<td>80061, 83700, 83701, 83704, 83721</td>
<td>3048F, 3049F, 3050F</td>
<td>2089-1, 12773-8, 13457-7, 18261-8, 18262-6, 22748-8, 39469-2, 49132-4, 55440-2, 69419-0</td>
</tr>
</tbody>
</table>

Table 18.5. Codes to Identify Exclusions

<table>
<thead>
<tr>
<th>Description</th>
<th>ICD-9-CM Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polycystic ovaries</td>
<td>256.4</td>
</tr>
<tr>
<td>Steroid induced</td>
<td>249, 251.8, 962.0</td>
</tr>
<tr>
<td>Gestational diabetes</td>
<td>648.8</td>
</tr>
</tbody>
</table>
Measure 12: Comprehensive Diabetes Care: Hemoglobin A1c Testing

National Committee for Quality Assurance

A. DESCRIPTION
The percentage of Medicaid enrollees ages 18 to 75 with diabetes (type 1 and type 2) who had a hemoglobin A1c (HbA1c) test.

Guidance for Reporting:
- This measure is based on the original HEDIS specification that includes multiple diabetes care indicators. Only the HbA1c testing indicator is included in this measure.
- This measure applies to Medicaid enrollees ages 18 to 75. For purposes of Medicaid Adult Core Set reporting, states should calculate and report this measure for two age groups (as applicable): ages 18 to 64 and ages 65 to 75.
- Include all paid, suspended, pending, reversed, and denied claims.

B. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Age</th>
<th>Ages 18 to 75 as of December 31 of the measurement year.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous enrollment</td>
<td>The measurement year.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>No more than 1-month gap in coverage.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>December 31 of the measurement year.</td>
</tr>
<tr>
<td>Benefit</td>
<td>Medical.</td>
</tr>
</tbody>
</table>

Event/diagnosis
There are two ways to identify Medicaid enrollees with diabetes: by pharmacy data and by claim/encounter data. The state must use both methods to identify the eligible population, but an enrollee only needs to be identified by one method to be included in the measure. Medicaid enrollees may be identified as having diabetes during the measurement year or the year prior to the measurement year.

Pharmacy data. Medicaid enrollees who were dispensed insulin or oral hypoglycemics/antihyper-glycemics during the measurement year or year prior to the measurement year on an ambulatory basis (Table 19.1).

Claim/encounter data. Medicaid enrollees who had two face-to-face encounters, in an outpatient setting or nonacute inpatient setting, on different dates of service, with a diagnosis of diabetes (Table 19.2), or one face-to-face encounter in an acute inpatient or ED setting, with a diagnosis of diabetes, during the measurement year or the year prior to the measurement year. The state may count services that occur over both years. Refer to Table 19.3 for codes to identify visit type.
Table 19.1. Prescriptions to Identify Medicaid Enrollees with Diabetes

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-glucosidase inhibitors</td>
<td>Acarbose</td>
</tr>
<tr>
<td></td>
<td>Miglitol</td>
</tr>
<tr>
<td>Amylin analogs</td>
<td>Pramlintide</td>
</tr>
<tr>
<td>Antidiabetic combinations</td>
<td>Glimepiride-pioglitazone</td>
</tr>
<tr>
<td></td>
<td>Glimepiride-rosiglitazone</td>
</tr>
<tr>
<td></td>
<td>Glipizide-metformin Glyburide-metformin Linagliptin-metformin</td>
</tr>
<tr>
<td></td>
<td>Metformin-pioglitazone</td>
</tr>
<tr>
<td></td>
<td>Metformin-rosiglitazone</td>
</tr>
<tr>
<td></td>
<td>Metformin-saxagliptin</td>
</tr>
<tr>
<td></td>
<td>Metformin-sitagliptin</td>
</tr>
<tr>
<td></td>
<td>Saxagliptin</td>
</tr>
<tr>
<td></td>
<td>Sitagliptin-simvastatin</td>
</tr>
<tr>
<td>Insulin</td>
<td>Insulin aspart</td>
</tr>
<tr>
<td></td>
<td>Insulin aspart-insulin aspart protamine</td>
</tr>
<tr>
<td></td>
<td>Insulin detemir</td>
</tr>
<tr>
<td></td>
<td>Insulin glargine</td>
</tr>
<tr>
<td></td>
<td>Insulin glulisine</td>
</tr>
<tr>
<td></td>
<td>Insulin inhalation</td>
</tr>
<tr>
<td></td>
<td>Insulin isophane beef-pork</td>
</tr>
<tr>
<td></td>
<td>Insulin isophane human</td>
</tr>
<tr>
<td></td>
<td>Insulin isophane-insulin regular</td>
</tr>
<tr>
<td></td>
<td>Insulin lispro</td>
</tr>
<tr>
<td></td>
<td>Insulin lispro-insulin lispro protamine</td>
</tr>
<tr>
<td></td>
<td>Insulin regular human</td>
</tr>
<tr>
<td></td>
<td>Insulin zinc human</td>
</tr>
<tr>
<td>Meglitinides</td>
<td>Nateglinide</td>
</tr>
<tr>
<td></td>
<td>Repaglinide</td>
</tr>
<tr>
<td>Miscellaneous antidiabetic agents</td>
<td>Exenatide</td>
</tr>
<tr>
<td></td>
<td>Linagliptin</td>
</tr>
<tr>
<td></td>
<td>Liraglutide</td>
</tr>
<tr>
<td></td>
<td>Metformin-repaglinide</td>
</tr>
<tr>
<td></td>
<td>Sitagliptin</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>Acetohexamide</td>
</tr>
<tr>
<td></td>
<td>Chlorpropamide</td>
</tr>
<tr>
<td></td>
<td>Glimepiride</td>
</tr>
<tr>
<td></td>
<td>Glipizide</td>
</tr>
<tr>
<td></td>
<td>Glyburide</td>
</tr>
<tr>
<td></td>
<td>Tolazamide</td>
</tr>
<tr>
<td></td>
<td>Tolbutamide</td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>Pioglitazone</td>
</tr>
<tr>
<td></td>
<td>Rosiglitazone</td>
</tr>
</tbody>
</table>

Note: Glucophage/metformin is not included because it is used to treat conditions other than diabetes; members with diabetes on these medications are identified through diagnosis codes only.
Table 19.2. Codes to Identify Diabetes

<table>
<thead>
<tr>
<th>Description</th>
<th>ICD-9-CM Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>250, 357.2, 362.0, 366.41, 648.0</td>
</tr>
</tbody>
</table>

Table 19.3. Codes to Identify Visit Type

<table>
<thead>
<tr>
<th>Description</th>
<th>CPT</th>
<th>UB Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outpatient</td>
<td>99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 99456</td>
<td>051x, 0520-0523, 0526-0529, 057x-059x, 082x-085x, 088x, 0982, 0983</td>
</tr>
<tr>
<td>Nonacute inpatient</td>
<td>99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337</td>
<td>0118, 0128, 0138, 0148, 0158, 019x, 0524, 0525, 055x, 066x</td>
</tr>
<tr>
<td>Acute inpatient</td>
<td>99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291</td>
<td>010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x, 021x, 072x, 080x, 0987</td>
</tr>
<tr>
<td>ED</td>
<td>99281-99285</td>
<td>045x, 0981</td>
</tr>
</tbody>
</table>

C. ADMINISTRATIVE SPECIFICATION

Denominator: The eligible population.

Numerator: An HbA1c test performed during the measurement year, as identified by claim/encounter or automated laboratory data. Use any code listed in Table 19.4.

Table 19.4.Codes to Identify HbA1c Tests

<table>
<thead>
<tr>
<th>CPT</th>
<th>CPT Category II</th>
<th>LOINC</th>
</tr>
</thead>
<tbody>
<tr>
<td>83036, 83037</td>
<td>3044F, 3045F, 3046F</td>
<td>4548-4, 4549-2, 17856-6, 59261-8, 62388-4, 71875-9</td>
</tr>
</tbody>
</table>

Table 19.5. Codes to Identify Exclusions

<table>
<thead>
<tr>
<th>Description</th>
<th>ICD-9-CM Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polycystic ovaries</td>
<td>256.4</td>
</tr>
<tr>
<td>Steroid induced</td>
<td>249, 251.8, 962.0</td>
</tr>
<tr>
<td>Gestational diabetes</td>
<td>648.8</td>
</tr>
</tbody>
</table>
Measure 13: Antidepressant Medication Management

National Committee for Quality Assurance

A. DESCRIPTION

The percentage of Medicaid enrollees age 18 and older with a diagnosis of major depression that were newly treated with antidepressant medication, and remained on an antidepressant medication treatment. Two rates are reported:

- Effective Acute Phase Treatment. The percentage of newly diagnosed and treated Medicaid enrollees who remained on an antidepressant medication for at least 84 days (12 weeks)
- Effective Continuation Phase Treatment. The percentage of newly diagnosed and treated Medicaid enrollees who remained on an antidepressant medication for at least 180 days (6 months)

Guidance for Reporting:

- This measure applies to Medicaid enrollees age 18 and older. For purposes of Medicaid Adult Core Set reporting, states should calculate and report the two rates listed above for each of the two age groups (as applicable): ages 18 to 64 and age 65 and older.
- Include all paid, suspended, pending, reversed, and denied claims.

B. DEFINITIONS

<table>
<thead>
<tr>
<th>Intake Period</th>
<th>The 12-month window starting on May 1 of the year prior to the measurement year and ending on April 30 of the measurement year.</th>
</tr>
</thead>
<tbody>
<tr>
<td>IESD</td>
<td>Index Episode Start Date. The earliest encounter during the Intake Period with any diagnosis of major depression and a 90-day (3-month) Negative Medication History. For an inpatient (acute or nonacute) claim/encounter, the IESD is the date of discharge. For a direct transfer, the IESD is the discharge date from the facility to which the enrollee was transferred.</td>
</tr>
<tr>
<td>IPSD</td>
<td>Index Prescription Start Date. The earliest prescription dispensing date for an antidepressant medication during the period of 30 days prior to the IESD (inclusive) through 14 days after the IESD (inclusive).</td>
</tr>
<tr>
<td>Negative Medication History</td>
<td>A period of 90 days (3 months) prior to the IPSD when the enrollee had no pharmacy claims for either new or refill prescriptions for an antidepressant medication.</td>
</tr>
<tr>
<td>Treatment Days</td>
<td>The actual number of calendar days covered with prescriptions within the specified 180-day (6-month) measurement interval. For Effective Continuation Phase Treatment, a prescription of 90 days (3 months) supply dispensed on the 151st day will have 80 days counted in the 231-day interval.</td>
</tr>
</tbody>
</table>
C. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Age</th>
<th>Age 18 and older as of April 30 of the measurement year.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous enrollment</td>
<td>90 days (3 months) prior to the IESD through 245 days after the IESD.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>No more than 1-month gap in coverage.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>IESD.</td>
</tr>
<tr>
<td>Benefits</td>
<td>Medical and pharmacy.</td>
</tr>
<tr>
<td>Event/diagnosis</td>
<td>Follow the steps below to identify the eligible population which should be used for both rates.</td>
</tr>
</tbody>
</table>

Table 20.1. Codes to Identify Major Depression

<table>
<thead>
<tr>
<th>Description</th>
<th>ICD-9-CM Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major depression</td>
<td>296.20-296.25, 296.30-296.35, 298.0, 311</td>
</tr>
</tbody>
</table>

Table 20.2. Codes to Identify Visit Type

<table>
<thead>
<tr>
<th>Description</th>
<th>CPT</th>
<th>HCPCS</th>
<th>UB Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED</td>
<td>99281-99285</td>
<td></td>
<td>045x, 0981</td>
</tr>
</tbody>
</table>

CPT POS

<table>
<thead>
<tr>
<th>CPT</th>
<th>POS</th>
</tr>
</thead>
<tbody>
<tr>
<td>90801, 90802, 90816-90819, 90821-90824, 90826-90829, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251-99255</td>
<td>WITH</td>
</tr>
<tr>
<td>03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 24, 33, 49, 50, 52, 53, 71, 72</td>
<td></td>
</tr>
</tbody>
</table>

D. ADMINISTRATIVE SPECIFICATION

Denominator: The eligible population.

Numerator 1: Effective Acute Phase Treatment

- At least 84 days (12 weeks) of continuous treatment with antidepressant medication (Table 20.3) during the 114-day period following the IPSD (inclusive). The continuous treatment allows gaps in medication treatment up to a total of 30 days during the 114-day period. Gaps can include either washout period gaps to change medication or treatment gaps to refill the same medication.
• Regardless of the number of gaps, there may be no more than 30 gap days. Count any combination of gaps (e.g., two washout gaps of 15 days each, or two washout gaps of 10 days each and one treatment gap of 10 days)

Table 20.3. Antidepressant Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miscellaneous antidepressants</td>
<td>Bupropion</td>
</tr>
<tr>
<td></td>
<td>Vilazodone</td>
</tr>
<tr>
<td>Monoamine oxidase inhibitors</td>
<td>Isocarboxazid</td>
</tr>
<tr>
<td></td>
<td>Phenelzine</td>
</tr>
<tr>
<td></td>
<td>Selegiline</td>
</tr>
<tr>
<td></td>
<td>Tranylcypromine</td>
</tr>
<tr>
<td>Phenylpiperazine antidepressants</td>
<td>Nefazodone</td>
</tr>
<tr>
<td></td>
<td>Trazodone</td>
</tr>
<tr>
<td>Psychotherapeutic combinations</td>
<td>Amitriptyline-chlordiazepoxide</td>
</tr>
<tr>
<td></td>
<td>Amitriptyline-perphenazine</td>
</tr>
<tr>
<td></td>
<td>Fluoxetine-olanzapine</td>
</tr>
<tr>
<td>SSNRI antidepressants</td>
<td>Desvenlafaxine</td>
</tr>
<tr>
<td></td>
<td>Duloxetine</td>
</tr>
<tr>
<td></td>
<td>Venlafaxine</td>
</tr>
<tr>
<td>SSRI antidepressants</td>
<td>Citalopram</td>
</tr>
<tr>
<td></td>
<td>Escitalopram</td>
</tr>
<tr>
<td></td>
<td>Fluoxetine</td>
</tr>
<tr>
<td></td>
<td>Fluvoxamine</td>
</tr>
<tr>
<td></td>
<td>Paroxetine</td>
</tr>
<tr>
<td></td>
<td>Sertraline</td>
</tr>
<tr>
<td>Tetracyclic antidepressants</td>
<td>Maprotiline</td>
</tr>
<tr>
<td></td>
<td>Mirtazapine</td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
<td>Amitriptyline</td>
</tr>
<tr>
<td></td>
<td>Amoxapine</td>
</tr>
<tr>
<td></td>
<td>Clomipramine</td>
</tr>
<tr>
<td></td>
<td>Desipramine</td>
</tr>
<tr>
<td></td>
<td>Doxepin</td>
</tr>
<tr>
<td></td>
<td>Imipramine</td>
</tr>
<tr>
<td></td>
<td>Nortriptyline</td>
</tr>
<tr>
<td></td>
<td>Protriptyline</td>
</tr>
<tr>
<td></td>
<td>Trimipramine</td>
</tr>
</tbody>
</table>

Numerator 2: Effective Continuation Phase Treatment

• At least 180 days (6 months) of continuous treatment with antidepressant medication (Table 20.3) during the 231-day period following the IPSD (inclusive). Continuous treatment allows gaps in medication treatment up to a total of 51 days during the 231-day period. Gaps can include either washout period gaps to change medication or treatment gaps to refill the same medication

• Regardless of the number of gaps, gap days may total no more than 51. Count any combination of gaps (e.g., two washout gaps, each 25 days or two washout gaps of 10 days each and one treatment gap of 10 days)

E. ADDITIONAL NOTES

There may be different methods for billing intensive outpatient encounters and partial hospitalizations. Some methods may be comparable to outpatient billing, with separate claims for each date of service; others may be comparable to inpatient billing, with an admission date, a discharge date and units of service. Where billing methods are comparable to inpatient billing, each unit of service may be counted as an individual visit. The unit of service must have occurred during the required time frame for the rate (e.g., during the Intake Period).
**Measure 15: Adherence to Antipsychotics for Individuals with Schizophrenia**

National Committee for Quality Assurance

A. DESCRIPTION

The percentage of Medicaid enrollees ages 19 to 64 with schizophrenia that were dispensed and remained on an antipsychotic medication for at least 80 percent of their treatment period.

Guidance for Reporting:
- Include all paid, suspended, pending, reversed, and denied claims.

B. DEFINITIONS

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPSD</td>
<td>Index prescription start date. The earliest prescription dispensing date for any antipsychotic medication between January 1 and September 30 of the measurement year.</td>
</tr>
<tr>
<td>Treatment Period</td>
<td>The period of time beginning on the IPSD through the last day of the measurement year.</td>
</tr>
<tr>
<td>PDC</td>
<td>Proportion of days covered. The number of days a member is covered by at least one antipsychotic medication prescription, divided by the number of days in the treatment period.</td>
</tr>
<tr>
<td>Oral Medication Dispensing Event</td>
<td>One prescription of an amount lasting 30 days or less. To calculate dispensing events for prescriptions longer than 30 days, divide the days supply by 30 and round down to convert. For example, a 100-day prescription is equal to three dispensing events. Multiple prescriptions for different medications dispensed on the same day are counted as separate dispensing events. If multiple prescriptions for the same medication are dispensed on the same day, use the prescription with the longest days supply. Use the Drug ID to determine if the prescriptions are the same or different.</td>
</tr>
<tr>
<td>Long-Acting Injections Dispensing Event</td>
<td>Injections count as one dispensing event. Multiple J codes or NDCs for the same or different medication on the same day are counted as a single dispensing event.</td>
</tr>
</tbody>
</table>
### Calculating Number of Days Covered for Oral Medications

If multiple prescriptions for the same or different oral medications are dispensed on the same day, calculate number of days covered by an antipsychotic medication (for the numerator) using the prescription with the longest days supply.

If multiple prescriptions for different oral medications are dispensed on different days, count each day within the treatment period only once toward the numerator.

If multiple prescriptions for the same oral medication are dispensed on different days, sum the days supply and use the total to calculate the number of days covered by an antipsychotic medication (for the numerator). For example, if three antipsychotic prescriptions for the same oral medication are dispensed on different days, each with a 30-day supply; sum the days supply for a total of 90 days covered by an oral antipsychotic (even if there is overlap).

Use the drug ID provided on the NDC list to determine if the prescriptions are the same or different.

### Calculating Number of Days Covered for Long-Acting Injections

Calculate number of days covered (for the numerator) for long-acting injections using the days-supply specified for the medication in Table 21.1. For multiple J Codes or NDCs for the same or different medications on the same day, use the medication with the longest days supply. For multiple J Codes or NDCs for the same or different medications on different days with overlapping days supply, count each day within the treatment period only once toward the numerator.

### C. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Age</th>
<th>Ages 19 to 64 as of December 31 of the measurement year.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous enrollment</td>
<td>The measurement year.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>No more than 1-month gap in coverage.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>December 31 of the measurement year.</td>
</tr>
<tr>
<td>Benefits</td>
<td>Medical and pharmacy.</td>
</tr>
<tr>
<td>Event/diagnosis</td>
<td>Follow the steps below to identify the eligible population.</td>
</tr>
</tbody>
</table>

### D. ADMINISTRATIVE SPECIFICATION

**Denominator:** The eligible population.

**Numerator:** The number of Medicaid enrollees who achieved a PDC of at least 80 percent for their antipsychotic medications (Table 21.1) during the measurement year.
Measure 16: Postpartum Care Rate

National Committee for Quality Assurance

A. DESCRIPTION

The percentage of deliveries of live births between November 6 of the year prior to the measurement year and November 5 of the measurement year that had a postpartum visit on or between 21 and 56 days after delivery.

Guidance for Reporting:

- This measure applies to both Medicaid and CHIP enrolled females that meet the measurement eligibility criteria.
- Include all paid, suspended, pending, reversed, and denied claims.

B. DEFINITIONS

<table>
<thead>
<tr>
<th>Description</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Term</td>
<td>A neonate whose birth occurs through the end of the last day of the 37th week (259th day) following the onset of the last menstrual period.</td>
</tr>
<tr>
<td>Post-Term</td>
<td>A neonate whose birth occurs from the beginning of the first day of the 43rd week (295th day) following the onset of the last menstrual period.</td>
</tr>
<tr>
<td>Start Date of the Last Enrollment Segment</td>
<td>For women with a gap in enrollment during pregnancy, the last enrollment segment is the enrollment start date during the pregnancy that is closest to the delivery date.</td>
</tr>
</tbody>
</table>

C. ELIGIBLE POPULATION

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>None specified.</td>
</tr>
<tr>
<td>Continuous enrollment</td>
<td>43 days prior to delivery through 56 days after delivery.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>No allowable gap during the continuous enrollment period.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>Date of delivery.</td>
</tr>
<tr>
<td>Event/diagnosis</td>
<td>Delivered a live birth on or between November 6 of the year prior to the measurement year and November 5 of the measurement year. Include women who delivered in a birthing center. Refer to Tables 26.1 and 26.2 for codes to identify live births. Multiple births. Women who had two separate deliveries (different dates of service) between November 6 of the year prior to the measurement year and November 5 of the measurement year should be counted twice. Women who had multiple live births during one pregnancy should be counted once in the measure.</td>
</tr>
</tbody>
</table>

D. ADMINISTRATIVE SPECIFICATION

Denominator:

Follow the first two steps below to identify the eligible population.

Numerator:

Postpartum Care
A postpartum visit (Table 26.3) for a pelvic exam or postpartum care on or between 21 and 56 days after delivery.

The practitioner requirement only applies to the Hybrid Specification. The enrollee is compliant if any code from Table 26.3 is submitted.

Table 26.3. Codes to Identify Postpartum Visits

<table>
<thead>
<tr>
<th>CPT</th>
<th>CPT Category II</th>
<th>HCPCS</th>
<th>ICD-9-CM Diagnosis</th>
<th>ICD-9-CM Procedure</th>
<th>UB Revenue</th>
<th>LOINC</th>
</tr>
</thead>
</table>

Note: Generally, these codes are used on the date of delivery, not on the date of the postpartum visit, so this code may be used only if the claim form indicates when postpartum care was rendered.

E. ADDITIONAL NOTES

When counting postpartum visits, include visits with physician assistants, nurse practitioners, midwives and registered nurses if a physician cosignatory is present, if required by state law.

Services that occur over multiple visits count toward this measure as long as all services are within the time frame established in the measure. Ultrasound and lab results alone should not be considered a visit; they must be linked to an office visit with an appropriate practitioner in order to count for this measure.

A Pap test alone is acceptable for the Postpartum Care rate. A colposcopy alone is not numerator compliant for the rate.

The intent is that a visit is with a PCP or OB/GYN. Ancillary services (lab, ultrasound) may be
Appendix 2B—Selected Measures from Healthcare Effectiveness Data and Information Set (HEDIS) 2014

Measure: Persistence of Beta-Blocker Treatment after a Heart Attack

Origin: HEDIS 2014

Description:
The percentage of members 18 years of age and older during the measurement year who were hospitalized and discharged alive from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of AMI and who received persistent beta-blocker treatment for six months after discharge.

Numerator:
A 180-day course of treatment with beta-blockers.

Identify all members in the denominator population whose dispensed days supply is ≥ 135 days in the 180 days following discharge. Persistence of treatment for this measure is defined as at least 75 percent of the days supply filled.

Denominator:
The eligible population.
Measure: Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

Origin: HEDIS 2014

Description:
The percentage of members 19-64 years of age during the measurement year with schizophrenia who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.

- The percentage of discharges for which the member received follow-up within 30 days of discharge.
- The percentage of discharges for which the member received follow-up within 7 days of discharge.

Numerator
- The number of members who achieved a PDC of at least 70% for their antipsychotic medications during the measurement year.

Denominator
- The eligible population.
Measure: Annual Monitoring for Patients on Persistent Medications (MPM)

Origin: HEDIS 2014

Description:
The percentage of members 18 years of age and older who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent during the measurement year and at least one therapeutic monitoring event for the therapeutic agent in the measurement year. For each product line, report each of the four rates separately and as a total rate.

Annual monitoring for members on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB).
Annual monitoring for members on digoxin.
Annual monitoring for members on diuretics.
Annual monitoring for members on anticonvulsants.
Total rate (the sum of the four numerators divided by the sum of the four denominators).

Numerators

Annual monitoring for members on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB)

- At least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year. Any of the following during the measurement meet criteria:
  - A lab panel test
  - A serum potassium test **and** a serum creatinine test
  - A serum potassium test **and** a blood urea nitrogen test

- Note: The tests do not need to occur on the same service date, only within the measurement year.

Annual monitoring for members on Digoxin

- At least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year. Any of the following during the measurement meet criteria:
  - A lab panel test
  - A serum potassium test **and** a serum creatinine test
  - A serum potassium test **and** a blood urea nitrogen test

- Note: The tests do not need to occur on the same service date, only within the measurement year.

Annual monitoring for members on Diuretics

- At least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year. Any of the following during the measurement meet criteria:
  - A lab panel test
  - A serum potassium test **and** a serum creatinine test
- A serum potassium test and a blood urea nitrogen test
  - Note: The tests do not need to occur on the same service date, only within the measurement year.

Annual monitoring for members on Anticonvulsants
  - At least one drug serum concentration level monitoring rest for the prescribed drug during the measurement year as identified by the following value sets:
    - Members prescribed phenobarbital must have at least one drug serum concentration for phenobarbital
    - Members prescribed carbamazepine must have at least one drug serum concentration for carbamazepine
    - Members prescribed phenytoin must have at least one drug serum concentration for phenytoin
    - Members prescribed valproic acid or divalproex sodium must have at least one drug serum concentration for valproic acid
Measure: Adults’ Access to Preventive/Ambulatory Health Services (AAP)

Origin: HEDIS 2014

Description:
The percentage of members 20 years and older who had an ambulatory or preventive care visit. The organization reports three separate percentages for each product line.

Medicaid and Medicare members who had an ambulatory or preventive care visit during the measurement year.

Commercial members who had an ambulatory or preventive care visit during the measurement year or the two years prior to the measurement year.

Numerator

Medicaid and Medicare: One or more ambulatory or preventive care visits during the measurement year.

Commercial: One or more ambulatory or preventive care visits during the measurement year or the two years prior to the measurement year.

Use the following value sets to identify ambulatory or preventive care visits:

- Ambulatory Visits Value Set
- Other Ambulatory Visits Value Set

Denominator

The eligible population (report each age stratification separately).
Measure: Frequency of Selected Procedures (FSP)

**Origin:** HEDIS 2014

**Description:**
This measure summarizes the utilization of frequently performed procedures that often show wide regional variation and have generated concern regarding potentially inappropriate utilization.

**Selected Procedures**

- **Tonsillectomy**
  - With or without adenoidectomy. Do not report adenoidectomy performed alone.

- **Bariatric weight loss surgery**
  - Report the number of bariatric weight loss surgeries.

- **Hysterectomy**
  - Report abdominal and vaginal hysterectomy separately.

- **Cholecystectomy**
  - Report open and laparoscopic cholecystectomy separately.

- **Back surgery**
  - Report all spinal fusion and disc surgery, including codes relating to laminectomy with and without disc removal

- **Percutaneous Coronary Intervention (PCI)**
  - Report all PCIs performed separately. Do not report PCI or cardiac catheterization performed in conjunction with a CABG in the PCI rate or the cardiac catheterization rate; report only the CABG.

- **Cardiac Catheterization**
  - Report all cardiac catheterizations performed separately. Do not report a cardiac catheterization performed in conjunction with a PCI in the cardiac catheterization rate; report only the PCI.
  - Do not report PCI or cardiac catheterization performed in conjunction with a CABG in the PCI rate or the cardiac catheterization rate; report only the CABG.

- **Coronary Artery Bypass Graft (CABG)**
  - Report each CABG only once for each date of service per patient, regardless of the number of arteries involved or the number or types of grafts involved.
  - Do not report PCI or cardiac catheterization performed in conjunction with a CABG in the PCI rate or the cardiac catheterization rate; report only the CABG.

- **Prostatectomy**
  - Report the number of prostatectomies.

- **Total Hip Replacement**
  - Report the number of total hip replacements.

- **Total Knee Replacement**
  - Report the number of total knee replacements.
Carotid Endarterectomy
  o Report the number of carotid endarterectomies.

Mastectomy
  o Report the number of mastectomies. Report bilateral mastectomy procedures as two procedures, even if performed on the same date

Lumpectomy
  o Report the number of lumpectomies. Report multiple lumpectomies on the same date of service as one lumpectomy procedure per patient.
  o Note: Calls abandoned within 30 seconds and calls sent directly to voicemail remain in the measure and are noncompliant for the numerator.
Measure: Ambulatory Care (AMB)

Origin: HEDIS 2014

Description:
This measure summarizes utilization of ambulatory care in the following categories:

Outpatient Visits
ED Visits

Outpatient Visits
Count multiple codes with the same practitioner on the same date of service as a single visit. Count visits with different practitioners separately (count visits with different providers on the same date of service as different visits). Report services without regard to practitioner type, training, or licensing.

ED Visits
Count each visit to an ED that does not result in an inpatient encounter once, regardless of the intensity or duration of the visit. Count multiple ED visits on the same date of service as one visit. Identify ED visits using either of the following:

- An ED visit
- A procedure code with an ED place of service code

Exclusions (required)
The measure does not include mental health or chemical dependency services. Exclude claims and encounters that indicate the encounter was for mental health or chemical dependency.

Note
This measure provides a reasonable proxy for professional ambulatory encounters. It is neither a strict accounting of ambulatory resources nor an effort to be all-inclusive.
Measure: Inpatient Utilization – General Hospital/Acute Care (IPU)

Origin: HEDIS 2014

Description:
This measure summarizes utilization of acute inpatient care and services in the following categories:

- Total inpatient
- Maternity
- Surgery
- Medicine

Product Lines
Report the following tables for each applicable product line:

- Table IPU-1a Total Medicaid
- Table IPU-1b Medicaid/Medicare Dual-Eligibles
- Table IPU-1c Medicaid—Disabled
- Table IPU-1d Medicaid—Other Low Income
- Table IPU-2 Commercial—by Product or Combined HMO/POS
- Table IPU-3 Medicare
Appendix 2C

Consumer Assessment of Healthcare Providers and Systems Survey

Health Plan 5.0
Consumer Assessment of Healthcare Providers and Systems Survey

Selected measures from the CAHPS 5.0 Health Plan survey are being used according to the Agency for Healthcare Research and Quality’s protocol. The survey is attached.
CAHPS® Health Plan Surveys

Version: Adult Commercial Survey 5.0

Language: English

Notes

• **Release of 5.0 version:** The CAHPS Health Plan Surveys were updated in the Spring of 2012. The updates are limited to minor changes to the wording of several items and a change in the placement of one item. These edits reflect the CAHPS Consortium’s most recent findings from testing of related survey instruments. For specific information about the updates to this survey, please read CAHPS Health Plan Surveys: Overview of the Questionnaires, which is available at [https://www.cahps.ahrq.gov/Surveys-Guidance/HP/Get-Surveys-and-Instructions.aspx](https://www.cahps.ahrq.gov/Surveys-Guidance/HP/Get-Surveys-and-Instructions.aspx).

• **Supplemental items:** Survey users may add questions to this survey. A document with supplemental items developed by the CAHPS Consortium and descriptions of major item sets are available in the Health Plan Surveys and Instructions ([http://www.cahps.ahrq.gov/Surveys-Guidance/HP/Get-Surveys-and-Instructions.aspx](http://www.cahps.ahrq.gov/Surveys-Guidance/HP/Get-Surveys-and-Instructions.aspx)).
Instructions for Front Cover

• Replace the cover of this document with your own front cover. Include a user-friendly title and your own logo.
• Include this text regarding the confidentiality of survey responses:

  **Your Privacy is Protected.** All information that would let someone identify you or your family will be kept private. {VENDOR NAME} will not share your personal information with anyone without your OK. Your responses to this survey are also completely confidential. You may notice a number on the cover of the survey. This number is used only to let us know if you returned your survey so we don’t have to send you reminders.

  **Your Participation is Voluntary.** You may choose to answer this survey or not. If you choose not to, this will not affect the health care you get.

  **What To Do When You’re Done.** Once you complete the survey, place it in the envelope that was provided, seal the envelope, and return the envelope to [INSERT VENDOR ADDRESS].

  If you want to know more about this study, please call XXX-XXX-XXXX.

Instructions for Format of Questionnaire

Proper formatting of a questionnaire improves response rates, the ease of completion, and the accuracy of responses. The CAHPS team’s recommendations include the following:

• If feasible, insert blank pages as needed so that the survey instructions (see next page) and the first page of questions start on the right-hand side of the questionnaire booklet.
• Maximize readability by using two columns, serif fonts for the questions, and ample white space.
• Number the pages of your document, but remove the headers and footers inserted to help sponsors and vendors distinguish among questionnaire versions.

Survey Instructions

Answer each question by marking the box to the left of your answer.

You are sometimes told to skip over some questions in this survey. When this happens you will see an arrow with a note that tells you what question to answer next, like this:

☑ Yes → If Yes, go to #1 on page 1
☐ No
1. Our records show that you are now in {INSERT HEALTH PLAN NAME}. Is that right?
   1  Yes → If Yes, go to #3
   2  No

2. What is the name of your health plan?
   Please print: __________________________
   ______________________________________

Your Health Care in the Last 12 Months

These questions ask about your own health care. Do not include care you got when you stayed overnight in a hospital. Do not include the times you went for dental care visits.

3. In the last 12 months, did you have an illness, injury, or condition that needed care right away in a clinic, emergency room, or doctor’s office?
   1  Yes
   2  No → If No, go to #5

4. In the last 12 months, when you needed care right away, how often did you get care as soon as you needed?
   1  Never
   2  Sometimes
   3  Usually
   4  Always

5. In the last 12 months, did you make any appointments for a check-up or routine care at a doctor’s office or clinic?
   1  Yes
   2  No → If No, go to #7

6. In the last 12 months, how often did you get an appointment for a check-up or routine care at a doctor’s office or clinic as soon as you needed?
   1  Never
   2  Sometimes
   3  Usually
   4  Always

7. In the last 12 months, not counting the times you went to an emergency room, how many times did you go to a doctor’s office or clinic to get health care for yourself?
   □ None → If None, go to #10
   □ 1 time
   □ 2
   □ 3
   □ 4
   □ 5 to 9
   □ 10 or more times
8. Using any number from 0 to 10, where 0 is the worst health care possible and 10 is the best health care possible, what number would you use to rate all your health care in the last 12 months?

☐ 0  Worst health care possible
☐ 1
☐ 2
☐ 3
☐ 4
☐ 5
☐ 6
☐ 7
☐ 8
☐ 9
☐ 10  Best health care possible

9. In the last 12 months, how often was it easy to get the care, tests, or treatment you needed?

1☐ Never
2☐ Sometimes
3☐ Usually
4☐ Always

Your Personal Doctor

10. A personal doctor is the one you would see if you need a check-up, want advice about a health problem, or get sick or hurt. Do you have a personal doctor?

1☐ Yes
2☐ No  \rightarrow  If No, go to #17

11. In the last 12 months, how many times did you visit your personal doctor to get care for yourself?

☐ None  \rightarrow  If None, go to #16
☐ 1 time
☐ 2
☐ 3
☐ 4
☐ 5 to 9
☐ 10 or more times

12. In the last 12 months, how often did your personal doctor explain things in a way that was easy to understand?

1☐ Never
2☐ Sometimes
3☐ Usually
4☐ Always
13. In the last 12 months, how often did your personal doctor listen carefully to you?

1□ Never
2□ Sometimes
3□ Usually
4□ Always

14. In the last 12 months, how often did your personal doctor show respect for what you had to say?

1□ Never
2□ Sometimes
3□ Usually
4□ Always

15. In the last 12 months, how often did your personal doctor spend enough time with you?

1□ Never
2□ Sometimes
3□ Usually
4□ Always

16. Using any number from 0 to 10, where 0 is the worst personal doctor possible and 10 is the best personal doctor possible, what number would you use to rate your personal doctor?

☐ 0 Worst personal doctor possible
☐ 1
☐ 2
☐ 3
☐ 4
☐ 5
☐ 6
☐ 7
☐ 8
☐ 9
☐ 10 Best personal doctor possible

---

**Getting Health Care From Specialists**

When you answer the next questions, do not include dental visits or care you got when you stayed overnight in a hospital.

17. Specialists are doctors like surgeons, heart doctors, allergy doctors, skin doctors, and other doctors who specialize in one area of health care. In the last 12 months, did you make any appointments to see a specialist?

1□ Yes
2□ No \(\rightarrow\) If No, go to #21

18. In the last 12 months, how often did you get an appointment to see a specialist as soon as you needed?

1□ Never
2□ Sometimes
3□ Usually
4□ Always

19. How many specialists have you seen in the last 12 months?

☐ None \(\rightarrow\) If None, go to #21
☐ 1 specialist
☐ 2
☐ 3
☐ 4
☐ 5 or more specialists
20. We want to know your rating of the specialist you saw most often in the last 12 months. Using any number from 0 to 10, where 0 is the worst specialist possible and 10 is the best specialist possible, what number would you use to rate the specialist?

- 0 Worst specialist possible
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10 Best specialist possible

---

Your Health Plan

The next questions ask about your experience with your health plan.

21. In the last 12 months, did you get information or help from your health plan’s customer service?

- \( \blacksquare \) Yes
- \( \blacksquare \) No \( \rightarrow \) If No, go to #24

22. In the last 12 months, how often did your health plan’s customer service give you the information or help you needed?

- \( \blacksquare \) Never
- \( \blacksquare \) Sometimes
- \( \blacksquare \) Usually
- \( \blacksquare \) Always

23. In the last 12 months, how often did your health plan’s customer service staff treat you with courtesy and respect?

- \( \blacksquare \) Never
- \( \blacksquare \) Sometimes
- \( \blacksquare \) Usually
- \( \blacksquare \) Always
24. In the last 12 months, did your health plan give you any forms to fill out?

1. Yes
2. No → If No, go to #26

25. In the last 12 months, how often were the forms from your health plan easy to fill out?

1. Never
2. Sometimes
3. Usually
4. Always

26. Using any number from 0 to 10, where 0 is the worst health plan possible and 10 is the best health plan possible, what number would you use to rate your health plan?

0. Worst health plan possible
1
2
3
4
5
6
7
8
9
10. Best health plan possible

About You

27. In general, how would you rate your overall health?

1. Excellent
2. Very good
3. Good
4. Fair
5. Poor

28. In general, how would you rate your overall mental or emotional health?

1. Excellent
2. Very good
3. Good
4. Fair
5. Poor

29. In the past 12 months, did you get health care 3 or more times for the same condition or problem?

1. Yes
2. No → If No, go to #31

30. Is this a condition or problem that has lasted for at least 3 months? Do not include pregnancy or menopause.

1. Yes
2. No

31. Do you now need or take medicine prescribed by a doctor? Do not include birth control.

1. Yes
2. No → If No, go to #33
32. Is this medicine to treat a condition that has lasted for at least 3 months? Do **not** include pregnancy or menopause.

- [ ] Yes
- [ ] No

33. What is your age?

- [ ] 18 to 24
- [ ] 25 to 34
- [ ] 35 to 44
- [ ] 45 to 54
- [ ] 55 to 64
- [ ] 65 to 74
- [ ] 75 or older

34. Are you male or female?

- [ ] Male
- [ ] Female

35. What is the highest grade or level of school that you have completed?

- [ ] 8th grade or less
- [ ] Some high school, but did not graduate
- [ ] High school graduate or GED
- [ ] Some college or 2-year degree
- [ ] 4-year college graduate
- [ ] More than 4-year college degree

36. Are you of Hispanic or Latino origin or descent?

- [ ] Yes, Hispanic or Latino
- [ ] No, not Hispanic or Latino

37. What is your race? Mark one or more.

- [ ] White
- [ ] Black or African American
- [ ] Asian
- [ ] Native Hawaiian or Other Pacific Islander
- [ ] American Indian or Alaska Native
- [ ] Other

38. Did someone help you complete this survey?

- [ ] Yes
- [ ] No → **Thank you.**

**Please return the completed survey in the postage-paid envelope.**

39. How did that person help you? Mark one or more.

- [ ] Read the questions to me
- [ ] Wrote down the answers I gave
- [ ] Answered the questions for me
- [ ] Translated the questions into my language
- [ ] Helped in some other way

**Please print:** ______________

**________________________________________**

**________________________________________**

**Thank you.**

**Please return the completed survey in the postage-paid envelope.**
Appendix 2D

Consumer Assessment of Healthcare Providers and Systems Survey

Supplemental Items 4.0
Consumer Assessment of Healthcare Providers and Systems Survey

Selected measures from the CAHPS 4.0 Supplemental Items survey are being used according to the Agency for Healthcare Research and Quality’s protocol. The survey is attached.
CAHPS® Health Plan Survey 4.0

Supplemental Items for the Adult Questionnaires

Language: English
# TABLE OF CONTENTS

Behavioral Health ....................................................................................................................... 1
Chronic Conditions ...................................................................................................................... 2
Measures of Health Status ......................................................................................................... 4
Claims Processing ..................................................................................................................... 6
Communication ........................................................................................................................... 6
Cost Sharing ............................................................................................................................... 7
Covered By Multiple Plans ......................................................................................................... 7
Dental Care ................................................................................................................................ 7
Health Plan ................................................................................................................................ . 8
HEDIS® Set .............................................................................................................................. 10
Interpreter ................................................................................................................................ . 15
Medicaid Enrollment ................................................................................................................. 16
People With Mobility Impairments ............................................................................................ 17
  Your Personal Doctor ............................................................................................................... 17
  Your Health Plan .................................................................................................................... 19
  About You ............................................................................................................................. 20
Personal Doctor ........................................................................................................................ 21
Pregnancy Care ........................................................................................................................ 21
Prescription Medicine ............................................................................................................... 22
Quality Improvement ................................................................................................................ 23
  Access to Routine Care ........................................................................................................... 23
  Access to Specialist Care ....................................................................................................... 23
  After Hours Care .................................................................................................................... 24
  Calls to Personal Doctor’s Office ........................................................................................... 25
  Coordination of Care from Other Health Providers ........................................................... 26
  Customer Service .................................................................................................................. 28
  Health Plan Information and Materials ................................................................................. 29
Referrals ..................................................................................................................................... 31
Relation to Policyholder ............................................................................................................ 31
Transportation .......................................................................................................................... 31
Utilization ................................................................................................................................. 32
Important instructions

Placing Supplemental Items in the Core Questionnaires. After you copy one or more supplemental items into the core questionnaire:

- **Fix the formatting** of the items as needed to fit into the two-column format.
- **Renumber** the supplemental item and **ALL** subsequent items so that they are consecutive.
- **Revise ALL skip instructions** in the questionnaire to make sure they point the respondent to the correct item number.

**Definition of Health Providers.** If you choose to use one or more supplemental items that refer to other health providers, please insert this definition before the first of these items: “A health provider could be a general doctor, a specialist doctor, a nurse practitioner, a physician assistant, a nurse, or anyone else you would see for health care.”
Behavioral Health

Insert MH1 – MH4 after core question 8. For Medicaid, reference period should be stated as “In the last 6 months.”

MH1. In general, how would your rate your overall mental or emotional health?

1. Excellent
2. Very good
3. Good
4. Fair
5. Poor

MH2. In the last 12 months, did you need any treatment or counseling for a personal or family problem?

1. Yes
2. No → If No, go to core question 9

MH3. In the last 12 months, how often was it easy to get the treatment or counseling you needed through your health plan?

1. Never
2. Sometimes
3. Usually
4. Always

MH4. Using any number from 0 to 10, where 0 is the worst treatment or counseling possible and 10 is the best treatment or counseling possible, what number would you use to rate all your treatment or counseling in the last 12 months?

0. Worst treatment or counseling possible
1
2
3
4
5
6
7
8
9
10. Best treatment or counseling possible
Chronic Conditions

CC1 – CC23 – For Medicaid, reference period should be stated as “In the last 6 months,” except for CC21.

Insert CC1 – CC4 after core question 9.

CC1. Is this person a general doctor or a specialist doctor?
   1️⃣ General doctor (Family practice or internal medicine)
   2️⃣ Specialist doctor

CC2. How many months or years have you been going to your personal doctor?
   1️⃣ Less than 6 months
   2️⃣ At least 6 months but less than 1 year
   3️⃣ At least 1 year but less than 2 years
   4️⃣ At least 2 years but less than 5 years
   5️⃣ 5 years or more

CC3. Do you have a physical or medical condition that seriously interferes with your ability to work, attend school, or manage your day-to-day activities?
   1️⃣ Yes
   2️⃣ No → If No, go to core question 10

CC4. Does your personal doctor understand how any health problems you have affect your day-to-day life?
   1️⃣ Yes
   2️⃣ No

Insert CC5 after core question 18.

CC5. In the last 12 months, how many times did you go to specialists for care for yourself?
   □ 1
   □ 2
   □ 3
   □ 4
   □ 5 to 9
   □ 10 or more
Insert CC6 – CC8 after core question 14. Please refer to instructions at the front of this document about defining “health providers.”

CC6. We want to know how you, your doctors, and other health providers make decisions about your health care.

In the last 12 months, were any decisions made about your health care?

1. Yes
2. No → If No, go to core question 15

CC7. In the last 12 months, how often were you involved as much as you wanted in these decisions about your health care?

1. Never
2. Sometimes
3. Usually
4. Always

CC8. In the last 12 months, how often was it easy to get your doctors or other health providers to agree with you on the best way to manage your health conditions or problems?

1. Never
2. Sometimes
3. Usually
4. Always

Insert CC9 – CC14 after core question 8.

CC9. In the last 12 months, did you have a health problem for which you needed special medical equipment, such as a cane, a wheelchair, or oxygen equipment?

1. Yes
2. No → If No, go to question CC11

CC10. In the last 12 months, how often was it easy to get the medical equipment you needed through your health plan?

1. Never
2. Sometimes
3. Usually
4. Always
CC11. In the last 12 months, did you have any health problems that needed special therapy, such as physical, occupational, or speech therapy?

1 □ Yes
2 □ No → If No, go to question CC13

CC12. In the last 12 months, how often was it easy to get the special therapy you needed through your health plan?

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always

CC13. Home health care or assistance means home nursing, help with bathing or dressing, and help with basic household tasks.

In the last 12 months, did you need someone to come into your home to give you home health care or assistance?

1 □ Yes
2 □ No → If No, go to core question 9

CC14. In the last 12 months, how often was it easy to get home health care or assistance through your health plan?

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always

Measures of Health Status

Insert CC15 – CC17 after core question 28.

CC15. Because of any impairment or health problem, do you need the help of other persons with your personal care needs, such as eating, dressing, or getting around the house?

1 □ Yes
2 □ No
CC16. Because of any impairment or health problem, do you need help with your routine needs, such as everyday household chores, doing necessary business, shopping, or getting around for other purposes?
   1. Yes
   2. No

CC17. Do you have a physical or medical condition that seriously interferes with your independence, participation in the community, or quality of life?
   1. Yes
   2. No

Insert CC18 – CC22 after core question 28.

CC18. In the last 12 months, have you been a patient in a hospital overnight or longer?
   1. Yes
   2. No

CC19. In the past 12 months, have you seen a doctor or other health provider 3 or more times for the same condition or problem?
   1. Yes
   2. No → If No, go to core question 29

CC20. Is this condition a problem that has lasted for at least 3 months? Do not include pregnancy.
   1. Yes
   2. No

CC21. Do you now need to take medicine prescribed by a doctor? Do not include birth control.
   1. Yes
   2. No → If No, go to core question 29

CC22. Is this to treat a condition that has lasted for at least 3 months? Do not include pregnancy or menopause.
   1. Yes
   2. No
Claims Processing

Insert CP1 – CP3 before core question 20. For Medicaid, reference period should be stated as “In the last 6 months.” Please note that CP1 and CP2 repeat questions that appear in the HEDIS® set.

CP1. Claims are sent to a health plan for payment. You may send in the claims yourself, or doctors, hospitals, or others may do this for you. In the last 12 months, did you or anyone else send in any claims for your care to your health plan?

1. Yes  
2. No → If No, go to core question 20  
3. Don’t know → If Don’t know, go to core question 20

CP2. In the last 12 months, how often did your health plan handle your claims correctly?

1. Never  
2. Sometimes  
3. Usually  
4. Always  
5. Don’t know

CP3. In the last 12 months, before you went for care, how often did your health plan make it clear how much you would have to pay?

1. Never  
2. Sometimes  
3. Usually  
4. Always

Communication

Insert C1 after core question 12. For Medicaid, reference period should be stated as “In the last 6 months.”

C1. In the last 12 months, how often did you have a hard time speaking with or understanding your personal doctor because you spoke different languages?

1. Never  
2. Sometimes  
3. Usually  
4. Always
Cost Sharing

Insert CSH1 after core question 27.

CSH1. People can pay for their health insurance directly or out of their pay check. Do you or your family pay any part of the cost of your health insurance?

□ □ Yes
□ □ No

Covered By Multiple Plans

Insert MP1 after core question 2. If HP1 is included, insert after HP1.

MP1. Not counting dental insurance, are you covered by any other health plan?

□ □ Yes
□ □ No

Dental Care*

Insert D1 – D3 after core question 8. For Medicaid, reference period should be stated as “In the last 6 months.”

D1. In the last 12 months, did you get care from a dentist’s office or dental clinic?

□ □ Yes
□ □ No → If No, go to core question 9

D2. In the last 12 months, how many times did you go to a dentist’s office or dental clinic for care for yourself?

□ None → If None, go to core question 9
□ 1
□ 2
□ 3
□ 4
□ 5 to 9
□ 10 or more

* The CAHPS family of products includes a CAHPS Dental Plan Survey. For more information, go to https://www.cahps.ahrq.gov/content/products/Dental/PROD_Dental_Intro.asp.
D3. Using any number from 0 to 10, where 0 is the worst dental care possible and 10 is the best dental care possible, what number would you use to rate all your dental care in the last 12 months?

- [ ] 0 Worst dental care possible
- [ ] 1
- [ ] 2
- [ ] 3
- [ ] 4
- [ ] 5
- [ ] 6
- [ ] 7
- [ ] 8
- [ ] 9
- [ ] 10 Best dental care possible

---

**Health Plan**

Insert HP1 after core question 2.

**HP1.** How many months or years in a row have you been in this health plan?

- [ ] 1 Less than 1 year
- [ ] 2 At least 1 year but less than 2 years
- [ ] 3 At least 2 years but less than 5 years
- [ ] 4 At least 5 years but less than 10 years
- [ ] 5 10 years or more

Insert HP2 – HP7 after core question 21. For Medicaid, reference period should be stated as “In the last 6 months.” Please note that HP2 – HP7 repeat questions that appear in the HEDIS set.

**HP2.** In the last 12 months, did you look for any information in written materials or on the Internet about how your health plan works?

- [ ] 1 Yes
- [ ] 2 No → If No, go to core question 22
HP3. In the last 12 months, how often did the written materials or the Internet provide the information you needed about how your health plan works?

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always

HP4. Sometimes people need services or equipment beyond what is provided in a regular or routine office visit, such as care from a specialist, physical therapy, a hearing aid, or oxygen.

In the last 12 months, did you look for information from your health plan on how much you would have to pay for a health care service or equipment?

1 □ Yes
2 □ No → If No, go to core question 22

HP5. In the last 12 months, how often were you able to find out from your health plan how much you would have to pay for a health care service or equipment?

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always

HP6. In some health plans the amount you pay for a prescription medicine can be different for different medicines, or can be different for prescriptions filled by mail instead of at the pharmacy.

In the last 12 months, did you look for information from your health plan on how much you would have to pay for specific prescription medicines?

1 □ Yes
2 □ No → If No, go to core question 22

HP7. In the last 12 months, how often were you able to find out from your health plan how much you would have to pay for specific prescription medicines?

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always
HEDIS® Set

[Updated for HEDIS 2010]

The HEDIS Set is composed of items that the National Committee for Quality Assurance (NCQA) added to the core questionnaire to create their version of the CAHPS Health Plan Survey, known as CAHPS 4.0H. Survey sponsors can add these items to their questionnaire whether or not they are submitting results to NCQA. Please note that some of these items are repeated in other supplemental sets.

For Medicaid, reference period should be stated as “In the last 6 months.” Please refer to instructions at the front of this document about defining “health providers.”

Insert H1 – H4 after core question 7.

H1. In the last 12 months, how often did you and a doctor or other health provider talk about specific things you could do to prevent illness?

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always

H2. Choices for your treatment or health care can include choices about medicine, surgery, or other treatment. In the last 12 months, did a doctor or other health provider tell you there was more than one choice for your treatment or health care?

1 □ Yes
2 □ No → If No, go to core question 8

H3. In the last 12 months, did a doctor or other health provider talk with you about the pros and cons of each choice for your treatment or health care?

1 □ Definitely yes
2 □ Somewhat yes
3 □ Somewhat no
4 □ Definitely no
H4. In the last 12 months, when there was more than one choice for your treatment or health care, did a doctor or other health provider ask which choice you thought was best for you?

1. Definitely yes
2. Somewhat yes
3. Somewhat no
4. Definitely no

Insert H5 – H6 after core question 14.

H5. In the last 12 months, did you get care from a doctor or other health provider besides your personal doctor?

1. Yes
2. No → If No, go to core question 15

H6. In the last 12 months, how often did your personal doctor seem informed and up-to-date about the care you got from these doctors or other health providers?

1. Never
2. Sometimes
3. Usually
4. Always

Insert H7 – H12 after core question 21.

H7. In the last 12 months, did you look for any information in written materials or on the Internet about how your health plan works?

1. Yes
2. No → If No, go to question H9

H8. In the last 12 months, how often did the written materials or the Internet provide the information you needed about how your health plan works?

1. Never
2. Sometimes
3. Usually
4. Always
(H9 is the same as HP4)

H9. Sometimes people need services or equipment beyond what is provided in a regular or routine office visit, such as care from a specialist, physical therapy, a hearing aid, or oxygen.

In the last 12 months, did you look for information from your health plan on how much you would have to pay for a health care service or equipment?

1 Yes  
2 No → If No, go to question H11

(H10 is the same as HP5)

H10. In the last 12 months, how often were you able to find out from your health plan how much you would have to pay for a health care service or equipment?

1 Never  
2 Sometimes  
3 Usually  
4 Always

(H11 is the same as HP6)

H11. In some health plans, the amount you pay for a prescription medicine can be different for different medicines, or can be different for prescriptions filled by mail instead of at the pharmacy.

In the last 12 months, did you look for information from your health plan on how much you would have to pay for specific prescription medicines?

1 Yes  
2 No → If No, go to core question 22

(H12 is the same as HP7)

H12. In the last 12 months, how often were you able to find out from your health plan how much you would have to pay for specific prescription medicines?

1 Never  
2 Sometimes  
3 Usually  
4 Always
Insert H13 – H15 after core question 26.

(H13 is the same as CP1)

H13. Claims are sent to a health plan for payment. You may send in the claims yourself, or doctors, hospitals, or others may do this for you. In the last 12 months, did you or anyone else send in any claims for your care to your health plan?

1 ☐ Yes
2 ☐ No  →  If No, go to core question 27
3 ☐ Don’t know  →  If Don’t know, go to core question 27

H14. In the last 12 months, how often did your health plan handle your claims quickly?

1 ☐ Never
2 ☐ Sometimes
3 ☐ Usually
4 ☐ Always
5 ☐ Don’t know

(H15 is the same as CP2)

H15. In the last 12 months, how often did your health plan handle your claims correctly?

1 ☐ Never
2 ☐ Sometimes
3 ☐ Usually
4 ☐ Always
5 ☐ Don’t know

Insert H16 to H25 after core question 28.

H16. Have you had a flu shot since September 1, 2010?

1 ☐ Yes
2 ☐ No
3 ☐ Don’t know
H17. Do you now smoke cigarettes or use tobacco every day, some days, or not at all?

1 □ Every day
2 □ Some days
3 □ Not at all → If Not at all, go to question H21
4 □ Don’t know → If Don’t know, go to question H21

H18. In the last 12 months, how often were you advised to quit smoking or using tobacco by a doctor or other health provider in your plan?

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always

H19. In the last 12 months, how often was medication recommended or discussed by a doctor or health provider to assist you with quitting smoking or using tobacco? Examples of medication are: nicotine gum, patch, nasal spray, inhaler, or prescription medication.

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always

H20. In the last 12 months, how often did your doctor or health provider discuss or provide methods and strategies other than medication to assist you with quitting smoking or using tobacco? Examples of methods and strategies are: telephone helpline, individual or group counseling, or cessation program.

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always

H21. Do you take aspirin daily or every other day?

1 □ Yes
2 □ No
3 □ Don’t know
H22. Do you have a health problem or take medication that makes taking aspirin unsafe for you?

1  Yes
2  No
3  Don’t know

H23. Has a doctor or health provider ever discussed with you the risks and benefits of aspirin to prevent heart attack or stroke?

1  Yes
2  No

H24. Are you aware that you have any of the following conditions? Check all that apply.

1  High cholesterol
2  High blood pressure
3  Parent or sibling with heart attack before the age of 60

H25. Has a doctor ever told you that you have any of the following conditions? Check all that apply.

1  A heart attack
2  Angina or coronary heart disease
3  A stroke
4  Any kind of diabetes or high blood sugar

Interpreter

Insert I1 – I2 after core question 8. For Medicaid, reference period should be stated as “In the last 6 months.”

I1. An interpreter is someone who repeats or signs what one person says in a language used by another person.

In the last 12 months, did you need an interpreter to help you speak with doctors or other health providers?

1  Yes
2  No → If No, go to core question 9
I2. In the last 12 months, when you needed an interpreter to help you speak with doctors or other health providers, how often did you get one?

☐ Never
☐ Sometimes
☐ Usually
☐ Always

Insert I3 after core question 37.

I3. What language do you **mainly** speak at home?

☐ English
☐ [INSERT LANGUAGE 2]
☐ [INSERT LANGUAGE 3]
☐ [INSERT LANGUAGE 4]

**Medicaid Enrollment**

Insert ME1 to ME4 before core question 20. If you are including both ME1 and ME3 in your questionnaire, change the skip instruction for ME1 to “No → If No, go to question ME3.”

ME1. Some states pay health plans to care for people covered by {Medicaid/State name for Medicaid}. With these health plans, you may have to choose a doctor from the plan list or go to a clinic or health care center on the plan list.

Are you covered by a health plan like this?

☐ Yes
☐ No → If No, go to core question 20

ME2. Did you choose your health plan or were you told which plan you were in?

☐ You chose your plan
☐ You were told which plan you were in

ME3. You can get information about plan services in writing, by telephone, on the Internet, or in-person. Did you get any information about your health plan **before** you signed up for it?

☐ Yes
☐ No → If No, go to core question 20
### ME4.
How much of the information you were given before you signed up for the plan was correct?

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>All of it</td>
</tr>
<tr>
<td>2</td>
<td>Most of it</td>
</tr>
<tr>
<td>3</td>
<td>Some of it</td>
</tr>
<tr>
<td>4</td>
<td>None of it</td>
</tr>
</tbody>
</table>

---

**People With Mobility Impairments**

For Medicaid, reference period should be stated as “In the last 6 months.”

**Your Personal Doctor**

Insert IM1 – IM10 after core question 15.

#### IM1.
In the last 12 months, did you visit your personal doctor for care?

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>No  → If No, go to core question 16</td>
</tr>
</tbody>
</table>

#### IM2.
When you visited your personal doctor’s office in the last 12 months, how often were you examined on the examination table?

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Never</td>
</tr>
<tr>
<td>2</td>
<td>Sometimes</td>
</tr>
<tr>
<td>3</td>
<td>Usually</td>
</tr>
<tr>
<td>4</td>
<td>Always</td>
</tr>
</tbody>
</table>

#### IM3.
When you visited your personal doctor's office in the last 12 months, how often did someone weigh you?

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Never</td>
</tr>
<tr>
<td>2</td>
<td>Sometimes</td>
</tr>
<tr>
<td>3</td>
<td>Usually</td>
</tr>
<tr>
<td>4</td>
<td>Always</td>
</tr>
</tbody>
</table>

#### IM4.
When you visited your personal doctor's office in the last 12 months, did you try to use the restroom?

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>No  → If No, go to question IM6</td>
</tr>
</tbody>
</table>
IM5. In the last 12 months, how often was it easy to move around the restroom at your personal doctor’s office?
1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always

IM6. In the last 12 months, did you and your personal doctor talk about pain?
1 □ Yes
2 □ No

IM7. In the last 12 months, how often did pain limit your ability to do the things you needed to do?
1 □ Never → If Never, go to question IM9
2 □ Sometimes
3 □ Usually
4 □ Always

IM8. In the last 12 months, do you think that your personal doctor understood the impact that pain has on your life?
1 □ Yes
2 □ No

IM9. In the last 12 months, how often did fatigue limit your ability to do the things you needed to do?
1 □ Never → If Never, go to core question 16
2 □ Sometimes
3 □ Usually
4 □ Always

IM10. In the last 12 months, do you think that your personal doctor understood the impact that fatigue has on your life?
1 □ Yes
2 □ No
Your Health Plan

Insert IM11 – IM19 after core question 27.

IM11. In the last 12 months, did you need physical or occupational therapy?
   1 □ Yes
   2 □ No → If No, go to question IM13

IM12. In the last 12 months, how often was it easy to get this kind of therapy through your health plan?
   1 □ Never
   2 □ Sometimes
   3 □ Usually
   4 □ Always

IM13. In the last 12 months, did you need speech therapy?
   1 □ Yes
   2 □ No → If No, go to question IM15

IM14. In the last 12 months, how often was it easy to get speech therapy through your health plan?
   1 □ Never
   2 □ Sometimes
   3 □ Usually
   4 □ Always

IM15. Mobility equipment includes things like a wheelchair, scooter, walker, or cane. In the last 12 months, have you used any mobility equipment to move around your home or community?
   1 □ Yes
   2 □ No → If No, go to core question 28

IM16. In the last 12 months, did you try to get your mobility equipment repaired through your health plan?
   1 □ Yes
   2 □ No → If No, go to question IM18
IM17. In the last 12 months, how often was it easy to get your mobility equipment repaired through your health plan?

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always

IM18. In the last 12 months, did you try to get or replace any mobility equipment through your health plan?

1 □ Yes
2 □ No → If No, go to core question 28

IM19. In the last 12 months, how often was it easy to get or replace the mobility equipment that you needed through your health plan?

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always

About You

Insert IM20 – IM21 after core question 32.

IM20. A quarter mile is about 5 city blocks or 0.4 kilometers. In the last 12 months, were you able to walk that far?

1 □ Yes
2 □ No → If No, go to core question 33

IM21. In the last 12 months, did you have difficulty or need assistance to walk that far?

1 □ Yes
2 □ No
Personal Doctor

Insert PD1 – PD2 after core question 15.

PD1. Did you have the same personal doctor before you joined this health plan?

1. Yes → If Yes, go to core question 16
2. No

PD2. Since you joined your health plan, how often was it easy to get a personal doctor you are happy with?

1. Never
2. Sometimes
3. Usually
4. Always

Pregnancy Care

Insert P1 – P3 after core question 14. Remove core question 34 from the Adult Questionnaire, as it is duplicated in P1.

P1. Are you male or female?

1. Male → If Male, go to core question 15
2. Female

P2. Are you pregnant now?

1. Yes
2. No → If No, go to core question 15

P3. A health provider could be a general doctor, a specialist doctor, a nurse practitioner, a physician assistant, a nurse, a mid-wife, or anyone else you would see for health care when you are pregnant.

Have you been to a doctor or other health provider for a pregnancy care check-up for this pregnancy?

1. Yes
2. No
Prescription Medicine

Insert PM1 – PM3 after core question 27. For Medicaid, reference period should be stated as “In the last 6 months.”

PM1. In the last 12 months, did you get any new prescription medicines or refill a prescription?

1☐ Yes
2☐ No → If No, go to core question 28

PM2. In the last 12 months, how often was it easy to get your prescription medicine from your health plan?

1☐ Never
2☐ Sometimes
3☐ Usually
4☐ Always

PM3. In the last 12 months, how often did you get the prescription medicine you needed through your health plan?

1☐ Never
2☐ Sometimes
3☐ Usually
4☐ Always
Quality Improvement

For Medicaid, reference period should be stated as “In the last 6 months.”

Access to Routine Care

Insert AR1 – AR2 after core question 6. Please refer to instructions at the front of this document about defining “health providers.”

AR1. In the last 12 months, not counting the times you needed health care right away, how many days did you usually have to wait between making an appointment and actually seeing a health provider?

1. Same day
2. 1 day
3. 2 to 3 days
4. 4 to 7 days
5. 8 to 14 days
6. 15 to 30 days
7. 31 to 60 days
8. 61 to 90 days
9. 91 days or longer

AR2. In the last 12 months, how often did you have to wait for an appointment because the health provider you wanted to see worked limited hours or had few available appointments?

1. Never
2. Sometimes
3. Usually
4. Always

Access to Specialist Care

Insert AS1 after core question 17, which should be modified to include the skip instructions presented below.

17. In the last 12 months, how often was it easy to get appointments with specialists?

1. Never
2. Sometimes
3. Usually
4. Always → If Always, go to core question 18
AS1 was designed for and tested with a commercial population using primarily a self-administered format. Item wording and format may not be appropriate for other modes of administration or other populations (e.g., Medicaid, Medicare, low literacy).

AS1. Were any of the following a reason it was not easy to get an appointment with a specialist?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>Your doctor did not think you needed to see a specialist</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>b)</td>
<td>Your health plan approval or authorization was delayed</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>c)</td>
<td>You weren’t sure where to find a list of specialists in your health plan or network</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>d)</td>
<td>The specialists you had to choose from were too far away</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>e)</td>
<td>You did not have enough specialists to choose from</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>f)</td>
<td>The specialist you wanted did not belong to your health plan or network</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>g)</td>
<td>You could not get an appointment at a time that was convenient</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>h)</td>
<td>Some other reason</td>
</tr>
</tbody>
</table>

Please specify: __________________________________________________

________________________________________________

After Hours Care

Insert AH1 – AH3 after core question 8.

AH1. After hours care is health care when your usual doctor’s office or clinic is closed. In the last 12 months, did you need to visit a doctor’s office or clinic for after hours care?

1  Yes
2  No → If No, go to core question 9

AH2. In the last 12 months, how often was it easy to get the after hours care you thought you needed?

1  Never
2  Sometimes
3  Usually
4  Always → If No, go to core question 9
AH3 was designed for and tested with a commercial population using primarily a self-administered format. Item wording and format may not be appropriate for other modes of administration or other populations (e.g., Medicaid, Medicare, low literacy).

AH3. Were any of the following a reason it was not easy to get the after hours care you thought you needed?

a) You did not know where to go for after hours care
b) You weren’t sure where to find a list of doctor’s offices or clinics in your health plan or network that are open for after hours care
c) The doctor’s office or clinic that had after hours care was too far away
d) Office or clinic hours for after hours care did not meet your needs
e) Some other reason

Please specify: ______________________________________

Calls to Personal Doctor’s Office

Insert C1 – C5 after core question 14.

CO1. In the last 12 months, did you phone your personal doctor’s office during regular office hours to get help or advice for yourself?

1 □ Yes
2 □ No → If No, go to question CO3

CO2. In the last 12 months, when you phoned during regular office hours, how often did you get the help or advice you needed?

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always
CO3. In the last 12 months, did you phone your personal doctor’s office after regular office hours to get help or advice for yourself?

1 □ Yes  
2 □ No → If No, go to core question 15

CO4. In the last 12 months, when you phoned after regular office hours, how often did you get the help or advice you needed?

1 □ Never  
2 □ Sometimes  
3 □ Usually  
4 □ Always → If Always, go to core question 15

CO5 was designed for and tested with a commercial population using primarily a self-administered format. Item wording and format may not be appropriate for other modes of administration or other populations (e.g., Medicaid, Medicare, low literacy).

CO5. Were any of the following a reason you did not get the help or advice you thought you needed when you phoned after regular office hours?

a) You did not know what number to call
   1 □ Yes  
   2 □ No

b) You left a message but no one returned your call
   1 □ Yes  
   2 □ No

c) You could not leave a message at the number you phoned
   1 □ Yes  
   2 □ No

d) Another doctor was covering for your personal doctor
   1 □ Yes  
   2 □ No

e) Some other reason
   1 □ Yes  
   2 □ No

   Please specify: ____________________________________________

Co-ordination of Care from Other Health Providers

Insert OHP1 – OHP5 after core question 14. Please note that OHP1 – OHP2 repeat questions that appear in the HEDIS set. Please refer to instructions at the front of this document about defining “health providers.”

OHP1. In the last 12 months, did you get care from a doctor or other health provider besides your personal doctor?

1 □ Yes  
2 □ No → If No, go to core question 15
OHP2. In the last 12 months, how often did your personal doctor seem informed and up-to-date about the care you got from these doctors or other health providers?

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always

OHP3. In the last 12 months, did anyone from your health plan, doctor’s office, or clinic help coordinate your care among these doctors or other health providers?

1 □ Yes
2 □ No → If No, go to core question 15

OHP4. In the last 12 months, who helped to coordinate your care?

1 □ Someone from your health plan
2 □ Someone from your doctor’s office or clinic
3 □ Someone from another organization
4 □ A friend or family member
5 □ You

OHP5. How satisfied are you with the help you received to coordinate your care in the last 12 months?

1 □ Very dissatisfied
2 □ Dissatisfied
3 □ Neither dissatisfied nor satisfied
4 □ Satisfied
5 □ Very satisfied
Customer Service

Insert CS1 – CS2 after core question 23, which should be modified to include the skip instructions presented below. Core question 24 also provides useful drill-down data on consumer encounters with customer service.

23. In the last 12 months, how often did your health plan’s customer service give you the information or help you needed?

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always → If Always, go to question CS2

CS1 was designed for and tested with a commercial population using primarily a self-administered format. Item wording and format may not be appropriate for other modes of administration or other populations (e.g., Medicaid, Medicare, low literacy).

CS1. Were any of the following a reason you did not get the information or help you needed from your health plan’s customer service?

a) You had to call several times before you could speak with someone
   1 □ Yes 2 □ No

b) The information customer service gave you was not correct
   1 □ Yes 2 □ No

c) Customer service did not have the information you needed
   1 □ Yes 2 □ No

d) You waited too long for someone to call you back
   1 □ Yes 2 □ No

e) No one called you back
   1 □ Yes 2 □ No

f) Some other reason
   1 □ Yes 2 □ No

Please specify: ____________________________________________
   __________________________________________________

CS2. How many calls did it take for you to get the help or information you needed from your health plan’s customer service?

1 □ 1 call
2 □ 2
3 □ 3
4 □ 4
5 □ 5 or more calls
6 □ You are still waiting for help
Health Plan Information and Materials

Insert PW1 – PW8 after core question 21. Please note that PW1 – PW2 repeat questions that appear in the HEDIS set. If you use PW4 or PW8, please refer to instructions at the front of this document about defining “health providers.”

(PWI is the same as HP2)

PW1. In the last 12 months, did you look for any information in written materials or on the Internet about how your health plan works?

1. Yes
2. No → If No, go to core question 22

PW2. In the last 12 months, how often did the written materials or the Internet provide the information you needed about how your health plan works?

1. Never
2. Sometimes
3. Usually
4. Always

PW3. In the last 12 months, how often was it easy to use the information on how your health plan works?

1. Never
2. Sometimes
3. Usually
4. Always → If Always, go to question PW6
PW4 and PW5 were designed for and tested with a commercial population using primarily a self-administered format. Item wording and format may not be appropriate for other modes of administration or other populations (e.g., Medicaid, Medicare, low literacy).

PW4. What kind of information was **not** easy to use?

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>a) Benefits and coverage for doctor or specialist visits</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>b) Benefits and coverage for pharmacy</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>c) Getting a referral to a specialist</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>d) After hours or urgent care</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>e) Choosing a health provider</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>f) Getting care outside your network</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>g) Something else</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

*Please specify: _____________________________________________

PW5. Where did you get that information? Mark one or more.

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>a) From your health plan</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>b) From your employer</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>c) From your doctor’s office</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>d) From some other source</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>e) Not sure where you got it</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

PW6. When you looked for information in the last 12 months, did you go to your health plan’s Internet site?

1 □ Yes
2 □ No → **If No, go to core question 22**

PW7. How useful was the information you found on your health plan’s Internet site?

1 □ Not at all useful
2 □ A little useful
3 □ Somewhat useful
4 □ Very useful
PW8. In the last 12 months, did you use information on your health plan’s Internet site to choose a
doctor, specialist, or group of health providers?

☐ Yes
☐ No

Referrals

Insert R1 before core question 17. For Medicaid, reference period should be stated as “In the last 6 months.”

R1. In the last 12 months, how often was it easy to get a referral to a specialist that you needed to see?

☐ Never
☐ Sometimes
☐ Usually
☐ Always

Relation to Policyholder

Insert RP1 after core question 37.

RP1. Health insurance plans are usually in one person’s name, the policyholder. Are you the policyholder?

☐ Yes
☐ No

Transportation

Insert T1 – T3 after core question 27. For Medicaid, reference period should be stated as “In the last 6 months.”

T1. Some health plans help with transportation to doctors’ offices or clinics. This help can be a shuttle bus, tokens or vouchers for a bus or taxi, or payments for mileage.

In the last 12 months, did you phone your health plan to get help with transportation?

☐ Yes
☐ No → If No, go to core question 28
T2. In the last 12 months, when you phoned to get help with transportation from your health plan, how often did you get it?

1 □ Never → If Never, go to core question 28
2 □ Sometimes
3 □ Usually
4 □ Always

T3. In the last 12 months, how often did the help with transportation meet your needs?

1 □ Never
2 □ Sometimes
3 □ Usually
4 □ Always

Utilization

Insert UT1 after core question 6. For Medicaid, reference period should be stated as “In the last 6 months.”

UT1. In the last 12 months, how many times did you go to an emergency room to get care for yourself?

□ None
□ 1
□ 2
□ 3
□ 4
□ 5 to 9
□ 10 or more

Insert UT2 after core question 19. For Medicaid, reference period should be stated as “In the last 6 months.”

UT2. In the last 12 months, was the specialist you saw most often the same doctor as your personal doctor?

1 □ Yes
2 □ No
Appendix 3

Metrics and Hypotheses
<table>
<thead>
<tr>
<th>Metric Number</th>
<th>Indicator</th>
<th>Metric Name</th>
<th>Description</th>
<th>Data Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Medicaid Adult Core #1; CAHPS-H16; NCQA 0039</td>
<td>Flu Shots for Adults Ages 50 to 64</td>
<td>Rolling average represents the percentage of Medicaid enrollees ages 50 to 64 that received an influenza vaccination between September 1 of the measurement year and the date when the CAHPS 5.0H survey was completed</td>
<td>Survey</td>
</tr>
<tr>
<td>2</td>
<td>Medicaid Adult Core #3; NQF 0031</td>
<td>Breast Cancer Screening</td>
<td>Percentage of women ages 42 to 69 that received a mammogram in the measurement year or the year prior to the measurement year</td>
<td>Medical claims</td>
</tr>
<tr>
<td>3</td>
<td>Medicaid Adult Core #4; NQF 0032</td>
<td>Cervical Cancer Screening</td>
<td>Percentage of women ages 24 to 64 that received one or more PAP tests during the measurement year or the two years prior to the measurement year</td>
<td>Medical claims</td>
</tr>
<tr>
<td>4</td>
<td>Medicaid Adult Core #7; NQF 1768</td>
<td>Plan All-Cause Readmission Rate</td>
<td>For enrollees age 18 and older, the number of acute inpatient stays during the measurement year that were followed by an acute readmission for any diagnosis within 30 days and the predicted probability of an acute readmission</td>
<td>Medical claims</td>
</tr>
<tr>
<td>5</td>
<td>Medicaid Adult Core #9; PQI 01; NQF 0272</td>
<td>Diabetes Short-Term Complications Admission Rate</td>
<td>Number of discharges for diabetes short-term complications per 100,000 enrollees age 18 and older</td>
<td>Medical claims</td>
</tr>
<tr>
<td>6</td>
<td>Medicaid Adult Core #10; PQI 05; NQF 0275</td>
<td>Chronic Obstructive Pulmonary Disease (COPD) Admission Rate</td>
<td>Number of discharges for COPD per 100,000 enrollees age 18 and older</td>
<td>Medical claims</td>
</tr>
<tr>
<td>7</td>
<td>Medicaid Adult Core #10; PQI 08; NQF 0277</td>
<td>Congestive Heart Failure (CHF) Admission Rate</td>
<td>Number of discharges for CHF per 100,000 enrollees age 18 and older</td>
<td>Medical claims</td>
</tr>
<tr>
<td>8</td>
<td>Medicaid Adult Core #11; PQI 15; NQF 0283</td>
<td>Adult Asthma Admission Rate</td>
<td>Number of discharges for asthma per 100,000 enrollees age 18 and older</td>
<td>Medical claims</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------</td>
<td>-------------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>9</td>
<td>Medicaid Adult Core #13; NQF 0576</td>
<td>Follow-Up After Hospitalization for Mental Illness</td>
<td>Percentage of discharges for enrollees age 21 and older that were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an intensive outpatient encounter, or partial hospitalization with a mental health practitioner within 7 days of discharge and within 30 days of discharge</td>
<td>Medical claims</td>
</tr>
<tr>
<td>10</td>
<td>Medicaid Adult Core #16; NQF 0403</td>
<td>Annual HIV/AIDS Medical Visit</td>
<td>Percentage of enrollees age 18 and older with a diagnosis of HIV/AIDS and with at least two medical visits during the measurement year, with a minimum of 90 and 180 days between each visit</td>
<td>Medical claims</td>
</tr>
<tr>
<td>11</td>
<td>Medicaid Adult Core #18; NQF 0063</td>
<td>Comprehensive Diabetes Care: LDL-C Screening</td>
<td>Percentage of enrollees ages 18 to 75 with diabetes (type 1 and type 2) that had a LDL-C screening test</td>
<td>Medical claims</td>
</tr>
<tr>
<td>12</td>
<td>Medicaid Adult Core #19; NQF 0057</td>
<td>Comprehensive Diabetes Care: Hemoglobin A1c Testing</td>
<td>Percentage of enrollees ages 18 to 75 with diabetes (type 1 and type 2) that had a Hemoglobin A1C test</td>
<td>Medical claims</td>
</tr>
<tr>
<td>13</td>
<td>Medicaid Adult Core #20; NQFA 0105</td>
<td>Antidepressant Medication Management</td>
<td>Percentage of Medicaid enrollees age 18 and older with a diagnosis of major depression, that were newly treated with antidepressant medication, and who remained on an antidepressant medication treatment for at least 84 days (12 weeks) and for at least 180 days (6 months)</td>
<td>Medical claims</td>
</tr>
<tr>
<td>15</td>
<td>HEDIS NQF 1879</td>
<td>Adherence to Antipsychotics for Individuals with Schizophrenia</td>
<td>The percentage of members 18 or older during the measurement year with schizophrenia who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.</td>
<td>Medical claims</td>
</tr>
<tr>
<td>16</td>
<td>Medicaid Adult Core #26; NQF 1517</td>
<td>Postpartum Care Rate</td>
<td>Percentage of deliveries the year prior to the measurement year and that had a postpartum visit on or between 21 and 56 days after delivery.</td>
<td>Medical claims</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------</td>
<td>-------------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>17</td>
<td>HEDIS; NQF 0071</td>
<td>Persistence of Beta-Blocker Treatment After a Heart Attack</td>
<td>The percentage of members 18 years of age and older during the measurement year who were hospitalized and discharged alive from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of AMI and who received persistent beta-blocker treatment for six months after discharge.</td>
<td>Medical claims</td>
</tr>
<tr>
<td>18</td>
<td>NQF 0543</td>
<td>Adherence to Statin Therapy for Individuals with Coronary Artery Disease</td>
<td>The percentage of individuals with Coronary Artery Disease (CAD) who are prescribed statin therapy that had a Proportion of Days Covered (PDC) for statin medications of at least 0.8 during the measurement period (12 consecutive months).</td>
<td>Medical and pharmacy claims</td>
</tr>
<tr>
<td>19</td>
<td>HEDIS NQF 0021</td>
<td>Annual monitoring for patients on persistent medications</td>
<td>The percentage of members 18 years of age and older who received at least 180 treatment days of ambulatory medication therapy for select therapeutic agent during the measurement year and at least one therapeutic monitoring event for the therapeutic agent in the measurement year. For each product line, report each of the four rates separately and as a total rate.</td>
<td>Medical claims</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Annual monitoring for members on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB).</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Annual monitoring for members on digoxin.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Annual monitoring for members on diuretics.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Annual monitoring for members on anticonvulsants.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Total rate (the sum of the four numerators divided by the sum of the four denominators).</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>HEDIS</td>
<td>Adults’ Access to Preventive/ Ambulatory Health Services</td>
<td>Utilization rates per 1000 enrollees</td>
<td>Medical claims</td>
</tr>
<tr>
<td>21</td>
<td>HEDIS</td>
<td>Frequency of Selected Procedures</td>
<td>Utilization for selected procedures per 1000 enrollees</td>
<td>Medical claims</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------</td>
<td>-------------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>22</td>
<td>HEDIS</td>
<td>Ambulatory Care (Outpatient ER)</td>
<td>Utilization for selected procedures per 1000 enrollees</td>
<td>Medical claims</td>
</tr>
<tr>
<td>23</td>
<td>HEDIS</td>
<td>Inpatient Utilization—General Hospital/ Acute Care</td>
<td>Inpatient service use by age</td>
<td>Medical claims</td>
</tr>
<tr>
<td>24</td>
<td>CAHPS-4; NQF 0006</td>
<td>Got care for illness/injury as soon as needed</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>25</td>
<td>CAHPS-6; NQF 0006</td>
<td>Got non-urgent appointment as soon as needed</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>26</td>
<td>CAHPS-9; NQF 0006</td>
<td>How often it was easy to get necessary care, tests, or treatment</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>27</td>
<td>CAHPS-10; NQF 0006</td>
<td>Have a personal doctor</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>28</td>
<td>CAHPS-18; NQF 0006</td>
<td>Got appointment with specialists as soon as needed</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>29</td>
<td>CAHPS-HP1; NQF 0007</td>
<td>Number of months or years in a row enrolled in health plan</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>30</td>
<td>CAHPS-8; NQF 0007</td>
<td>Rating of all health care</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>31</td>
<td>CAHPS-16; NQF 0007</td>
<td>Rating of personal doctor</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>32</td>
<td>CAHPS-20; NQF 0007</td>
<td>Rating of specialist</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>33</td>
<td>CAHPS-26; NQF 0007</td>
<td>Rating of health plan</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>34</td>
<td>CAHPS-11; NQF 0007</td>
<td>Needed interpreter to help speak with doctors or other health providers</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>35</td>
<td>CAHPS-12; NQF 0007</td>
<td>How often got an interpreter when needed one</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>36</td>
<td>CAHPS-PD1; NQF 0007</td>
<td>Had same personal doctor before joining plan</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------</td>
<td>-------------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>37</td>
<td>CAHPS-PD2; NQF 0007</td>
<td>Easy to get personal doctor you were happy with</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>38</td>
<td>CAHPS-AR1; NQF 0007</td>
<td>Days wait time between making appointment and seeing provider</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>39</td>
<td>CAHPS-AR2; NQF 0007</td>
<td>How often had to wait for appointment because of provider's lack of hours/availability</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>40</td>
<td>CAHPS-R1; NQF 0007</td>
<td>Easy to get a referral to a specialist</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>41</td>
<td>CAHPS-UT1; NQF 0007</td>
<td>Times visited emergency room</td>
<td>Survey based assessment of enrollee experiences</td>
<td>Survey</td>
</tr>
<tr>
<td>42</td>
<td>AR Medicaid Eval 02</td>
<td>Non-emergency transportation access</td>
<td>Use of non-emergency transportation services</td>
<td>Transportation data</td>
</tr>
<tr>
<td>43</td>
<td>AR Medicaid Eval 03</td>
<td>Continuity of PCP care</td>
<td>Consistent use of the same primary care provider over time--proportion of primary care visits with same PCP</td>
<td>Medical claims</td>
</tr>
<tr>
<td>44</td>
<td>AR Medicaid Eval 04</td>
<td>Continuity of Specialist care</td>
<td>Consistent use of the same specialist provider over time--proportion of type specific same specialist visits over time</td>
<td>Medical claims</td>
</tr>
<tr>
<td>45</td>
<td>AR Medicaid Eval 05</td>
<td>PCP Network Adequacy</td>
<td>Adequacy of primary care provider network for enrolled populations--proportion of service area without primary care coverage within 30 miles</td>
<td>Carrier / Medicaid geomaps</td>
</tr>
<tr>
<td>46</td>
<td>AR Medicaid Eval 06</td>
<td>PCP Network Accessibility</td>
<td>Accessibility of primary care provider network for enrolled populations--proportion of enrollees with primary care accessible within 30 miles</td>
<td>Carrier / Medicaid geomaps</td>
</tr>
<tr>
<td>47</td>
<td>AR Medicaid Eval 07</td>
<td>Specialist network adequacy</td>
<td>Adequacy of specialist provider network for enrolled populations--proportion of service area without specialist coverage within 30 miles</td>
<td>Carrier / Medicaid geomaps</td>
</tr>
<tr>
<td>48</td>
<td>AR Medicaid Eval 08</td>
<td>Specialist network accessibility</td>
<td>Accessibility of specialist network for enrolled populations--proportion of enrollees with specialist accessible within 60 miles</td>
<td>Carrier / Medicaid geomaps</td>
</tr>
<tr>
<td>49</td>
<td>AR Medicaid Eval 09</td>
<td>Total and subgroup enrollment within carrier (e.g., market penetration)</td>
<td>Carrier, and carrier by market specific enrollment data</td>
<td>Enrollment</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------</td>
<td>-------------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>50</td>
<td>AR Medicaid Eval 10</td>
<td>Total and subgroup enrollment within each plan (e.g., plan differentiation)</td>
<td>Carrier, and carrier by market, and carrier by market by plan specific enrollment data</td>
<td>Enrollment</td>
</tr>
<tr>
<td>51</td>
<td>AR Medicaid Eval 11</td>
<td>Total and subgroup enrollment within each method of entry (e.g., enrollment path)</td>
<td>Carrier specific enrollment path</td>
<td>Enrollment</td>
</tr>
<tr>
<td>52</td>
<td>AR Medicaid Eval 12</td>
<td>Total and subgroup enrollment within each market (e.g., geographic uptake variation)</td>
<td>Carrier by market specific enrollment path</td>
<td>Enrollment</td>
</tr>
<tr>
<td>53</td>
<td>AR Medicaid Eval 13</td>
<td>Total and Subgroup Medicaid Clinical costs</td>
<td>Direct payments by state Medicaid per enrollee</td>
<td>Cost</td>
</tr>
<tr>
<td>54</td>
<td>AR Medicaid Eval 14</td>
<td>Total and Subgroup Medicaid Administrative costs</td>
<td>Direct administrative costs attributed per enrollee</td>
<td>Cost</td>
</tr>
<tr>
<td>55</td>
<td>AR Medicaid Eval 15</td>
<td>Total and Subgroup Plan Admin Costs per Enrollee</td>
<td>Direct wrap costs attributed per enrollee</td>
<td>Cost</td>
</tr>
<tr>
<td>56</td>
<td>AR Medicaid Eval 16</td>
<td>Total startup programmatic costs (e.g., medical needs screener)</td>
<td>Total Program Start Costs</td>
<td>Cost</td>
</tr>
<tr>
<td>57</td>
<td>AR Medicaid Eval 17</td>
<td>Total startup programmatic costs (e.g., medical needs screener)</td>
<td>Direct Premium Assistance paid per enrollee</td>
<td>Cost</td>
</tr>
<tr>
<td>58</td>
<td>AR Medicaid Eval 18</td>
<td>Total and Subgroup Plan Admin Costs per Enrollee</td>
<td>Estimated plan administrative costs for premium assistance</td>
<td>Cost</td>
</tr>
<tr>
<td>59</td>
<td>AR Medicaid Eval 19</td>
<td>Arkansas Program Characteristics</td>
<td>Arkansas specific health insurance exchange program characteristics (e.g., number of plans per market area, actuary risk, average 2nd lowest premium cost)</td>
<td>Cost</td>
</tr>
<tr>
<td>60</td>
<td>AR Medicaid Eval 20</td>
<td>Contiguous State Program Characteristics</td>
<td>Contiguous state specific health insurance exchange program characteristics</td>
<td>Cost</td>
</tr>
<tr>
<td>61</td>
<td>AR Medicaid Eval 21</td>
<td>Regional average program characteristics</td>
<td>Regional average state specific health insurance exchange program characteristics</td>
<td>Cost</td>
</tr>
</tbody>
</table>
Appendix 4

Candidate Metrics by Approach
## Candidate Metrics by Approach

This table attributes the metrics that are referenced in Appendix 3 to the corresponding analytical design approach that will be used to address each of the evaluation hypotheses.

<table>
<thead>
<tr>
<th>Hypotheses</th>
<th>Design Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Subgroup Comparison</td>
</tr>
<tr>
<td><strong>1—Access</strong></td>
<td></td>
</tr>
<tr>
<td>a.  Premium Assistance beneficiaries will have equal or better access to care, including primary care and specialty physician networks and services.</td>
<td></td>
</tr>
<tr>
<td>b.  Premium Assistance beneficiaries will have lower non-emergent use of emergency room services.</td>
<td>22, 41</td>
</tr>
<tr>
<td>c.  Premium Assistance beneficiaries will have lower rates of potentially preventable emergency department and hospital admissions.</td>
<td></td>
</tr>
<tr>
<td>d.  Premium Assistance beneficiaries who are young adults eligible for EPSDT benefits will have at least as satisfactory and appropriate access to these benefits.</td>
<td>18, 43-47</td>
</tr>
<tr>
<td>e.  Premium Assistance beneficiaries will have appropriate access to non-emergency transportation.</td>
<td>42</td>
</tr>
<tr>
<td><strong>2—Care/Outcomes</strong></td>
<td></td>
</tr>
<tr>
<td>a.  Premium Assistance beneficiaries will have equal or better access to preventive care services. (P – Primary Prevention; S – Secondary Prevention; T – Tertiary Prevention)</td>
<td>P: 2, 3</td>
</tr>
<tr>
<td></td>
<td>S: 9-10</td>
</tr>
<tr>
<td>b.  Premium Assistance beneficiaries will report equal or better experience in the care provided.</td>
<td></td>
</tr>
</tbody>
</table>
### 3—Continuity

| a. Premium Assistance beneficiaries will have fewer gaps in insurance coverage. | 49-52 | 29, 49-52 |
| b. Premium Assistance beneficiaries will maintain continuous access to the same health plans, and will maintain continuous access to providers. | 49-52 | 29, 36(m), 43-44, 49-52 |

### 4—Cost Effectiveness

| a. Premium Assistance beneficiaries, including those who become eligible for Exchange Marketplace coverage, will have fewer gaps in plan enrollment, improved continuity of care, and resultant lower administrative costs. | 2-4, 9-13, 16, 18-20, 22-23, 41-42, 54, 56-58 | 1-13, 16-28, 30-35, 37-52, 54, 56-58 |
| c. The cost for covering Premium Assistance beneficiaries will be comparable to what the costs would have been for covering the same expansion group in Arkansas Medicaid fee-for-service in accordance with STC 68 on determining cost effectiveness and other requirements in the evaluation design as approved by CMS. | 53-57 | 53-57 |

m = modification
Appendix 5

Arkansas Insurance Department
Network Adequacy Guidelines and Targets
Appendix 5
AID Network Adequacy Guidelines and Targets

45 CFR § 156.230 requires that Qualified Health Plans (QHPs) “…maintain a network that is sufficient in number and types of providers, including providers that specialize in mental health and substance abuse services, to assure that all services will be accessible without unreasonable delay.” AID has developed the following network adequacy targets and data submission requirements to ensure adequacy of provider networks in QHPs offered in the Federally-Facilitated Marketplace (FFM, or “Marketplace”). Failure to meet these standards may not preclude participation in the FFM in the first year of evaluation, but may require additional justification. AID will evaluate whether or not the targets should be adopted as QHP standards in future years.

Medical issuers who apply for participation in the Marketplace may already be accredited and so may not need to submit additional network access information as part of the application process. Non-accredited issuers and dental issuers will be required to submit network information. Additional detail on submission requirements is outlined below. All issuers, both accredited and non-accredited, will be required to comply with the provider directory and ECP guidelines.

Note that QHP service areas in Arkansas may change and network adequacy requirements in this standard must apply to updated service areas.

Accreditation

Issuers are required to receive accreditation on network policies and procedures from a qualifying accreditation entity (NCQA or URAQ) prior to second year of Marketplace participation. Proof of accreditation must be submitted with the QHP application (SERFF binder).

Accreditation entities have indicated that they will consider state standards in evaluating network adequacy. AID will communicate the time and distance targets below to URAC and NCQA to be used in the accreditation process. If carriers currently assess networks with more stringent internal network requirements (i.e. PCP available within 15 minutes or 15 miles), then they should proceed with existing internal standards.

Accredited issuers should report time and distance GeoAccess Maps and metrics according to the standards below as part of QHP submission.

Time and Distance Targets

AID recommends that issuers and accreditation entities evaluate networks based on the following targets. If an issuer is not accredited, GeoAccess maps and other information demonstrating network access based on these targets must be submitted.

- PCP target: 1 provider within 30 miles or 30 minutes
- Specialty care target: 1 provider within 60 miles or 60 minutes
- Mental Health, Behavioral Health, or Substance Abuse (MH/BH/SA): 1 provider within 45 minutes or 45 miles
GeoAccess Map Guidelines

GeoAccess Maps and compliance percentages must be submitted for each of the categories below. Accredited carriers will be required to submit GeoAccess maps for reporting purposes. Map data is only required for service areas that are included in the QHP application. Requested maps can be submitted separately or combined and distinguished by color or other method. Please note exceptions for dental carriers.

- **Primary Care**: GeoAccess Maps must be submitted demonstrating a 30 mile or 30 minute coverage radius from each general/family practitioner or internal medicine provider, and each family practitioner/pediatrician. Maps should also show providers accepting new patients. Dental carriers are not required to submit separate categories, but should include only non-specialists in this requirement.

- **Specialty Care**: GeoAccess Maps must be submitted demonstrating a 60 mile or 60 minute coverage radius from each category of specialist (see list of categories below). Maps should also show providers accepting new patients. Specialists should be categorized according to the list below. (Dental carriers do not need to categorize specialists.)
  - Hospitals*
  - Home Health Agencies
  - Cardiologists
  - Oncologists
  - Obstetricians
  - Pulmonologists
  - Endocrinologists
  - Skilled Nursing Facilities
  - Rheumatologists
  - Ophthalmologists
  - Urologists
  - Psychiatric and State Licensed Clinical Psychologist

  "Hospitals types should be categorized according to hospital licensure type in Arkansas.

- **MH/BH/SA**: GeoAccess Maps must be submitted demonstrating a 45 mile or 45 minute coverage radius from MH/BH/SA providers for each of the categories below. Maps should also show providers accepting new patients.
  - Psychiatric and State Licensed Clinical Psychologist
  - Other (submit document outlining provider or facility types included)

- **Essential Community Providers**: GeoAccess Maps must be submitted demonstrating a 30 mile or 30 minute coverage radius from ECPs for each of the categories below. The provider types included in each of the categories align with federal guidelines for ECP providers, with the addition of school-based providers included in the “Other ECP” category.
  - FQHC
  - Ryan White Provider
  - Family Planning Provider
  - Indian Provider
  - Hospital
  - Other ECP
Performance Metric Guidelines for Non-Accredited Carriers

Non-accredited issuers will be required to submit metrics demonstrating performance for each of the standards above for each county in the service area and overall service area. Accredited issuers will be required to submit these metrics for reporting purposes. These include:

- The number of members and percentage of total members within access to a PCP within 30 minutes/miles, a specialist within 60 minutes/miles, or a MH/BH/SA provider within 45 minutes/miles.
- The average distance to first, second, and third closest provider for each provider type.

These figures should be provided overall (entire state) for each category as well as stratified by county for each category.

For example, the percent of enrolled members that are within 30 minutes or 30 miles of a general/family practitioner will be submitted with percentages overall and for each county. The average distance to the first, second, and third closest provider will be submitted overall and for each county.

Issuers who do not yet have enrollees in the State of Arkansas will be exempt from this requirement and must attest to not currently having enrollees in Arkansas.

Network Access Policies and Procedures for Non-Accredited Carriers

Non-accredited carriers should submit an access plan describing company policies and procedures for ensuring adequate and sufficient network access. The access plan should include narrative description that addresses each of the following:

1. The Qualified Health Plan Issuer’s network is sufficient in numbers and types of providers to assure that all services to covered persons will be accessible without unreasonable delay. In the case of emergency services, covered persons shall have access twenty-four (24) hours per day, seven (7) days per week;
2. The Qualified Health Plan Issuer’s procedures for making referrals within and outside its network and notifying enrollees and potential enrollees regarding availability of network and out-of-network providers;
3. The Qualified Health Plan Issuer’s process for monitoring and assuring on an ongoing basis the sufficiency of the network to meet the health care needs of populations that enroll in its health benefit plans;
4. The Qualified Health Plan Issuer’s efforts to address the needs of covered persons with limited English proficiency and illiteracy, with diverse cultural and ethnic backgrounds, and with physical and mental disabilities;
5. The Qualified Health Plan Issuer’s methods for assessing the health care needs of covered persons;
6. The Qualified Health Plan Issuer’s method of informing covered persons of the plan’s services and features, including but not limited to, the plan’s grievance procedures, process for choosing and changing providers, and procedures for providing and approving emergency and specialty care;
7. The Qualified Health Plan Issuer’s method for assessing consumer satisfaction;
(8) The Qualified Health Plan Issuer’s method for using assessments of enrollee complaints and satisfaction to improve carrier performance;

(9) The Qualified Health Plan Issuer’s system for ensuring the coordination and continuity of care for covered persons referred to specialty providers, for covered persons using ancillary services, including social services and other community resources, and for ensuring appropriate discharge planning;

(10) The Qualified Health Plan Issuer’s process for enabling covered persons to change primary care professionals;

(11) The Qualified Health Plan Issuer’s proposed plan for providing continuity of care in the event of contract termination of the Qualified Health Plan Issuer and any of its participating providers, or in the event of the Qualified Health Plan Issuer’s insolvency or other inability to continue operations. This plan shall explain how covered persons will be notified of the contract termination, or the Qualified Health Plan Issuer’s insolvency or other cessation of operations, and transferred to other providers in a timely manner;

(12) The Qualified Health Plan Issuer shall provide access or coverage for health care providers as required by federal law;

(13) The Qualified Health Plan Issuer’s procedures to ensure reasonable proximity of participating providers to the business or personal residence of covered persons;

(14) The Qualified Health Plan Issuer’s plan that shows how it will continually monitor the ability, clinical capacity, financial capability and legal authority of its providers to furnish all contracted benefits to covered persons;

(15) The Qualified Health Plan Issuer’s procedures that ensure that if the Issuer has an insufficient number or type of participating providers to provide a covered benefit, the covered person obtains the covered benefit at no greater cost to the covered person than if the benefit were obtained from participating providers; and

(16) Qualified Health Plan Issuer should file with the Commissioner sample contract forms proposed for use with its participating providers and intermediaries

In addition, the applicant should describe the process for ensuring that if there is insufficient number or type of participating providers for an enrollee to access covered benefits that there is at least one participating provider in the next closest city or mileage and drive time radius.

**Standards for Essential Community Providers (ECPs)**

Issuers (accredited and non-accredited) must complete and submit the Essential Community Providers template and must include in the template all qualifying ECPs in the network. Qualifying ECPs include providers described in section 340B of the PHS Act and section 1927(c)(1)(D)(j)(IV) of the Social Security Act. AID will review plans according to the ECP standards in the April 5, 2013 Letter to Issuers unless CCIIO releases additional guidelines prior to the plan year 2015 certification period.

Each issuer will be required to meet conditions of the Private Option 1115 Waiver and offer at least one QHP that has at least one FQHC or RHC in each service area of the plan network.

ECPs in the provider network should be submitted in the FFM ECP template and the ECP Category below should be indicated (as in plan year 2014 QHP Certification).
FFM Categorization of ECPs in ECP Data Submission Template
(with addition of school-based providers)

<table>
<thead>
<tr>
<th>ECP Categories</th>
<th>ECP Providers</th>
</tr>
</thead>
<tbody>
<tr>
<td>FQHC</td>
<td>FQHC and FQHC look-alike clinic, Native Hawaiian Health Centers</td>
</tr>
<tr>
<td>Ryan White Provider</td>
<td>Ryan White HIV/AIDS Providers</td>
</tr>
<tr>
<td>Family Planning Provider</td>
<td>Title X Family Planning Clinics and Title X Look-Alike Family Planning Clinics</td>
</tr>
<tr>
<td>Indian Provider</td>
<td>Tribal and Urban Indian Organization Providers</td>
</tr>
<tr>
<td>Hospital</td>
<td>Disproportionate Share Hospitals (DSH), Children’s Hospitals, Rural Referral Centers, State Community Hospitals, Free-standing Cancer Centers, and Critical Access Hospitals</td>
</tr>
<tr>
<td>Other ECP Provider</td>
<td>Sexually Transmitted Disease (STD) Clinics, Tuberculosis (TB) Clinics, Hemophilia Treatment Centers, Black Lung Clinics, and School-Based Providers</td>
</tr>
</tbody>
</table>

Inclusion of School-Based Providers

Providers who are school-based providers and meet credentialing and certification standards of issuers will be included in the ECP template submission, categorized as “Other”. Issuers should submit a separate list of school-based providers as part of the QHP application. At a minimum, providers should be identified by NPI, physician or clinic name, address, and provider type.

The 2013 Letter to Issuers also requires that issuers offer contracts prior to the coverage year to:

- All available Indian providers in the service area, using the model QHP Addendum for Indian providers developed by CMS; and
- At least one ECP in each ECP category (see Table 2.1) in each county in the service area, where an ECP in that category is available.

The AR Marketplace will additionally require that issuers offer a contract to at least one school-based provider in each county in the service area, where a school-based provider is identifiable and available and meets issuer certification and credentialing standards.

Provider Directories

45 CFR Section 156.230(b) states that “… a QHP issuer must make its provider directory for a QHP available to the Exchange for publication online in accordance with guidance from the Exchange and to potential enrollees in hard copy upon request. In the provider directory, a QHP issuer must identify providers that are not accepting new patients.”

AID has the following additional requirements in regard to provider directories:

- Online provider directories must be available in Spanish.
- The directory search must include the ability to filter by each category of ECP.
- The directory search must include an indication of part-time or full-time as well as after-hours availability as reported by providers.
Specialty Services

AID is in the process of developing a rule with guidelines for in-state coverage of specialty services (i.e. transplant, burn center), including services provided at Centers of Excellence. More details forthcoming.
Appendix 6

Arkansas Insurance Department
Requirements for Qualified Health Plan Certification in the Arkansas Federally-Facilitated Partnership Exchange

June 25, 2013
BULLETIN NO. 3B-2013

TO: ALL LICENSED INSURERS, HEALTH MAINTENANCE ORGANIZATIONS (HMOs), FRATERNAL BENEFIT SOCIETIES, FARMERS’ MUTUAL AID ASSOCIATIONS OR COMPANIES, HOSPITAL MEDICAL SERVICE CORPORATIONS, NATIONAL ASSOCIATION OF INSURANCE COMMISSIONERS, PRODUCER AND COMPANY TRADE ASSOCIATIONS, AND OTHER INTERESTED PARTIES

FROM: ARKANSAS INSURANCE DEPARTMENT

SUBJECT: REQUIREMENTS FOR QUALIFIED HEALTH PLAN CERTIFICATION IN THE ARKANSAS FEDERALLY-FACILITATED PARTNERSHIP EXCHANGE (MARKETPLACE)

DATE: June 25, 2013

Qualified Health Plans (QHP), which are non-grandfathered individual or small group plans certified and offered through an Individual or SHOP Marketplace for Arkansas consumers, will be offered through the federally facilitated Health Insurance Marketplace beginning on October 1, 2013, with an effective date of coverage of January 1, 2014. The Affordable Care Act (ACA) requires that all issuers and plans participating in the Federally-facilitated Marketplace Plan Management Partnership (Partnership) meet federal and state certification standards for QHPs. The Arkansas Insurance Department (AID) will require QHP Issuers to meet all state licensure requirements and regulations, as well as state specific plan and QHP requirements and regulations. QHP Issuers will also be responsible for all other State and Federal regulations already prescribed to insurance companies in today’s market. The purpose of this Bulletin is to illustrate the new federal and state requirements to be a QHP in the Arkansas individual and SHOP Health Insurance Marketplace.

Beginning on March 5, 2013, and lasting through April 2013, NAIC provided training on the use of SERFF for application and plan submission to the Marketplace. Health Insurance Issuers responding to this guidance should submit their applications to become QHP Issuers together with included rate and form filings between March 28, 2013 and June 30, 2013. Stand Alone Dental (SAD) Issuers should submit their applications with their rate and form filings between May 20, 2013 and June 30, 2013. Toward a requirement that consumers in each of Arkansas’s 75 counties have a choice among at least two health insurance issuers, each issuer is required to submit to AID their planned service areas for 2014 by June 3, 2013 to allow the Commissioner adequate time for review of proposed service areas. If changes in a proposed issuer's service area are required, the Commissioner will contact the issuer as soon as possible. Please send this submission to insurance.exchange@arkansas.gov.

The Commissioner will maintain flexibility to conduct ongoing negotiations to achieve a competitive Arkansas Marketplace. AID will review issuer applications through July 31, 2013 and will submit all approved and recommended applications to CMS for certification on July 31, 2013. All issuers waiting until the final deadline to submit their application to offer a QHP should be aware that AID will strive to review all filings and work with issuers to make QHP recommendations to CMS by July 31. Plans will be reviewed in the order received. Any plans not having undergone complete review gaining state approval for recommendation prior to July 31 will be ineligible for offering a QHP through the Marketplace during the 2013 Open Enrollment Period. Issuers will be given an opportunity to address any data errors during the plan review period in
late August. CMS will notify all issuers of the QHP Certification decision and complete the certification agreement in early September 2013. The Federal Government has stated that there will not be any federal appeals related to non-certification during the 2014 plan year due to the shortened first year.

Issuers notified the Marketplace of their intent to participate in the certification process by March 8, 2013 by sending an email to insurance.exchange@arkansas.gov. A secondary bulletin notifying issuers of the intent to participate by SAD Issuers was published on March 15, 2013.

On April 23, 2013, Arkansas enacted the Health Care Independence Act of 2013, establishing the Health Care Independence Program (hereinafter referred to as the “Private Option”). The intent of the Private Option is to create a fiscally sustainable, cost-effective, and opportunity-driven program utilizing competitive and value-based purchasing to maximize available service options; promote accountability, personal responsibility and transparency; encourage and reward healthy outcomes and responsible choices; and promote efficiencies that will deliver value to Arkansans. The Act is expressly written to “improve access to quality health care...attract insurance carriers and enhance competition in the Arkansas Marketplace... [and] promote individually owned health insurance.” See Act 1498 of 2013, p.3. Through authority granted by the Health Care Independence Act and using the Medicaid premium assistance model, Arkansas Medicaid will purchase QHPs doing business in the Marketplace for certain Medicaid eligible beneficiaries. In 2014, Private Option eligible individuals will include childless adults between the ages of 19 and 65 with incomes below 138% of the federal poverty level (FPL) who are not enrolled in Medicare and parents between the ages of 19 and 65 with incomes between 17% of the FPL and 138% FPL who are not enrolled in Medicare. Individuals who have been determined disabled or who have been determined to be more effectively covered under the standard Medicaid program (such as an individual who is medically frail or other individuals for whom coverage through the Health Insurance Marketplace is determined to be impractical, overly complex or would undermine continuity or effectiveness of care) will not be eligible for the Private Option.

Plan Year 2014 is considered a "transition to market" year and, as such, AID will allow flexibility with some certification standards in an effort to attract more issuers to the changing Arkansas Marketplace. Year one certification standards are outlined in the table below. In Plan Year 2015, AID expects to update these standards to include:

- Transition of current identified Medicaid populations off of Medicaid and on to the Private Option;
- Development of cost sharing parameters for 50-100% FPL; and
- Development of Health Savings Account and Medical Savings Account models for populations above 50% FPL.

In 2014, Private Option eligible individuals at or below 138% of FPL will be permitted to shop among and enroll in QHPs offered at the Silver metal level in the Marketplace, at the following actuarial value variations:

- **Eligible Individuals with Incomes from 0-100% of the Federal Poverty Level**: Zero Cost Sharing Silver Plan Variation (100% actuarial value) for year one. In year two, AID will implement cost sharing for this income group where actuarial value can be attained (e.g. 50-100% FPL).

- **Eligible Individuals with Incomes from 101-138% FPL**: High-Value Silver Plan Variation (94% +/- 1% actuarial value). To facilitate implementation of a consistent approach to cost sharing across all High-Value Silver Plan enrollees, AID will require that all QHP Issuers’ High-Value Silver Plan variations conform with prescribed cost sharing amounts as defined
by AID. (See Bulletin Section “Plan Variations for Individuals Eligible for Cost Sharing: State Standards”)

AID reserves the right to seek modified proposals and/or recommend non-certification of plans to the extent necessary to ensure cost effective pricing of QHPs across all seven rating areas. Because of significant reduction of uncompensated care for uninsured patients and related cost shifting, and increased competition in the marketplace, the State expects deflationary pressure on the cost of care which should reduce premium pricing.

Arkansas’s outreach and enrollment efforts will be substantial in order to reach and enroll as many individuals eligible for QHP coverage and the Private Option during the Open Enrollment period beginning on October 1, 2013 and ending on March 31, 2014.” These efforts will include targeted outreach to individuals enrolled in other low income programs such as SNAP, parents of AR Kids First enrollees, those receiving child care assistance, etc. AID will also establish a rolling Special Enrollment Period for individuals who are determined eligible or re-determined eligible for the Private Option. All Marketplace requirements with respect to Open Enrollment and Special Enrollment Periods will apply to all QHPs doing business on the Marketplace.

<table>
<thead>
<tr>
<th>General Requirements</th>
<th>A QHP Issuer must—</th>
</tr>
</thead>
<tbody>
<tr>
<td>Federal Standard</td>
<td>(1) Comply with all certification requirements on an ongoing basis;</td>
</tr>
<tr>
<td>45 CFR §§ 153.400, 153.410</td>
<td>(2) Ensure that each QHP complies with benefit design standards;</td>
</tr>
<tr>
<td>45 CFR § 153.610</td>
<td>(3) Be licensed and in good standing to offer health insurance coverage in Arkansas;</td>
</tr>
<tr>
<td>45 CFR 156.20</td>
<td>(4) Implement and report on a quality improvement strategy or strategies consistent with the standards described within the ACA, disclose and report information on health care quality and outcomes as will be later defined by the Centers for Medicaid and Medicare Services (CMS), and implement appropriate enrollee satisfaction surveys as required by the ACA;</td>
</tr>
<tr>
<td>42 USC §18021</td>
<td>(5) Agree to charge the same premium rate for each QHP of the issuer without regard to whether the plan is offered through the Marketplace or whether the plan is offered directly from the issuer or through an agent;</td>
</tr>
<tr>
<td>42 USC §18022</td>
<td>(6) Pay any applicable user fees assessed;</td>
</tr>
<tr>
<td>42 USC §18031</td>
<td>(7) Comply with the standards related to the risk adjustment program administered by CMS;</td>
</tr>
<tr>
<td>CMS Guidance Rules</td>
<td>(8) Notify customers of the effective date of coverage;</td>
</tr>
<tr>
<td>ACA §1311</td>
<td>(9) Participate in initial and annual open enrollment periods, as well as special enrollment periods;</td>
</tr>
<tr>
<td>ACA §1002</td>
<td>(10) Collect enrollment information, transmit such to the Marketplace and reconcile enrollment files with the Marketplace enrollment files monthly;</td>
</tr>
<tr>
<td>ACA § 1341</td>
<td>(11) Provide and maintain notice of termination of coverage. A standard policy must be established and include a grace period for certain enrollees that is applied uniformly. Notice of payment delinquency must be provided;</td>
</tr>
<tr>
<td>ACA§ 1343</td>
<td>(12) Segregate funds if abortion is offered as a benefit, other than in the case of an abortion provided under the Hyde Amendment exception;</td>
</tr>
<tr>
<td></td>
<td>(13) Timely notify the Marketplace if it plans to not seek recertification, fulfill coverage obligations through the end of the plan/benefit year, fulfill data reporting obligations from the last</td>
</tr>
</tbody>
</table>
plan/benefit year, provide notice to enrollees, and terminate coverage for enrollees, providing written notice;

(14) In the event that the QHP becomes decertified, terminate coverage after the notification to enrollees and after enrollees have had an opportunity to enroll in other coverage;

(15) Meet all readability and accessibility standards;

(16) Pay the same commission to producers and brokers for the sale of plans inside the SHOP as to similar plans sold in the outside market;

(17) Provide a matching benefit plan and price off of the Marketplace if the plan offered within the Marketplace offers all ten Essential Health Benefits;

(18) Participate in the reinsurance program, including making reinsurance contributions and receiving reinsurance payments; and

(19) Participate in risk adjustment.

### State Standard

AID will utilize a certification approach to reviewing, recommending, and submitting the rate, form and QHP Issuer application filings for compliance with federal and state rules and regulations. Certification will be good for a period of one (1) plan year. If an issuer wishes to continue offering a certain QHP following that plan year, the issuer must apply to have that QHP recertified. As part of the application, the QHP Issuer must fill out and submit the checklist that is attached in SERFF and is included for reference purposes only in this Bulletin as Appendix A.

AID will review the pricing of QHPs, to ensure that all QHPs are adequately and appropriately priced for the Arkansas Marketplace.

AID will work with CMS and the QHP Issuers to move enrollees to other available certified QHPs should a certified QHP in which a consumer is enrolled become decertified or allows its certification to expire. Additionally, AID will allow individuals to enroll in or change from one QHP to another as a result of an individual being determined eligible for or re-determined eligible for the Private Option.

AID will also require all QHP Issuers offering a plan which has pediatric dental imbedded as part of its benefits to also offer an identical plan which does not include pediatric dental as part of its benefits. This requirement will be null and void and all QHP Issuers will be required to have an imbedded pediatric dental benefit should no SAD plans become certified on the Marketplace. Three (3) SAD Issuers notified AID of their intent to participate as published in AID Bulletin 8-2013. Another SAD Issuer has since given AID notice to participate. This requirement will not have any affect on the QHP's actuarial value (AV) results related to either the embedded or unembedded plan as the AV Calculator does not review pediatric dental as part of the standard population.

Furthermore, in future years of the Marketplace, AID may limit the number of plans or benefit designs that may be offered by a carrier per “metal tier” level on the Marketplace.
<table>
<thead>
<tr>
<th>Licensure and Solvency</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Federal Requirements</strong></td>
<td>45 CFR 156.200</td>
</tr>
<tr>
<td><strong>State Requirements</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A QHP Issuer must have unrestricted authority to write its authorized lines of business in Arkansas in order to be considered “in good standing” and to offer a QHP through the Marketplace. AID is the sole source of a determination of whether an issuer is in good standing.</td>
</tr>
<tr>
<td></td>
<td>AID determinations of good standing will be based on authority found in Ark. Code Ann. § 23-63-202. Such authority may include restricting a QHP Issuer's ability to issue new or renew existing coverage for an enrollee.</td>
</tr>
<tr>
<td></td>
<td>An issuer will be allowed to apply for Arkansas licensure and QHP Issuer and plan certification simultaneously during the first QHP certification cycle; however, a QHP Issuer may not be certified for participation in the Marketplace until state licensure has been established.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Network Adequacy</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Federal Standard</strong></td>
<td>45 CFR 156.230</td>
</tr>
<tr>
<td></td>
<td>45 CFR 156.235</td>
</tr>
<tr>
<td></td>
<td>Public Health Services Act (PHS) §2702(c)</td>
</tr>
<tr>
<td></td>
<td>A QHP Issuer must ensure that the provider network of each of its QHPs is available to all enrollees and:</td>
</tr>
<tr>
<td></td>
<td>(1) (a) Includes essential community providers (ECP) in sufficient number and geographic distribution where available to ensure reasonable and timely access to a broad range of such providers for low income and medically underserved individuals in QHP service area.</td>
</tr>
<tr>
<td></td>
<td>This must be done by demonstrating one of the following during the first year of the Marketplace:</td>
</tr>
<tr>
<td></td>
<td>• That the issuer achieved at least 20% ECP participation in network in the service area, agreed to offer contracts to at least 1 ECP of each type available by county;</td>
</tr>
<tr>
<td></td>
<td>• That the issuer achieved at least 10% ECP participation in the network service area and submits a satisfactory narrative justification as part of its Issuer Application; or</td>
</tr>
<tr>
<td></td>
<td>• That the issuer failed to achieve either standard but submitted a satisfactory narrative justification as part of its Issuer Application.</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td>(b) If an issuer provides a majority of covered services through employed physicians or a single contracted medical group complying with the alternate ECP standard identified within federal regulations, the issuer must verify one of the following:</td>
</tr>
<tr>
<td></td>
<td>• That the issuer has at least the same number of providers located in designated low income areas as the</td>
</tr>
</tbody>
</table>
equivalent of at least 20% of available ECPs in the service area;

- That the issuer has at least the same number of providers located in designated low income areas as the equivalent of at least 10% of available ECPs in the service area, and submits a satisfactory narrative justification as part of its Issuer Application; or

- That the issuer failed to achieve either standard but submitted a satisfactory narrative justification as part of its Issuer Application.

(2) Maintains a network that is sufficient in number and types of providers, including providers that specialize in mental health and substance use disorder treatment services, to assure that all services will be accessible without unreasonable delay; and

(3) Makes its provider directory for a QHP available to the Marketplace for publication online in accordance with guidance from the Marketplace and to potential enrollees in hard copy upon request noting which providers are not accepting new patients.

<table>
<thead>
<tr>
<th>State Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>AID will require an attestation from the QHP Issuer that states it is in compliance with all network adequacy requirements in addition to one of the following:</td>
</tr>
</tbody>
</table>

- The QHP Issuer provides evidence that it has accreditation from an HHS approved accrediting organization that reviews network adequacy as a part of accreditation; or

- The QHP Issuer provides sufficient information through a PDF submission related to its policies and procedures to determine that the QHP Issuer's network meets the minimum federal requirements and complies with all requirements in AID Bulletin 11A-2013

Any QHP Issuer that fails to achieve at least 10% ECP participation will undergo a stricter review of its Issuer Application. AID will not impose standards that exceed federal ACA standards in the first year. The percentage of ECPs in a network will be measured against the federal lists that can be found at [https://data.cms.gov/dataset/List-of-Essential-Community-Providers-ECPs-that-Pr/nwve-k4qu](https://data.cms.gov/dataset/List-of-Essential-Community-Providers-ECPs-that-Pr/nwve-k4qu) and [https://data.cms.gov/dataset/Non-Exhaustive-List-of-Essential-Community-Provide/ibqy-mswq](https://data.cms.gov/dataset/Non-Exhaustive-List-of-Essential-Community-Provide/ibqy-mswq). To the extent that issuers subject to the alternate standard cannot meet the safe harbor or minimum expectation levels, factors and circumstances identified in the supplemental response along with an explanation of how the issuer will provide access to low-income and underserved populations will be taken into account. AID reserves the right to add additional state standards for future plan years of the Marketplace.
<table>
<thead>
<tr>
<th>Accreditation</th>
</tr>
</thead>
</table>
| **Federal Standard**  
45 CFR 156.275  
45 CFR 155.1045 |
| - QHP Issuers, excluding SAD Issuers, must maintain accreditation on the basis of local performance in the following categories by an accrediting entity recognized by HHS: Clinical quality measures, such as the HEDIS; Patient experience ratings on a standardized Consumer Assessment of Healthcare Providers and Systems (CAHPS®)\(^1\) survey; Consumer access; Utilization management; Quality assurance; Provider credentialing; Complaints and appeals; Network adequacy and access; and Patient information programs.  
- The Partnership will accept existing commercial or Marketplace health plan accreditation from HHS-recognized accrediting entities. For the purposes of QHP Issuer certification in 2013, these are the National Committee for Quality Assurance (NCQA) and URAC.  
  - To verify the accreditation information, QHP Issuers must upload their current and relevant accreditation certificates.  
  - QHP Issuers must complete attestations about the accreditation data that will be displayed on the Marketplace website.  
  - QHP Issuers will be required to authorize the release of their accreditation survey data and any official correspondence related to accreditation status to AID and the Partnership  
- QHP Issuers without existing commercial or Marketplace health plan accreditation from HHS-recognized accrediting entities must schedule an accreditation review during their first year of certification and receive accreditation on QHP Issuer policies and procedures prior to their second year of QHP Issuer certification.  
- Prior to the QHP Issuer’s fourth year of QHP Issuer certification and in every subsequent year of certification, a QHP Issuer must be accredited in accordance with 45 CFR 156.275. |
| **State Standard** |
| AID will follow the Federal requirements related to accreditation and will require the authorized release of all accreditation data. Additionally, AID will require an attestation by QHP Issuers not already accredited that those QHP Issuers will schedule, become accredited on policies and procedures in the plan types used, and provide proof of such accreditation on policies and procedures prior to submission of any application for recertification. The QHP Issuer must also indicate  
\(^1\) CAHPS® is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ) of HHS. |
that it will receive and provide proof of receipt of full Marketplace accreditation prior to its third recertification application.

<table>
<thead>
<tr>
<th>Service Area</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Federal Standard</strong></td>
</tr>
<tr>
<td>45 CFR 155.30 &amp; 155.70</td>
</tr>
<tr>
<td>Service area for the Individual Marketplace is the geographic area in which an individual must reside. Service area may additionally be the geographic area where an individual is employed for the purposes of SHOP. A QHP Issuer must specify what service areas it will be utilizing. The service area must be established without regard to racial, ethnic, language or health status related factors or other factors that exclude specific high utilization, high cost or medically underserved populations.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>State Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>All QHP Issuers must file a statement of intent by June 3, 2013 indicating what service area(s) they intend to serve in 2014. Service areas will have the same geographic boundaries as rating areas as defined in Appendix C. The state will allow QHP Issuers to choose their service area(s) for year one with a goal of having at least three or more issuers per service area. The Commissioner reserves the right to require broader service areas as needed to achieve the state’s coverage requirements of at least two issuers per service area. Any application not meeting this standard requires a justification as to why the QHP should be considered for certification and will be subject to stricter review.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rating Area</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Federal Standard</strong></td>
</tr>
<tr>
<td>45 CFR §156.255</td>
</tr>
<tr>
<td>As it applies to QHPs, the ACA defines a “Rating Area” as a geographic area established by a state that provides boundaries by which issuers can adjust premiums. The ACA requires that each state establish one (1) or more rating areas, but no more than nine (9) rating areas, within the State of Arkansas based upon its metropolitan areas for purposes of applying the requirement of this title.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>State Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>AID has approved a configuration of seven (7) rating areas to be utilized in Arkansas. These areas are specifically described in Appendix C.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Quality Improvement Standards</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Federal Standard</strong></td>
</tr>
<tr>
<td>45 CFR 156.20</td>
</tr>
<tr>
<td>ACA §1311</td>
</tr>
<tr>
<td>ACA §2717</td>
</tr>
<tr>
<td>A QHP Issuer must implement and report on a quality improvement strategy or strategies consistent with standards of the ACA to disclose and report information on healthcare quality and outcomes and implement appropriate enrollee satisfaction surveys which include but are not limited to the implementation of:</td>
</tr>
<tr>
<td>• A payment structure for health care providers that provides incentives for improving health outcomes through the implementation of activities that shall include quality reporting, effective case management, care coordination, chronic disease management, medication and care compliance initiatives, including through the use of the medical home model, for treatment or services under the plan or coverage;</td>
</tr>
<tr>
<td>• Activities to prevent hospital readmissions through a</td>
</tr>
</tbody>
</table>
comprehensive program for hospital discharge that includes patient-centered education and counseling, comprehensive discharge planning, and cost discharge reinforcement by an appropriate health care professional;

- Activities to improve patient safety and reduce medical errors through the appropriate use of best clinical practices, evidence based medicine, and health information technology under the plan or coverage;

- Wellness and health promotion activities; and

- Activities to reduce health and health care disparities, including through the use of language services, community outreach, and cultural competency trainings.

| State Standard | AID will require all QHP Issuers to participate and report on the implementation of their quality improvement standards and results no less than quarterly. Any changes to the issuer’s quality improvement initiatives must be reported to AID within thirty (30) days. Federal quality criterion is not established and therefore cannot be implemented until a future date. AID will notify issuers during the 2014 plan year as the measures are developed. Until the measures are adopted and implemented, AID intends to use Consumer Assessment of Healthcare Providers and Systems (CAHPS) data results from accredited commercial product lines when the data are available for the same QHP product types and adult/child populations. In order to advance quality and affordability, Arkansas will require participation in Arkansas’s Payment Improvement Initiative no later than year two of the Marketplace. As part of the participation requirements for Plan Year 2015, Arkansas intends to transition participation in the Arkansas Payment Improvement Initiative by requiring, at a minimum, that QHP Issuers will assign a primary care clinician; provide support for patient-centered medical home; and provide access of clinical performance data for providers. Participation in the Arkansas Payment Improvement Initiative will also include a requirement to contribute claims and encounter data for the purposes of measuring cost, quality and access. Timing and processes related to these requirements are still under development and will be released in a future Bulletin.  

AID intends to establish during plan year 2014 a QHP submission process for 2014 claims and encounter data utilizing the X12 standards ([www.X12.org](http://www.X12.org)) in eligibility files and medical claims, and the National Council for Prescription Drug Programs Standards in Pharmacy Claims Files. Submission will be implemented no sooner than three months from the end of the plan year (e.g., no sooner than April 2015) to support rate requests, assess network adequacy and support quality and payment improvement. |
| Federal Standard | A QHP Issuer must offer at least one QHP in the silver coverage level and at least one QHP in the gold coverage level and a child-only plan at the same level of coverage as any QHP offered through either the individual Marketplace or SHOP to individuals who, as of the beginning of the plan year, have not attained the age of 21. This requirement may also be met by submitting an attestation that there is no substantive difference between having a child-only plan and issuing child only policies, and that the QHP Issuer will accept child only enrollees. QHP Issuers may also choose to offer a bronze or platinum metal level plan. All of the plans must meet the AV requirements as specified in 45 CFR 155 and will be verified by use of the AV Calculator. However, SAD plans may not use the AV Calculator and must demonstrate that the SAD plan offers the pediatric dental EHB at either a low level of coverage with an AV of 70% or a high level of coverage with an AV of 85%, and with a de minimis variation of +/-2%. This must be certified by an actuary accredited with the American Academy of Actuaries. Additionally, a catastrophic plan may be filed to be sold on the Marketplace in addition to the tiered metal levels. It should be noted that child-only policies are only available in the individual Marketplace. |
| CMS Guidance Rules | All offerings by a QHP Issuer, excluding stand alone dental issuers, on a single metal tier must show a meaningful difference between the plans and comply with standards in the best interest of the consumer. Moreover, the QHP, excluding pediatric dental, must provide coverage for dependents up to age 26 if the Plan offers dependent coverage. Pediatric dental and vision is required to cover dependents to age 19. The QHP must cover emergency services with no prior authorization, no limitation to participating or in-network providers. Emergency services must be covered at in-network cost-sharing level. |
| IRS Revenue Procedure 2013-25 Letter to Issuers | Additionally, QHP Issuers will be required to meet all annual limitation and cost sharing requirements without affecting the AV of the plans within each of the tiers. The QHP Issuer must demonstrate in an Exhibit filed with the Plan that annual out of pocket cost sharing under the Plan does not exceed the limits established by federal and state laws and regulations. IRS published the high-deductible health plan limit for 2014 on May 6, 2013 stating that the annual limitation on cost sharing for embedded plans in the 2014 plan year will be $6,350 for self-only coverage and $12,700 for family coverage. For small group market plans, Issuers may establish separate out-of-pocket limits for medical and dental coverage as long as the total out-of-pocket limit does not exceed the total QHP limit for high deductible health plans. Moreover, the QHP must contain no lifetime limits on the dollar value of any EHB, including the specific benefits and services covered under the EHB-Benchmark Plan. |
| | For plans issued in the small group market, the deductible under the plan shall not exceed either: |
| | • $2,000 in the case of a plan covering a single individual; and |
| | • $4,000 in the case of any other plan. |
| | However, an issuer may propose a higher deductible in order to meet |
the actuarial value of the plan that is proposed.

SAD plans must demonstrate that they have a reasonable annual limitation on cost sharing. For 2014, “reasonable” means any annual limitation on cost sharing that is at or below $700 for a plan with one child enrollee or $1,400 for a plan with two or more child enrollees. Catastrophic plans can be sold to individuals that have not attained the age of 30 before the beginning of the plan year; or an individual who has a certification in effect for any plan year exempt from the Shared Responsibility Payment by reason of lack of affordable coverage or hardship. If offered, Catastrophic Plans are offered only in the individual Marketplace and not in the SHOP. Additionally, child-only plans are not required to be offered at the catastrophic level of coverage.

A QHP Issuer must comply with all federal and state laws related to rating rules, factors and tables used to determine rates. Such rates must be based upon the analysis of the plan rating assumptions and rate increase justifications in coordination with AID and timely submitted to the FFE-SHOP if appropriate. It should be noted that no additional age rating may be included in SAD plans for pediatric dental for purposes of completing the QHP application, but SAD Issuers may indicate whether the rate is estimated or guaranteed. If the rate is estimated, the SAD Issuer may later add more age rating factors.

If a QHP Issuer would like to participate in the individual market, the QHP Issuer must also participate in the SHOP if the following requirements are met:

- The QHP Issuer offers products in the small group market and has at least a 20% market share in the small group market; or
- The QHP Issuer is part of a holding company that also owns other issuers that participate in the small group market and that have at least a 20% market share of the small group market.
  - If the QHP Issuer under this example does not currently participate in the small group market, the affiliated QHP Issuer holding at least 20% of the small business market must participate in the SHOP.
  - If the QHP Issuer under this example does participate in the small group market, the QHP Issuer must participate in SHOP.

If a QHP Issuer offers a QHP in the SHOP, the QHP issuer will not be required to offer a QHP in the individual market.

<table>
<thead>
<tr>
<th>State Standard</th>
<th>Specific state rate and form filing requirements may be found in Appendix A, attached.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>To the extent that Arkansas has benefits subject to “mandatory offering” statutes, these benefits, if not already imbedded into the QHP, must be offered by:</td>
</tr>
<tr>
<td></td>
<td>- Providing a link to a plan brochure that describes the</td>
</tr>
</tbody>
</table>
mandatory offering benefits and how to purchase; and
- Including an application and description of mandatory offering
  benefits in the mailing with the consumer's plan identification
  card.

Information regarding Arkansas mandatory offerings can be found at:

### Essential Health Benefit Standards

| Federal Standards | The QHP Issuer must offer coverage that is substantially equal to the
<table>
<thead>
<tr>
<th></th>
<th>coverage offered by the state's base benchmark plan.</th>
</tr>
</thead>
</table>
| 45 CFR 156.115    | A QHP Issuer is not required to offer abortion coverage within their
| 42 U.S.C. § 18022 | benefit plans. The QHP Issuer will determine whether the benefits
| 45 CFR §147.130   | offered include abortion. If the QHP Issuer chooses to offer abortion
| 45 CFR §148.170   | benefits, public funds may not be used to pay for these services unless
| 45 CFR §155.170   | the services are covered as part of the Hyde Amendment exceptions.
| 45 CFR §156.110   | The QHP Issuer must provide notice through its summary of benefits if
| 45 CFR §156.125   | such benefit is being made available.

The QHP must cover preventive services without cost sharing
requirements including deductibles, co-payments, and co-insurance.
Covered preventive services include evidence-based items or services
that have in effect a rating of A or B in the current recommendations of
the United States Preventive Services Task Force (USPSTF); certain
immunizations, screenings provided for in HRSA guidelines for infants,
children, adolescents, and women (including compliance with
standards related to benefits for and current recommendations of the
USPSTF regarding breast cancer screening, mammography, and
prevention). Additionally, coverage for the medical treatment of
mental illness and substance use disorder must be provided under the
same terms and conditions as that coverage provided for other
illnesses and diseases.

Finally, any state mandates in effect as of December 2011 must apply as
an EHB in the same way they apply in the current market. These
benefits, as with all EHBs, must be offered without annual or lifetime
dollar limitations.

| State Standards | AID has adopted the Health Advantage Point of Service Plan as the Base
|                 | Benchmark Plan to set the essential health benefits for Arkansas. AID
|                 | substituted the mental health benefit with the Federal QualChoice
|                 | Mental Health Benefit. AID also supplemented the Health Advantage
|                 | Plan with the AR Kids B (CHIP) pediatric dental and vision plans.
|                 | Finally, AID has adopted a definition of habilitative services, which may
|                 | be found in Appendix B to this Bulletin.

Additionally, Act 72 of 2013 was adopted which prohibits offering
coverage of elective abortions as a part of EHBs on an Exchange
established by Arkansas.

AID will require an attestation from the QHP Issuer that states the
issuer is in compliance with all EHB standards.
| **Essential Health Benefit Formulary Review** |  |
| **Federal Standards** | **The QHP must cover at least the greater of one drug in every U.S. Pharmacopeial Convention (USP) category and class or the same number of drugs in each category and class as the base benchmark plan.**  
Issuers must report data such as the following to U.S. DHHS on prescription drug distribution and costs (paid by Pharmacy Benefit Management (PBM) or issuer); percentage of all prescriptions that were provided through retail pharmacies compared to mail order pharmacies; percentage of prescriptions for which a generic drug was available and dispensed compared to all drugs dispensed, broken down by pharmacy type; aggregate amount and type of rebates, discounts or price concessions that the issuer or its contracted PBM negotiates that are attributable to patient utilization and passed through to the issuer; total number of prescriptions that were dispensed; aggregate amount of the difference between the amount the issuer pays its contracted PBM and the amounts that the PBM pays retail pharmacies, and mail order pharmacies. |
| **State Standards** | **AID will require an attestation of compliance with EHB Formulary Standards.**  
AID will require an attestation that the issuer: (1) provides response by telephone or other telecommunication device within 72 hours of a request for prior authorization, and (2) provides for the dispensing of at least a 72-hour supply of covered drugs in an emergency situation. |
| **Non-Discrimination Standards in Marketing and Benefit Design** | **(1) A QHP Issuer must:**  
- Be able to pass a review and an outlier analysis or other automated test to identify possible discriminatory benefits; and  
- Refrain from:  
  - Adjusting premiums based on genetic information;  
  - Discriminating with respect to its QHP on the basis of race, color, national origin, disability, expected length of life, present or predicted disability, degree of medical dependency, quality of life, sex, gender identity, sexual orientation or other health conditions;  
  - Utilizing any preexisting condition exclusions;  
  - Requesting/requiring genetic testing; or  
  - Collecting genetic information from an individual prior to, or in connection with enrollment in a plan, or at any time for underwriting purposes. |
(2) A QHP Issuer may not employ marketing practices or benefit designs that will have the effect of discouraging the enrollment of individuals with significant health needs.

Outliers in benefit design with regards to QHP cost sharing as part of its QHP certification reviews to target QHPs for more in-depth reviews will be identified.

<table>
<thead>
<tr>
<th>State Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>QHP Issuers and QHPs must comply with state laws and regulations regarding marketing by health insurance issuers, including Ark. Code Ann. §23-66-201 et seq., Unfair Trade Practices Act and the requirements defined in Rules 11 and 19.</td>
</tr>
</tbody>
</table>

QHP Issuers may inform consumers in QHP marketing materials that the QHP is certified by the Partnership as a QHP. The QHP Issuer cannot inform consumers that the certification of a QHP implies any form of further endorsement or support of the QHP.

AID will require prior submission of QHP marketing material and an attestation that the QHP Issuer meets all Marketing Standards. Marketing materials must be submitted in PDF format. Any multimedia marketing materials should be provided through a link within a pdf document. AID reserves a right to request a timely upload of the multi-media files for review. If AID determines through its regulatory efforts that unfair or discriminatory marketing is occurring, AID will enforce through use of state remedies up to and including the recommendation of the QHP for decertification.

<table>
<thead>
<tr>
<th>Actuarial Value Standards</th>
</tr>
</thead>
<tbody>
<tr>
<td>Federal Standards</td>
</tr>
<tr>
<td>45 CFR 156.135</td>
</tr>
<tr>
<td>Plans being offered at the various metal tiers within the Marketplace must meet the specified levels of AV (or fall within the allowable variation):</td>
</tr>
<tr>
<td>Bronze plan: 60% (58 to 62%)</td>
</tr>
<tr>
<td>Silver plan: 70% (68 to 72%)</td>
</tr>
<tr>
<td>Gold plan: 80% (78 to 82%)</td>
</tr>
<tr>
<td>Platinum plan: 90% (88% to 92%)</td>
</tr>
<tr>
<td>SAD plans must offer plans at either a 70% or 85% AV level.</td>
</tr>
</tbody>
</table>

State Standards: AID will require an attestation of compliance with AV standards.

<table>
<thead>
<tr>
<th>Quality Rating Standards</th>
</tr>
</thead>
<tbody>
<tr>
<td>Federal Standard</td>
</tr>
<tr>
<td>45 CFR §156.265 (b)(2)</td>
</tr>
<tr>
<td>45 CFR §156.265 (f);</td>
</tr>
<tr>
<td>45 CFR §156.400 (d)</td>
</tr>
<tr>
<td>45 CFR §156.285 (c)</td>
</tr>
<tr>
<td>PHSA 2794</td>
</tr>
<tr>
<td>HHS intends to propose a phased approach to new quality reporting and display requirements for all Marketplaces with reporting requirements related to all QHP Issuers expected to start in 2016. HHS intends to support the calculation of the QHP-specific quality rating for all QHP Issuers in all Marketplaces. The results of such surveys and rating will be available to consumers. HHS intends to issue future rulemaking on quality reporting and disclosure requirements.</td>
</tr>
</tbody>
</table>
| QHP Issuers must also provide plain language information/data on claims payment policies and practices, periodic financial disclosures,
<table>
<thead>
<tr>
<th>State Standard</th>
<th>The state will adopt the Quality Rating Standards as provided in federal guidance. Any AID requests for quality information must be made available upon request.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rate Filing</strong></td>
<td>Premiums may be varied by the geographic rating area, but premium rates for the same plan must be the same inside and outside the Marketplace.</td>
</tr>
<tr>
<td><strong>Federal Standard</strong></td>
<td>Rating will be allowed on a per member basis. For SHOP plans, the geographic premium rating factor will be based on the geographic area of the employer.</td>
</tr>
<tr>
<td></td>
<td>ACA: premium rate may vary by individual/family, rating area, age (3:1), and tobacco use (1.5:1)</td>
</tr>
<tr>
<td></td>
<td>All rates filed for individual QHPs will be set for an entire benefit/plan year.</td>
</tr>
<tr>
<td></td>
<td>For Marketplace plans with an embedded dental benefit, the dental issuer is not allowed to use different geographic area factors and/or network factors than the medical plan geographic and network factors. However, SAD Issuers will be able to make premium adjustments for their SAD plans that are considered excepted benefits upon consumer enrollment, but must indicate that rates are not guaranteed for QHPs offered on the Marketplace.</td>
</tr>
<tr>
<td></td>
<td>Outlier identification on QHP rates will be conducted to identify rates that are relatively high or low compared to other QHP rates in the same rating area. Identification of a QHP rate as an outlier does not necessarily indicate inappropriate rate development. CMS will notify AID of the results of its outlier identification process. If AID confirms that the rate is justified, CMS expects to certify the QHP if the QHP meets all other standards.</td>
</tr>
<tr>
<td></td>
<td>QHP Issuers, but not SAD Issuers, are required to submit the Unified Rate Review Template for rate increase.</td>
</tr>
<tr>
<td><strong>State Standard</strong></td>
<td>AID will continue to effectuate its rate review program and will review all rate filings and rate increases for prior approval. Rate filing information must be submitted to AID with any rate increase justification prior to the implementation of an increase. A QHP Issuer must prominently post the justification for any rate increase on its Website.</td>
</tr>
<tr>
<td></td>
<td>AID will limit the use of tobacco use as a rating factor to 1.2:1, applicable only to the individuals in the family that smoke. AID may later issue additional standards related to tobacco cessation.</td>
</tr>
</tbody>
</table>
# Plan Variations for Individuals Eligible for Cost Sharing

## Federal Standard

<table>
<thead>
<tr>
<th>Rule</th>
<th>Text</th>
</tr>
</thead>
<tbody>
<tr>
<td>45 CFR §155.1030</td>
<td>The QHP Issuer must offer three silver plan variations for each silver QHP, one zero cost sharing plan variation, and one limited cost sharing plan variation for each metal level QHP. Silver plan variations must have a reduced annual limitation on cost sharing, cost sharing requirements and AVs that meet the required levels within a de minimis range. Benefits, networks, non-EHB cost sharing, and premiums cannot change. All cost sharing must be eliminated for the zero cost sharing plan variation. Cost sharing for certain services must be eliminated for the limited cost sharing plan variation. SAD plans are excluded from cost-sharing reduction (CSR) requirements. However, SAD plans must have a “reasonable” annual limit on cost sharing that is at or below $700 for a plan with one child enrollee or $1,400 for a plan with two or more child enrollees. This will be completed via rate and benefit templates.</td>
</tr>
<tr>
<td>45 CFR §156.420</td>
<td></td>
</tr>
</tbody>
</table>

## State Standard

<table>
<thead>
<tr>
<th>Text</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AID will require an attestation of compliance with Plan Variation Standards. In support of the Private Option, AID will require that all QHP Issuers’ High-Value Silver Plan variations (94% +/-1% AV) conform to prescribed cost sharing amounts as defined by AID in Appendix D.</td>
<td></td>
</tr>
</tbody>
</table>

## Stand Alone Dental Plans

### Federal Standard

<table>
<thead>
<tr>
<th>Rule</th>
<th>Text</th>
</tr>
</thead>
<tbody>
<tr>
<td>45 CFR 155 and 156</td>
<td>SAD Issuers and SAD plans must meet the same QHP certification standards as medical plans unless exceptions were noted in the above sections. Additionally, SAD plans are not subject to the insurance market reform provisions of the Affordable Care Act such as guaranteed availability and renewability of coverage. Moreover, SAD plans may impose up to a 24 month waiting period for orthodontia services. SAD plans intended to be utilized outside the Marketplace only for use to supplement medical plans such that the medical plans will comply with federal requirement of offering all 10 EHBs outside the Marketplace as required under the Public Health Services Act must follow the Marketplace certification filing process as described within this Bulletin.</td>
</tr>
<tr>
<td>45 C.F.R. § 155.1065</td>
<td></td>
</tr>
<tr>
<td>PHS Act section 2791</td>
<td></td>
</tr>
<tr>
<td>45 C.F.R. § 146.145(c)</td>
<td></td>
</tr>
<tr>
<td>45 C.F.R. § 156.440(b)</td>
<td></td>
</tr>
</tbody>
</table>

### State Standard

<table>
<thead>
<tr>
<th>Text</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>There are no additional state standards for SAD plans. SAD plans must comply with the AR EHB benchmark plan: AR Kids B (CHIP) pediatric dental.</td>
<td></td>
</tr>
</tbody>
</table>
### QHP Issuer Application Receipt

- Marketplace application data is complete
- Received Final QHP Issuer Application Submission Attestations, including:
  - Service Area Attestation
  - Rating Areas Attestation
  - Network Adequacy
  - Actuarial Value
  - Plan Variation Standards
  - Marketing Regulations and Transparency
  - Market Reform Rules
  - Licensure and solvency
  - Compliance with Essential Health Benefits
  - Accreditation
  - Child Only policy equivalence (if applicable)
  - AHIP EHB Formulary Compliance
  - AHIP Pharmacy Prior Authorization

### Evaluation of QHP Issuer Application

#### Accreditation and Quality Standards

<table>
<thead>
<tr>
<th>Statute Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>45 CFR 156.275</td>
</tr>
</tbody>
</table>

- Applicant has Marketplace accreditation through NCQA and/or URAC, or:
  - **Year 1** - Applicant has applied for Marketplace accreditation through NCQA and/or URAC
  - **Year 2** - Issuer procedures and policies are accredited

- Attestations and supporting documentation are accurate and complete or accreditation is verified in SERFF

- Issuer has authorized release of accreditation data

#### Complaint and Compliance

- Requested complaint and compliance information (from consumer services division) received and reviewed

### Cost-Sharing Reductions

- Three silver plan cost-sharing variations are submitted for each silver-level QHP.
- High-Value Silver Plan Variation (94% +/- 1% actuarial value) meets AHIP requirements.
- SAD plans must have a “reasonable” annual limit on cost sharing that is at or below $700 for a plan with one child enrollee or $1,400 for a plan with two or more child enrollees.
For each QHP at each level of coverage issuer must submit to the Exchange for certification the health plan and two variations of the health plan:

- No Cost Sharing Plan for individuals eligible for cost-sharing reductions under § 155.350(a)
- Limited Cost Sharing Plan for individuals eligible for cost-sharing reductions under § 155.350(b)

Cost-sharing incurred under plan do not exceed the dollar amount limits established by federal and state laws and regulations ($6,350 for self-only coverage and $12,700 for family coverage in plan year 2014).

<table>
<thead>
<tr>
<th>Benefit Design</th>
<th>45 CFR 156.225; 42 USC 18022</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Actuarial Value</strong></td>
<td></td>
</tr>
</tbody>
</table>
Issuer has separately offered at least one QHP at each of the following Actuarial Values: 
Gold: 80% (78 to 82%) 
Silver: 70% (68 to 72%) |
| **Child-Only Plans** | 
Child-Only Plans are offered at each level of coverage (submitted as separate plans or confirmed by issuer attestation that there is no substantive difference between having a child-only plan and issuing child only policies, and that the QHP Issuer will accept child only enrollees. Catastrophic plans are excluded from this requirement. |
| **Actuarial Memorandum and Certification Received** | PPACA 1302(f) |
| **Verify that plan is substantially equal to benchmark plan** | |
| **If the issuer is substituting benefits, confirm that the issuer has demonstrated actuarial equivalence of substituted benefits** | 45 CFR 156.115 |
| **Compliance with premium rating factors including:** | PPACA 1201  SEC. 2701(a) |
| Self-only or family enrollment, | PHS 2701 |
| geographic rating areas (7 areas) | |
| Age (3:1 for adults) | |
| Tobacco use (1.2:1) | |
| **Justification information received for rate increase, if applicable** | |
| **Confirm Benefit Substitution A/V** | |
| **Confirm Actuarial Metal Level Submitted** | 
Bronze (60%) 
Silver (70%) 
Gold (80%) 
Platinum (90%) 
Catastrophic (<58%) 
(Allowable variance: +/- 2% )

For Stand Alone Dental: 
Low (70%) 
High (85) 
(Allowable variance +/- 2%)

**Meaningful Difference**
Compare all plans an issuer offers to identify multiple, identical plans that are offered in the same counties or have limited variation between deductible and out-of-pocket maximum.

**Inclusion of all 10 Essential Health Benefits that meet or exceed benchmark plan, including:**

**Ambulatory patient services**
Primary care physician visits  
Specialist office visit  
Services and procedures provided in the Specialist office other than consultation and evaluation  
Outpatient Services  
Surgical Services - Outpatient  
Ambulatory Surgical Center Services  
Outpatient Diagnostics  
Advanced Diagnostic Imaging, subject to prior auth  
Outpatient Physical Therapy  
Outpatient Occupational Therapy  
Home Health  
Hospice Care for individuals with life expectancy of less than 6 months  
Qualified Assistant Surgeon Services

<table>
<thead>
<tr>
<th>Emergency services</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergency Care Services</td>
</tr>
<tr>
<td>After-hours clinic or urgent care center</td>
</tr>
<tr>
<td>Observation services</td>
</tr>
<tr>
<td>Transfer to in-network hospital</td>
</tr>
<tr>
<td>Ambulance Services</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hospitalization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital Services</td>
</tr>
<tr>
<td>Physician Hospital Visits</td>
</tr>
<tr>
<td>Inpatient Services</td>
</tr>
<tr>
<td>Hospital services in connection with Dental Treatment</td>
</tr>
<tr>
<td>Surgical Services - Inpatient</td>
</tr>
<tr>
<td>Inpatient Physical Therapy</td>
</tr>
<tr>
<td>Inpatient Occupational Therapy</td>
</tr>
<tr>
<td>Skilled Nursing Facility Services</td>
</tr>
<tr>
<td>Organ Transplant Services</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Maternity and newborn care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certified nurse midwives</td>
</tr>
<tr>
<td>Newborn care in the hospital</td>
</tr>
<tr>
<td>In vitro fertilization for PPO plans</td>
</tr>
<tr>
<td>Genetic testing to determine presence of existing anomaly or disease</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mental health and substance use disorders, including behavioral health treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professional Services(by licensed practitioners acting within the scope of their license)</td>
</tr>
<tr>
<td>Diagnostics</td>
</tr>
<tr>
<td>Inpatient hospital or other covered facility</td>
</tr>
<tr>
<td>Outpatient hospital or other covered facility</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prescription drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescription Drugs:</td>
</tr>
<tr>
<td>Plan covers at least the greater of: (1) One drug in every category and class; or (2) the same number of drugs in each category and class as the EHB-benchmark plan</td>
</tr>
</tbody>
</table>
| Includes barbiturates, benzodiazepines, and agents used to promote smoking cessation,
including agents approved by the Food and Drug Administration as over-the-counter drugs for the purposes of promoting tobacco cessation.

<table>
<thead>
<tr>
<th>Rehabilitative and habilitative services and devices</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical, Occupational, and Speech Therapies</td>
</tr>
<tr>
<td>Developmental services</td>
</tr>
<tr>
<td>Durable Medical Equipment</td>
</tr>
<tr>
<td>Prosthetic and Orthotic Devices</td>
</tr>
<tr>
<td>Cochlear and other implantable devices for hearing, but not hearing aids</td>
</tr>
<tr>
<td>Medical supplies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Laboratory services</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testing and Evaluation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Preventive and wellness services and chronic disease management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case Management Communications made by PCP</td>
</tr>
<tr>
<td>Preventive Health Services</td>
</tr>
<tr>
<td>Routine immunizations</td>
</tr>
<tr>
<td>US Preventive Services Task Force A or B rated benefits</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pediatric Dental (if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consultations</td>
</tr>
<tr>
<td>Radiographs</td>
</tr>
<tr>
<td>Children's Preventive Services</td>
</tr>
<tr>
<td>Space maintainers</td>
</tr>
<tr>
<td>Restorations</td>
</tr>
<tr>
<td>Crowns</td>
</tr>
<tr>
<td>Endodontia</td>
</tr>
<tr>
<td>Peridontal Procedures</td>
</tr>
<tr>
<td>Removable prosthetic services</td>
</tr>
<tr>
<td>Oral Surgery</td>
</tr>
<tr>
<td>Professional visits</td>
</tr>
<tr>
<td>Hospital Services</td>
</tr>
<tr>
<td>Oral Surgery</td>
</tr>
<tr>
<td>Childhood development testing</td>
</tr>
<tr>
<td>Dental Anesthesia</td>
</tr>
<tr>
<td>Medically-Necessary Orthodontia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pediatric Vision</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye Exam</td>
</tr>
<tr>
<td>Surgical evaluation</td>
</tr>
<tr>
<td>Eyeglasses – one pair per year</td>
</tr>
<tr>
<td>Lenses</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medically-Necessary Contact lenses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye prosthesis</td>
</tr>
</tbody>
</table>
### Polishing services
- Vision Therapy Developmental Testing

### Miscellaneous
- Complications from Smallpox vaccine

### State Mandated Benefits

<table>
<thead>
<tr>
<th>Service</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autism Spectrum Disorders</td>
<td>23-99-418</td>
</tr>
<tr>
<td>Breast Reconstruction/Mastectomy</td>
<td>23-99-405</td>
</tr>
<tr>
<td>Children's Preventive Health Care</td>
<td>23-79-141 et al &amp; Rule 45</td>
</tr>
<tr>
<td>Colorectal Cancer Screening</td>
<td>23-79-1201 et al</td>
</tr>
<tr>
<td>Dental Anesthesia</td>
<td>23-86-121</td>
</tr>
<tr>
<td>Diabetic Supplies/Education</td>
<td>23-79-601 et al &amp; Rule 70</td>
</tr>
<tr>
<td>Diabetes Management Services</td>
<td></td>
</tr>
<tr>
<td>Equity in Prescription Insurance &amp; Contraceptive Coverage</td>
<td>23-79-1101 et al</td>
</tr>
<tr>
<td>Formula PKU/Medical Foods &amp; Low Protein Modified Food</td>
<td>23-79-701 et al</td>
</tr>
<tr>
<td>Medical Foods and Low Protein Modified Foods</td>
<td></td>
</tr>
<tr>
<td>Gastric Pacemakers</td>
<td>23-85-137, 23-86-118 &amp; Rule 1</td>
</tr>
<tr>
<td>In-Vitro Fertilization (insurance companies only)</td>
<td>23-79-130</td>
</tr>
<tr>
<td>Loss or Impairment of Speech or Hearing</td>
<td>23-99-404; 23-79-129</td>
</tr>
<tr>
<td>Maternity &amp; Newborn Coverage</td>
<td>23-79-501 et al</td>
</tr>
<tr>
<td>Mental Health parity</td>
<td>23-79-147</td>
</tr>
<tr>
<td>Off-Label Drug Use</td>
<td>23-79-1301</td>
</tr>
<tr>
<td>Prostate Cancer Screening</td>
<td>23-79-419</td>
</tr>
<tr>
<td>Orthotic &amp; Prosthetic Devices or Services</td>
<td></td>
</tr>
</tbody>
</table>

### Mandated Persons Covered, including:
- **Adopted Children**
- **Handicapped Dependents**

### Mandated Providers
- Ambulatory Surgery Center, Audiologyists, Chiropractors, Dentists, Emergency Services, Nurse Anesthetists, Optometrists, Podiatrists, Psychologists, Physician Assistant

### Mandated Benefit Offerings
- Mandatory benefit offerings not in the benchmark plan (including hearing aids and TMJ) are included in the QHP, OR issuer demonstrates that they will be offered through URL to brochure that describes the mandatory offering benefits and how to purchase or mailed with an application and description of mandatory benefit offerings with the consumer’s plan identification card.

### Elective Abortion
Coverage of Elective Abortion is prohibited

Act 72 of 2013

### Discriminatory benefit design

- PPACA §1311(c)(1)(A); PPACA §1302(b)(4)(B)

- Plan does not employ benefit designs that have the effect of discouraging the enrollment of individuals with significant health care needs

- PPACA §1311(c)(1)(A)
| Benefits not designed in a way that discriminates against individuals because of age, disability, or expected length of life | PPACA §1302(b)(4)(B) |
| Completed form filings for certification that submission meets provisions of the Unfair Sex Discrimination rule in Sale of Insurance (New or revised filings must contain this certification) | AID Rule and Regulation 19, Ark Code Ann. 23-66-201 |

**Pre-existing conditions**

| Plan must contain no preexisting condition exclusions | 42 USC 300gg-3 |

**State licensure, solvency, and good standing**

| Issuer properly licensed | 45 CFR 156.200(b)(4) |
| Company financially solvent and in good standing | |

**Marketing Standards**

| Meets requirement for transparency of coverage with attestation to include: Cost-sharing data is published on Internet Web Site Reporting requirements as listed in 45 CFR 156.22 | 45 CFR 156.220 |

| Received Attestation of compliance with marketing/discriminatory benefit design regulations | PHS 2701; PHS 2702; PHS 2703; PPACA 1302(e); PPACA 1312(c); PPACA 1402; 42 CFR 156; 42 CFR 147 |

**Market Reform Rules**

| QHP compliance with market reform rules in accordance with state and federal requirements | |
| Received QHP Market Reform Attestation of QHP compliance with market reform rules in accordance with state and federal requirements. | 45 CFR §147.104 |
| Guaranteed Availability of Coverage | 45 CFR §147.104 |
| Guaranteed Renewability of Coverage | 45 CFR §147.104 |
### Single Risk Pool

<table>
<thead>
<tr>
<th>Catastrophic Plan Requirements, including but not limited to:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Provides coverage for at least three primary care visits per year before the deductible is met.</td>
</tr>
<tr>
<td>• No annual limits on the dollar value of EHBs;</td>
</tr>
<tr>
<td>• Covers preventive services without cost-sharing requirements including deductibles, co-payments, and co-insurance;</td>
</tr>
<tr>
<td>• Plan is offered only in individual market, not in SHOP;</td>
</tr>
<tr>
<td>• Coverage for emergency services required; and</td>
</tr>
<tr>
<td>• Does not provide a bronze, silver, gold, or platinum level of coverage.</td>
</tr>
</tbody>
</table>

### Network Adequacy

<table>
<thead>
<tr>
<th>Submission of provider-enrollee ratios for each QHP network</th>
</tr>
</thead>
<tbody>
<tr>
<td>45 CFR § 156.80</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Submission of time/distance measures for each QHP network</th>
</tr>
</thead>
<tbody>
<tr>
<td>45 CFR § 156.80</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Essential community providers listed</th>
</tr>
</thead>
<tbody>
<tr>
<td>45 CFR § 156.80</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Accredited policies and procedures that includes network adequacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHS SEC.2702(c)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evaluation of issuer’s network OR Attestation detailing issuer’s ability to meet network adequacy standards including company policy for ensuring an adequate network</th>
</tr>
</thead>
<tbody>
<tr>
<td>State Partnership Guidance 1/2013</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Provider directory is available for online publication with indication of providers no longer accepting new patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPACA § 156.230</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Provider directory available to individuals in English and Spanish</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPACA § 156.230</td>
</tr>
</tbody>
</table>

### Rating Areas and Actuarial Value

<table>
<thead>
<tr>
<th>Rate-setting practices are consistent with the approved metrics</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHS SEC.2701(a)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Attestation of compliance with state rating areas (7 rating areas)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHS SEC.2701(b)</td>
</tr>
</tbody>
</table>

### Service Areas

<table>
<thead>
<tr>
<th>QHP service area covers at least one geographic rating area, OR issuer has submitted a hardship waiver that is approved by the Commissioner.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPACA § 155.1055(a)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evaluate that QHP service area is established without regard to racial, ethnic, language, health status related factors, or other specified factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPACA § 155.1055(b); PHS Act 2705</td>
</tr>
</tbody>
</table>

### Receive Rate and Benefit Data and Information

<table>
<thead>
<tr>
<th>Plan data and supporting documentation complete</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issuer submission of data completed before end of open enrollment period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>QHP rate and benefit data and information approved</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

### QHP Certification Agreement

<table>
<thead>
<tr>
<th>Issuer application and plan data approved</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Submit issuer and plan data to CMS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

---

147.106

45 CFR § 156.80

501x729

45

CFR

§

156.80

45

CFR

§

156.155

45

CFR

156.230;

45

CFR

156.235;

PHS

SEC.2702(c);

PPACA

156.230

45

CFR

156.230

45

CFR

156.230

45

CFR

156.230

45

CFR

156.235

PPACA

156.230

PPACA

156.230

PHS SEC.2701(a)

PHS SEC.2701(b)

PPACA § 155.1055(a)

PPACA § 155.1055(b); PHS Act 2705

Arkansas Health Care Independence Program -- Waiver Evaluation

Appendix 6
<table>
<thead>
<tr>
<th>Issue or Plan Non Certification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Notify issuer of non-certification of QHP(s) or Issuer</td>
</tr>
<tr>
<td>Update QHP(s) and Issuer Account Information</td>
</tr>
</tbody>
</table>
APPENDIX B

DEFINITION OF HABILITATIVE SERVICES
Habilitative Services are services provided in order for a person to attain and maintain a skill or function that was never learned or acquired and is due to a disabling condition.

COVERAGE OF HABILITATIVE SERVICES
Subject to permissible terms, conditions, exclusions and limitations, health benefit plans, when required to provide essential health benefits, shall provide coverage for physical, occupational and speech therapies, developmental services and durable medical equipment for developmental delay, developmental disability, developmental speech or language disorder, developmental coordination disorder and mixed developmental disorder.
APPENDIX C

STATE RATING AND SERVICE AREAS

Arkansas Counties by Region

<table>
<thead>
<tr>
<th>Region</th>
<th>Cleburne</th>
<th>Conway</th>
<th>Faulkner</th>
<th>Grant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Rating Area 1</td>
<td>Lonoke</td>
<td>Perry</td>
<td>Pope</td>
<td>Prairie</td>
</tr>
<tr>
<td></td>
<td>Pulaski</td>
<td>Saline</td>
<td>Van Buren</td>
<td>White</td>
</tr>
<tr>
<td>Northeast Rating Area 2</td>
<td>Clay</td>
<td>Craighead</td>
<td>Crittenden</td>
<td>Cross</td>
</tr>
<tr>
<td></td>
<td>Fulton</td>
<td>Greene</td>
<td>Independence</td>
<td>Izzard</td>
</tr>
<tr>
<td></td>
<td>Jackson</td>
<td>Lawrence</td>
<td>Mississippi</td>
<td>Poinsett</td>
</tr>
<tr>
<td></td>
<td>Randolph</td>
<td>Sharp</td>
<td>St. Francis</td>
<td>Stone</td>
</tr>
<tr>
<td>Northwest Rating Area 3</td>
<td>Baxter</td>
<td>Benton</td>
<td>Boone</td>
<td>Carroll</td>
</tr>
<tr>
<td></td>
<td>Madison</td>
<td>Marion</td>
<td>Newton</td>
<td>Searcy</td>
</tr>
<tr>
<td></td>
<td>Washington</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Central Rating Area 4</td>
<td>Clark</td>
<td>Garland</td>
<td>Hot Spring</td>
<td>Montgomery</td>
</tr>
<tr>
<td></td>
<td>Pike</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Southeast Rating Area 5</td>
<td>Arkansas</td>
<td>Ashley</td>
<td>Bradley</td>
<td>Chicot</td>
</tr>
<tr>
<td></td>
<td>Cleveland</td>
<td>Dallas</td>
<td>Desha</td>
<td>Drew</td>
</tr>
<tr>
<td></td>
<td>Jefferson</td>
<td>Lee</td>
<td>Lincoln</td>
<td>Monroe</td>
</tr>
<tr>
<td></td>
<td>Phillips</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Southwest Rating Area 6</td>
<td>Calhoun</td>
<td>Columbia</td>
<td>Hempstead</td>
<td>Howard</td>
</tr>
<tr>
<td></td>
<td>Lafayette</td>
<td>Little River</td>
<td>Miller</td>
<td>Nevada</td>
</tr>
<tr>
<td></td>
<td>Ouachita</td>
<td>Sevier</td>
<td>Union</td>
<td></td>
</tr>
<tr>
<td>West Central Rating Area 7</td>
<td>Crawford</td>
<td>Franklin</td>
<td>Johnson</td>
<td>Logan</td>
</tr>
<tr>
<td></td>
<td>Scott</td>
<td>Sebastian</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Polk</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## HIGH LEVEL SILVER PLAN COST SHARING VARIATION REQUIREMENT

### High-Value Silver Plan

<table>
<thead>
<tr>
<th>Service Description</th>
<th>Subject to Deductible</th>
<th>Unit of Service</th>
<th>Copays</th>
<th>Coinsurance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Behavioral Health - IP</td>
<td>Yes</td>
<td>Day</td>
<td>$140</td>
<td>100%</td>
</tr>
<tr>
<td>Behavioral Health - OP</td>
<td>No</td>
<td>Visit</td>
<td>$4</td>
<td>100%</td>
</tr>
<tr>
<td>Behavioral Health - Professional</td>
<td>No</td>
<td>Visit</td>
<td>$4</td>
<td>100%</td>
</tr>
<tr>
<td>Durable Medical Equipment</td>
<td>No</td>
<td>Service</td>
<td>$4</td>
<td>100%</td>
</tr>
<tr>
<td>Emergency Room Services</td>
<td>No</td>
<td>Visit</td>
<td>$20</td>
<td>100%</td>
</tr>
<tr>
<td>FQHC</td>
<td>No</td>
<td>Visit</td>
<td>$8</td>
<td>100%</td>
</tr>
<tr>
<td>Inpatient</td>
<td>Yes</td>
<td>Day</td>
<td>$140</td>
<td>100%</td>
</tr>
<tr>
<td>Lab and Radiology</td>
<td>No</td>
<td>Visit</td>
<td>$-</td>
<td>100%</td>
</tr>
<tr>
<td>Skilled Nursing Facilty</td>
<td>Yes</td>
<td>Day</td>
<td>$20</td>
<td>100%</td>
</tr>
<tr>
<td>Other</td>
<td>No</td>
<td>Visit</td>
<td>$4</td>
<td>100%</td>
</tr>
<tr>
<td>Other Medical Professionals</td>
<td>No</td>
<td>Visit</td>
<td>$4</td>
<td>100%</td>
</tr>
<tr>
<td>Outpatient Facility</td>
<td>Yes</td>
<td>Visit</td>
<td>$-</td>
<td>91%</td>
</tr>
<tr>
<td>Primary Care Physician</td>
<td>No</td>
<td>Visit</td>
<td>$8</td>
<td>100%</td>
</tr>
<tr>
<td>Specialty Physician</td>
<td>No</td>
<td>Visit</td>
<td>$10</td>
<td>100%</td>
</tr>
<tr>
<td>Pharmacy - Generics</td>
<td>No</td>
<td>Prescription</td>
<td>$4</td>
<td>100%</td>
</tr>
<tr>
<td>Pharmacy - Preferred Brand Drugs</td>
<td>No</td>
<td>Prescription</td>
<td>$4</td>
<td>100%</td>
</tr>
<tr>
<td>Pharmacy - Non-Preferred Brand Drugs</td>
<td>No</td>
<td>Prescription</td>
<td>$8</td>
<td>100%</td>
</tr>
<tr>
<td>Pharmacy - Specialty Drugs (i.e. high-cost)</td>
<td>No</td>
<td>Prescription</td>
<td>$8</td>
<td>100%</td>
</tr>
</tbody>
</table>
SUMMARY OF CHANGES FROM FEBRUARY 19, 2013 RELEASE

- “Exchange” was changed to “Marketplace” throughout.
- Page 1, A Letter of Intent to cover specific service areas to the Commissioner must be submitted by June 1.
- Page 2-3, Information was added related to the Health Care Independence Program, including the requirement to submit a letter of intent to AID by June 1, 2013 describing the QHP Issuer’s intended service areas.
- Page 3-4, General Requirements: Lines numbered 16 and 17 were added to be in compliance with the recently released federal rule.
- Page 4, General Requirements/State Standards: Additional information related to the high value silver plan variations was added. Clarifications to requirements for SAD Issuers and Plans were included.
- Page 7, Network Adequacy/State Standards: A link to the ECP lists was included, as well as information clarifying how the standard would be measured.
- Page 7, Accreditation: Additional information was added related to SAD and clarifying what accreditation information must be submitted.
- Page 8, Service Area: Updated service area requirements.
- Page 8, Rating Areas: The federal definition of rating areas was updated to be in compliance with the recently released federal rule.
- Page 9, Quality Improvement Standards: Requirements to participate in the Arkansas Payment Improvement Initiative and reporting requirements were added.
- Page 10, General Offering Requirement: Information related to requirements for SHOP, child-only plans, mandatory benefit offerings, and high deductible health plan limits, SAD plan rating limitations were all added.
- Page 13, Essential Health Benefit Standards/State Standards: Notification of requirement to provide medically necessary orthodontia and prohibition to offer coverage of elective abortion as an EHB.
- Page 14, Essential Health Benefit Formulary Review: Requirement to provide at least a 72 hour supply of drugs in emergency situations, as well as the requirement to cover additional pharmaceuticals.
- Page 14-15, Nondiscrimination Standards in Marketing and Benefit Design: Marketing must be submitted to AID before it may be used. The original bulletin stated that all
marketing must be prior approved. CMS has since clarified its position that all marketing is not required to be prior approved, but that a state must at a minimum provide for spot checking marketing material. This new standard will allow for the state to be able to maintain compliance with that standard while giving more flexibility to the QHP issuers. Additionally, information related to outlier benefit review was included.

- Page 16, Rate Filing: Information added related to SAD Issuer/Plan rating requirements, outlier analysis Unified Rate Review Template and SHOP rating requirements.
- Page 17, Plan Variation for Individuals Eligible for Cost Sharing: Added information related to SAD Issuers/Plans and requirements for the high level silver plan variation.
- Page 18, Stand Alone Dental Plans: New section related to SAD Issuer/Plan requirements.
- Page 18, Appendix A: Checklist updated to match new information as included above.
- Page 37, Appendix C: Added rating area numbers to match federal templates and updated name to indicate that this is indicative of both rating and service areas.
- Page 38, Appendix D: Added High Level Silver Plan Cost Sharing Variation requirements.

**SUMMARY OF CHANGES FROM JUNE 25, 2013 RELEASE**

- The State Standard section under Quality Improvement standards was updated to show requirements related to the Arkansas Payment Improvement Initiative.
- Appendix D was updated with new information.
## ATTACHMENT B

### Copayment and Coinsurance Amounts

<table>
<thead>
<tr>
<th>General Service Description</th>
<th>QHP-Level Cost Sharing</th>
<th>Cost Sharing Applicable for Individuals with Incomes from 50-100% FPL Who Do Not Make Monthly Contributions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Behavioral Health – Inpatient</td>
<td>$140/day</td>
<td>$75/stay</td>
</tr>
<tr>
<td>Behavioral Health – Outpatient</td>
<td>$4</td>
<td>$4</td>
</tr>
<tr>
<td>Behavioral Health – Professional</td>
<td>$4</td>
<td>$4</td>
</tr>
<tr>
<td>Durable Medical Equipment</td>
<td>$4</td>
<td>$4</td>
</tr>
<tr>
<td>Emergency Room Services</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>FQHC</td>
<td>$8</td>
<td>$4</td>
</tr>
<tr>
<td>Inpatient</td>
<td>$140/day</td>
<td>$75/stay</td>
</tr>
<tr>
<td>Lab and Radiology</td>
<td>-</td>
<td>$4</td>
</tr>
<tr>
<td>Skilled Nursing Facility</td>
<td>$20/day</td>
<td>$75/stay</td>
</tr>
<tr>
<td>Other</td>
<td>$4</td>
<td>$4</td>
</tr>
<tr>
<td>Other Medical Professionals</td>
<td>$4</td>
<td>$4</td>
</tr>
<tr>
<td>Outpatient Facility</td>
<td>-</td>
<td>$4</td>
</tr>
<tr>
<td>Primary Care Physician</td>
<td>$8</td>
<td>$4</td>
</tr>
<tr>
<td>Specialty Physician</td>
<td>$10</td>
<td>$4</td>
</tr>
<tr>
<td>Pharmacy – Generics</td>
<td>$4</td>
<td>$4</td>
</tr>
<tr>
<td>Pharmacy – Preferred Brand Drugs</td>
<td>$4</td>
<td>$4</td>
</tr>
<tr>
<td>Pharmacy – Non-Preferred Brand Drugs, including specialty drugs</td>
<td>$8</td>
<td>$8</td>
</tr>
</tbody>
</table>